2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons

WRITING GROUP MEMBERS*

Rick A. Nishimura, MD, MACC, FAHA, Co-Chair
Catherine M. Otto, MD, FACC, FAHA, Co-Chair
Robert O. Bonow, MD, MACC, FAHA†
Blase A. Carabello, MD, FACC**
John P. Erwin III, MD, FACC, FAHA†
Lee A. Fleisher, MD, FACC, FAHA‡
Hani Jneid, MD, FACC, FAHA, FSCAI§
Michael J. Mack, MD, FACC*‡
Christopher J. McLeod, MBChB, PhD, FACC, FAHA†
Patrick T. O’Gara, MD, FACC, FAHA†
Vera H. Rigolin, MD, FACC†
Thoralf M. Sundt III, MD, FACC#
Annemarie Thompson, MD**

ACC/AHA TASK FORCE MEMBERS

Glenn N. Levine, MD, FACC, FAHA, Chair
Patrick T. O’Gara, MD, FACC, FAHA, Chair-Elect
Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair††
Sana M. Al-Khatib, MD, MHS, FACC, FAHA
Kim K. Birtcher, PharmD, MS, AACC
Biykem Bozkurt, MD, PhD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC††
Joaquin E. Cigarroa, MD, FACC
Lesley H. Curtis, PhD, FAHA
Lee A. Fleisher, MD, FACC, FAHA
Federico Gentile, MD, FACC
Samuel Gidding, MD, FAHA
Mark A. Hlatky, MD, FACC
John Ikonomidis, MD, PhD, FAHA
José Joglar, MD, FACC, FAHA
Susan J. Pressler, PhD, RN, FAHA
Duminda N. Wijeysundera, MD, PhD

*Focused Update writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix I for detailed information. †ACC/AHA Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §SCAI Representative. ¶STS Representative. ‡‡ASE Representative. #AATS Representative. **SCA Representative. ††Former Task Force member; current member during the writing effort.

This document was approved by the American College of Cardiology Clinical Policy Approval Committee on behalf of the Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee in January 2017, and the American Heart Association Executive Committee in February 2017.

The online Comprehensive RWI Data Supplement table is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC1.

The online Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC2.


This article has been copublished in the Journal of the American College of Cardiology.
Table of Contents

Preamble........................................................................................................................................................................... 4

1. Introduction.................................................................................................................................................................... 7
   1.1. Methodology and Evidence Review .................................................................................................................. 7
   1.2. Organization of the Writing Group ....................................................................................................................... 7
   1.3. Document Review and Approval .......................................................................................................................... 8

2. General Principles ............................................................................................................................................................ 8
   2.4. Basic Principles of Medical Therapy .................................................................................................................. 8
      2.4.1. Anticoagulation for Atrial Fibrillation in Patients With VHD (New Section) ........................................ 10

3. Aortic Stenosis .................................................................................................................................................................. 11
   3.2. Aortic Stenosis ......................................................................................................................................................... 11
      3.2.4. Choice of Intervention: Recommendations ................................................................................................. 11

7. Mitral Regurgitation .......................................................................................................................................................... 15
   7.2. Stages of Chronic MR ........................................................................................................................................ 15
   7.3. Chronic Primary MR .......................................................................................................................................... 18
   7.4. Chronic Secondary MR ...................................................................................................................................... 20
      7.4.3. Intervention: Recommendations .................................................................................................................. 20

11. Prosthetic Valves ......................................................................................................................................................... 22
   11.1. Evaluation and Selection of Prosthetic Valves ................................................................................................. 22
      11.1.2. Intervention: Recommendations .................................................................................................................. 22
   11.2. Antithrombotic Therapy for Prosthetic Valves ................................................................................................. 25
      11.2.1. Diagnosis and Follow-Up .......................................................................................................................... 25
      11.2.2. Medical Therapy: Recommendations ......................................................................................................... 25
   11.3. Bridging Therapy for Prosthetic Valves ............................................................................................................... 28
      11.3.1. Diagnosis and Follow-Up .......................................................................................................................... 28
      11.3.2. Medical Therapy: Recommendations ......................................................................................................... 28
   11.6. Acute Mechanical Prosthetic Valve Thrombosis .............................................................................................. 30
      11.6.1. Diagnosis and Follow-Up: Recommendation ............................................................................................ 30
      11.6.3. Intervention: Recommendation .................................................................................................................. 31
   11.7. Prosthetic Valve Stenosis ...................................................................................................................................... 32
      11.7.3. Intervention: Recommendation .................................................................................................................. 33
   11.8. Prosthetic Valve Regurgitation ........................................................................................................................... 34
      11.8.3. Intervention: Recommendations .................................................................................................................. 34

12. Infective Endocarditis .................................................................................................................................................... 36
   12.2. Infective Endocarditis ......................................................................................................................................... 36
      12.2.3. Intervention: Recommendations .................................................................................................................. 36

Appendix 1. Author Relationships With Industry and Other Entities (Relevant) ................................................... 39
Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) ................................ 41
Appendix 3. Abbreviations ............................................................................................................................................... 48
References........................................................................................................................................................................ 48
Preamble
Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a cornerstone for quality cardiovascular care. The ACC and AHA sponsor the development and publication of guidelines without commercial support, and members of each organization volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA.

Intended Use
Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a global impact. Although guidelines may be used to inform regulatory or payer decisions, their intent is to improve patients’ quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment.

Clinical Implementation
Guideline recommended management is effective only when followed by healthcare providers and patients. Adherence to recommendations can be enhanced by shared decision making between healthcare providers and patients, with patient engagement in selecting interventions based on individual values, preferences, and associated conditions and comorbidities.

Methodology and Modernization
The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations including the Institute of Medicine (1,2) and on the basis of internal reevaluation. Similarly, the presentation and delivery of guidelines are reevaluated and modified on the basis of evolving technologies and other factors to facilitate optimal dissemination of information at the point of care to healthcare professionals. Given time constraints of busy healthcare providers and the need to limit text, the current guideline format delineates that each recommendation be supported by limited text (ideally, <250 words) and hyperlinks to supportive evidence summary tables. Ongoing efforts to further limit text are underway. Recognizing the importance of cost–value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology (3).

To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles. Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual (4) and other methodology articles (5-8).

Selection of Writing Committee Members
The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and
scopes of clinical practice. The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers.

**Relationships With Industry and Other Entities**


**Evidence Review and Evidence Review Committees**

When developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data (4-7). Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited.

An independent evidence review committee (ERC) is commissioned when there are 1 or more questions deemed of utmost clinical importance that merit formal systematic review. This systematic review will strive to determine which patients are most likely to benefit from a drug, device, or treatment strategy and to what degree. Criteria for commissioning an ERC and formal systematic review include: a) the absence of a current authoritative systematic review, b) the feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline, c) the relevance to a substantial number of patients, and d) the likelihood that the findings can be translated into actionable recommendations. ERC members may include methodologists, epidemiologists, healthcare providers, and biostatisticians. When a formal systematic review has been commissioned, the recommendations developed by the writing committee on the basis of the systematic review are marked with “SR”.

**Guideline-Directed Management and Therapy**

The term *guideline-directed management and therapy* (GDMT) encompasses clinical evaluation, diagnostic testing, and pharmacological and procedural treatments. For these and all recommended drug treatment regimens, the reader should confirm the dosage by reviewing product insert material and evaluate the treatment regimen for contraindications and interactions. The recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States.

**Class of Recommendation and Level of Evidence**

The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1) (4-6).

Glenn N. Levine, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Practice Guidelines
Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)

<table>
<thead>
<tr>
<th>CLASS (STRENGTH) OF RECOMMENDATION</th>
<th>LEVEL (QUALITY) OF EVIDENCE‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASS I (STRONG)</td>
<td><strong>LEVEL A</strong></td>
</tr>
<tr>
<td>Benefit &gt;&gt; Risk</td>
<td>High-quality evidence‡ from more than 1 RCT</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>Is recommended</td>
<td>Meta-analyses of high-quality RCTs</td>
</tr>
<tr>
<td>Is indicated/useful/effective/beneficial</td>
<td>One or more RCTs corroborated by high-quality registry studies</td>
</tr>
<tr>
<td>Should be performed/administered/other</td>
<td></td>
</tr>
<tr>
<td>Comparative-Effectiveness Phrases‡:</td>
<td></td>
</tr>
<tr>
<td>Treatment_strategy A is recommended/indicated in preference to treatment B</td>
<td></td>
</tr>
<tr>
<td>Treatment A should be chosen over treatment B</td>
<td></td>
</tr>
<tr>
<td>CLASS IIa (MODERATE)</td>
<td><strong>LEVEL B-R</strong></td>
</tr>
<tr>
<td>Benefit &gt;&gt; Risk</td>
<td>(Randomized)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>Is reasonable</td>
<td>Moderate-quality evidence‡ from 1 or more RCTs</td>
</tr>
<tr>
<td>Can be useful/effective/beneficial</td>
<td>Meta-analyses of moderate-quality RCTs</td>
</tr>
<tr>
<td>Comparative-Effectiveness Phrases‡:</td>
<td></td>
</tr>
<tr>
<td>Treatment_strategy A is probably recommended/indicated in preference to treatment B</td>
<td></td>
</tr>
<tr>
<td>It is reasonable to choose treatment A over treatment B</td>
<td></td>
</tr>
<tr>
<td>CLASS IIb (WEAK)</td>
<td><strong>LEVEL B-NR</strong></td>
</tr>
<tr>
<td>Benefit ≥ Risk</td>
<td>(Nonrandomized)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>May/might be reasonable</td>
<td>Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies</td>
</tr>
<tr>
<td>May/might be considered</td>
<td>Meta-analyses of such studies</td>
</tr>
<tr>
<td>Usefulness/effectiveness is unknown/unclear/uncertain or not well established</td>
<td></td>
</tr>
<tr>
<td>CLASS III: No Benefit (MODERATE)</td>
<td><strong>LEVEL C-LD</strong></td>
</tr>
<tr>
<td>Benefit = Risk</td>
<td>(Limited Data)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>Is not recommended</td>
<td>Randomized or nonrandomized observational or registry studies with limitations of design or execution</td>
</tr>
<tr>
<td>Is not indicated/useful/effective/beneficial</td>
<td>Meta-analyses of such studies</td>
</tr>
<tr>
<td>Should not be performed/administered/other</td>
<td></td>
</tr>
<tr>
<td>CLASS III: Harm (STRONG)</td>
<td><strong>LEVEL C-EQ</strong></td>
</tr>
<tr>
<td>Risk &gt; Benefit</td>
<td>(Expert Opinion)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>Potentially harmful</td>
<td>Consensus of expert opinion based on clinical experience</td>
</tr>
<tr>
<td>Causes harm</td>
<td></td>
</tr>
<tr>
<td>Associated with excess morbidity/mortality</td>
<td></td>
</tr>
<tr>
<td>Should not be performed/administered/other</td>
<td></td>
</tr>
</tbody>
</table>

COR and LOE are determined independently (any COR may be paired with any LOE). A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EQ, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trials.
1. Introduction

The focus of the “2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease” (9,10) (2014 VHD guideline) was the diagnosis and management of adult patients with valvular heart disease (VHD). The field of VHD is rapidly progressing, with new knowledge of the natural history of patients with valvular disease, advances in diagnostic imaging, and improvements in catheter-based and surgical interventions. Several randomized controlled trials (RCTs) have been published since the 2014 VHD guideline, particularly with regard to the outcomes of interventions. Major areas of change include indications for transcatheter aortic valve replacement (TAVR), surgical management of the patient with primary and secondary mitral regurgitation (MR), and management of patients with valve prostheses.

All recommendations (new, modified, and unchanged) for each clinical section are included to provide a comprehensive assessment. The text explains new and modified recommendations, whereas recommendations from the previous guideline that have been deleted or superseded no longer appear. Please consult the full-text version of the 2014 VHD guideline (10) for text and evidence tables supporting the unchanged recommendations and for clinical areas not addressed in this focused update. Individual recommendations in this focused update will be incorporated into the full-text guideline in the future. Recommendations from the prior guideline that remain current have been included for completeness but the LOE reflects the COR/LOE system used when initially developed. New and modified recommendations in this focused update reflect the latest COR/LOE system, in which LOE B and C are subcategorized for greater specificity (4-7). The section numbers correspond to the full-text guideline sections.

1.1. Methodology and Evidence Review

To identify key data that might influence guideline recommendations, the Task Force and members of the 2014 VHD guideline writing committee reviewed clinical trials that were presented at the annual scientific meetings of the ACC, AHA, European Society of Cardiology, and other groups and that were published in peer-reviewed format from October 2013 through November 2016. The evidence is summarized in tables in the Online Data Supplement (http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC2).

1.2. Organization of the Writing Group

For this focused update, representative members of the 2014 VHD writing committee were invited to participate, and they were joined by additional invited members to form a new writing group, referred to as the 2017 focused update writing group. Members were required to disclose all RWI relevant to the data under consideration. The group was composed of experts representing cardiovascular medicine, cardiovascular imaging, interventional cardiology, electrophysiology, cardiac surgery, and cardiac anesthesiology. The writing group included representatives from the ACC, AHA, American Association for Thoracic Surgery (AATS),
1.3. Document Review and Approval

The focused update was reviewed by 2 official reviewers each nominated by the ACC and AHA; 1 reviewer each from the AATS, ASE, SCAI, SCA, and STS; and 40 content reviewers. Reviewers’ RWI information is published in this document (Appendix 2).

This document was approved for publication by the governing bodies of the ACC and the AHA and was endorsed by the AATS, ASE, SCAI, SCA, and STS.

2. General Principles

2.4. Basic Principles of Medical Therapy

2.4.2. Infective Endocarditis Prophylaxis: Recommendation

With the absence of RCTs that demonstrated the efficacy of antibiotic prophylaxis to prevent infective endocarditis (IE), the practice of antibiotic prophylaxis has been questioned by national and international medical societies (11-14). Moreover, there is not universal agreement on which patient populations are at higher risk of developing IE than the general population. Protection from endocarditis in patients undergoing high-risk procedures is not guaranteed. A prospective study demonstrated that prophylaxis given to patients for what is typically considered a high-risk dental procedure reduced but did not eliminate the incidence of bacteremia (15). A 2013 Cochrane Database systematic review of antibiotic prophylaxis of IE in dentistry concluded that there is no evidence to determine whether antibiotic prophylaxis is effective or ineffective, highlighting the need for further study of this longstanding clinical dilemma (13). Epidemiological data conflict with regard to incidence of IE after adoption of more limited prophylaxis, as recommended by the AHA and European Society of Cardiology (16-20), and no prophylaxis, as recommended by the U.K. NICE (National Institute for Health and Clinical Excellence) guidelines (21). Some studies indicate no increase in incidence of endocarditis with limited or no prophylaxis, whereas others suggest that IE cases have increased with adoption of the new guidelines (16-22). The consensus of the writing group is that antibiotic prophylaxis is reasonable for the subset of patients at increased risk of developing IE and at high risk of experiencing adverse outcomes from IE. There is no evidence for IE prophylaxis in gastrointestinal procedures or genitourinary procedures, absent known active infection.
**Recommendation for IE Prophylaxis**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>Prophylaxis against IE is reasonable before dental procedures that involve manipulation of gingival tissue, manipulation of the periapical region of teeth, or perforation of the oral mucosa in patients with the following (13,15,23-29):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Prosthetic cardiac valves, including transcatheter-implanted prostheses and homografts.</td>
<td>MODIFIED: LOE updated from B to C-LD. Patients with transcatheter prosthetic valves and patients with prosthetic material used for valve repair, such as annuloplasty rings and chords, were specifically identified as those to whom it is reasonable to give IE prophylaxis. This addition is based on observational studies demonstrating the increased risk of developing IE and high risk of adverse outcomes from IE in these subgroups. Categories were rearranged for clarity to the caregiver.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Prosthetic material used for cardiac valve repair, such as annuloplasty rings and chords.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Previous IE.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. Unrepaired cyanotic congenital heart disease or repaired congenital heart disease, with residual shunts or valvular regurgitation at the site of or adjacent to the site of a prosthetic patch or prosthetic device.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5. Cardiac transplant with valve regurgitation due to a structurally abnormal valve.</td>
<td></td>
</tr>
</tbody>
</table>

The risk of developing IE is higher in patients with underlying VHD. However, even in patients at high risk of IE, evidence for the efficacy of antibiotic prophylaxis is lacking. The lack of supporting evidence, along with the risk of anaphylaxis and increasing bacterial resistance to antimicrobials, led to a revision in the 2007 AHA recommendations for prophylaxis limited to those patients at highest risk of adverse outcomes with IE (11). These included patients with a history of prosthetic valve replacement, patients with prior IE, select patients with congenital heart disease, and cardiac transplant recipients. IE has been reported to occur after TAVR at rates equal to or exceeding those associated with surgical aortic valve replacement (AVR) and is associated with a high 1-year mortality rate of 75% (30,31). IE may also occur after valve repair in which prosthetic material is used, usually necessitating urgent operation, which has high in-hospital and 1-year mortality rates (32,33). IE appears to be more common in heart transplant recipients than in the general population, according to limited data (23). The risk of IE is highest in the first 6 months after transplantation because of endothelial disruption, high-intensity immunosuppressive therapy, frequent central venous catheter access, and frequent endomyocardial biopsies (23). Persons at risk of developing bacterial IE should establish and maintain the best possible oral health to reduce potential sources of bacterial seeding. Optimal oral health is maintained through regular professional dental care and the use of appropriate dental products, such as manual, powered, and ultrasonic toothbrushes; dental floss; and other plaque-removal devices.
### 2.4.3. Anticoagulation for Atrial Fibrillation in Patients With VHD (New Section)

<table>
<thead>
<tr>
<th>Recommendations for Anticoagulation for Atrial Fibrillation (AF) in Patients With VHD</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COR</strong></td>
<td><strong>LOE</strong></td>
</tr>
<tr>
<td>1</td>
<td>B-NR</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A retrospective analysis of administrative claims databases (>20,000 DOAC-treated patients) showed no difference in the incidence of stroke or major bleeding in patients with rheumatic and nonrheumatic MS if treated with DOAC versus warfarin (35). However, the writing group continues to recommend the use of VKA for patients with rheumatic MS until further evidence emerges on the efficacy of DOAC in this population. (See Section 6.2.2 on Medical Management of Mitral Stenosis in the 2014 guideline.)

| 1 | C-LD | **Anticoagulation is indicated in patients with AF and a CHA₂DS₂-VASc score of 2 or greater with native aortic valve disease, tricuspid valve disease, or MR (36-38).** |
| | | **NEW:** Post hoc subgroup analyses of large RCTs comparing DOAC versus warfarin in patients with AF have analyzed patients with native valve disease other than MS and patients who have undergone cardiac surgery. These analyses consistently demonstrated that the risk of stroke is similar to or higher than that of patients without VHD. Thus, the indication for anticoagulation in these patients should follow GDMT according to the CHA₂DS₂-VASc score (35-38). |

Many patients with VHD have AF, yet these patients were not included in the original studies evaluating the risk of stroke or in the development of the risk schema such as CHADS₂ or CHA₂DS₂-VASc (39,40). Post hoc subgroup analyses of large RCTs comparing apixaban, rivaroxaban, and dabigatran (DOACs) versus warfarin (36-38) included patients with VHD, and some included those with bioprosthetic valves or those undergoing valvuloplasty. Although the criteria for nonvalvular AF differed for each trial, patients with significant MS and valve disease requiring an intervention were excluded. There is no clear evidence that the presence of native VHD other than rheumatic MS need be considered in the decision to anticoagulate a patient with AF. On the basis of these findings, the writing group supports the use of anticoagulation in patients with VHD and AF when their CHA₂DS₂-VASc score is 2 or greater. Patients
with a bioprosthetic valve or mitral repair and AF are at higher risk for embolic events and should undergo anticoagulation irrespective of the CHA2DS2-VASc score.

<table>
<thead>
<tr>
<th>IIa</th>
<th>C-LD</th>
<th>It is reasonable to use a DOAC as an alternative to a VKA in patients with AF and native aortic valve disease, tricuspid valve disease, or MR and a CHA2DS2-VASc score of 2 or greater (35-38).</th>
</tr>
</thead>
</table>

**NEW:** Several thousand patients with native VHD (exclusive of more than mild rheumatic MS) have been evaluated in RCTs comparing DOACs versus warfarin. Subgroup analyses have demonstrated that DOACs, when compared with warfarin, appear as effective and safe in patients with VHD as in those without VHD.

DOACs appear to be as effective and safe in patients with VHD as they are in those without VHD. In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), and RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) trials, 2,003, 4,808, and 3,950 patients, respectively, had significant VHD (36-38). This included MR, mild MS, aortic regurgitation, aortic stenosis (AS), and tricuspid regurgitation. These trials consistently demonstrated at least equivalence to warfarin in reducing stroke and systemic embolism. Retrospective analyses of administrative claims databases (>20,000 DOAC-treated patients) correlate with these findings (35). In addition, the rate of intracranial hemorrhage in each trial was lower among patients randomized to dabigatran, rivaroxaban, or apixaban than among those randomized to warfarin, regardless of the presence of VHD (36-38). There is an increased risk of bleeding in patients with VHD versus those without VHD, irrespective of the choice of the anticoagulant.

### 3. Aortic Stenosis

#### 3.2. Aortic Stenosis

**3.2.4. Choice of Intervention: Recommendations**

The recommendations for choice of intervention for AS apply to both surgical AVR and TAVR; indications for AVR are discussed in Section 3.2.3 in the 2014 VHD guideline. The integrative approach to assessing risk of surgical AVR or TAVR is discussed in Section 2.5 in the 2014 VHD guideline. The choice of proceeding with surgical AVR versus TAVR is based on multiple factors, including the surgical risk, patient frailty, comorbid conditions, and patient preferences and values (41). Concomitant severe coronary artery disease may also affect the optimal intervention because severe multivessel coronary disease may best be served by surgical AVR and coronary artery bypass graft surgery (CABG). See Figure 1 for an algorithm on choice of TAVR versus surgical AVR.
## Recommendations for Choice of Intervention

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C</td>
<td>For patients in whom TAVR or high-risk surgical AVR is being considered, a heart valve team consisting of an integrated, multidisciplinary group of healthcare professionals with expertise in VHD, cardiac imaging, interventional cardiology, cardiac anesthesia, and cardiac surgery should collaborate to provide optimal patient care.</td>
<td>2014 recommendation remains current.</td>
</tr>
</tbody>
</table>

### MODIFIED: LOE updated from A to B-NR.

Surgical AR is recommended for symptomatic patients with severe AS (Stage D) and asymptomatic patients with severe AS (Stage C) who meet an indication for AVR when surgical risk is low or intermediate (42,43).

See Online Data Supplements 5 and 9 (Updated From 2014 VHD Guideline)

AVR is indicated for survival benefit, improvement in symptoms, and improvement in left ventricular (LV) systolic function in patients with severe symptomatic AS (Section 3.2.3 in the 2014 VHD guideline) (42-48).

Given the magnitude of the difference in outcomes between those undergoing AVR and those who refuse AVR in historical series, an RCT of AVR versus medical therapy would not be appropriate in patients with a low-to-intermediate surgical risk (Section 2.5 in the 2014 VHD guideline). Outcomes after surgical AVR are excellent in patients who do not have a high procedural risk (43-46,48). Surgical series demonstrate improved symptoms after AVR, and most patients have an improvement in exercise tolerance, as documented in studies with pre- and post-AVR exercise stress testing (43-46,48). The choice of prosthetic valve type is discussed in Section 11.1 of this focused update.

| I   | A   | Surgical AVR or TAVR is recommended for symptomatic patients with severe AS (Stage D) and high risk for surgical AVR, depending on patient-specific procedural risks, values, and preferences (49-51). | MODIFIED: COR updated from IIA to I, LOE updated from B to A. Longer-term follow-up and additional RCTs have demonstrated that TAVR is equivalent to surgical AVR for severe symptomatic AS when |

See Online Data Supplement 9 (Updated From 2014 VHD Guideline)
TAVR has been studied in RCTs, as well as in numerous observational studies and multicenter registries that include large numbers of high-risk patients with severe symptomatic AS (49,50,52-56). In the PARTNER (Placement of Aortic Transcatheter Valve) IA trial of a balloon-expandable valve (50,53), TAVR (n=348) was noninferior to surgical AVR (n=351) for all-cause death at 30 days, 1 year, 2 years, and 5 years (p=0.001) (53,54). The risk of death at 5 years was 67.8% in the TAVR group, compared with 62.4% in the surgical AVR group (hazard ratio [HR]: 1.04, 95% confidence interval [CI]: 0.86 to 1.24; p=0.76) (50). TAVR was performed by the transfemoral approach in 244 patients and the transapical approach in 104 patients. There was no structural valve deterioration requiring repeat AVR in either the TAVR or surgical AVR groups.

In a prospective study that randomized 795 patients to either self-expanding TAVR or surgical AVR, TAVR was associated with an intention-to-treat 1-year survival rate of 14.2%, versus 19.1% with surgical AVR, equivalent to an absolute risk reduction of 4.9% (49). The rate of death or stroke at 3 years was lower with TAVR than with surgical AVR (37.3% versus 46.7%; p=0.006) (51). The patient’s values and preferences, comorbidities, vascular access, anticipated functional outcome, and length of survival after AVR should be considered in the selection of surgical AVR or TAVR for those at high surgical risk. The specific choice of a balloon-expandable valve or self-expanding valve depends on patient anatomy and other considerations (57). TAVR has not been evaluated for asymptomatic patients with severe AS who have a high surgical risk. In these patients, frequent clinical monitoring for symptom onset is appropriate, as discussed in Section 2.3.3 in the 2014 VHD guideline.
death or major morbidity (all causes) >50% at 30 days; disease affecting ≥3 major organ systems that is not likely to improve postoperatively; or anatomic factors that preclude or increase the risk of cardiac surgery, such as a heavily calcified (e.g., porcelain) aorta, prior radiation, or an arterial bypass graft adherent to the chest wall (58-61).

<table>
<thead>
<tr>
<th>IIa</th>
<th>B-R</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAVR is a reasonable alternative to surgical AVR for symptomatic patients with severe AS (Stage D) and an intermediate surgical risk, depending on patient-specific procedural risks, values, and preferences (62-65).</td>
<td>NEW: New RCT showed noninferiority of TAVR to surgical AVR in symptomatic patients with severe AS at intermediate surgical risk.</td>
</tr>
</tbody>
</table>

In the PARTNER II (Placement of Aortic Transcatheter Valve II) RCT (62), which enrolled symptomatic patients with severe AS at intermediate risk (STS score ≥4%), there was no difference between TAVR and surgical AVR for the primary endpoint of all-cause death or disabling stroke at 2 years (HR: 0.89; 95% CI: 0.73 to 1.09; p=0.25). All-cause death occurred in 16.7% of those randomized to TAVR, compared with 18.0% of those treated with surgical AVR. Disabling stroke occurred in 6.2% of patients treated with TAVR and 6.3% of patients treated with surgical AVR (62).

In an observational study of the SAPIEN 3 valve (63), TAVR was performed in 1,077 intermediate-risk patients with severe symptomatic AS, with the transfemoral approach used in 88% of patients. At 1 year, the rate of all-cause death was 7.4%, disabling stroke occurred in 2%, reintervention was required in 1%, and moderate or severe paravalvular aortic regurgitation was seen in 2%. In a propensity score–matched comparison of SAPIEN 3 TAVR patients and PARTNER 2A surgical AVR patients, TAVR was both noninferior and superior to surgical AVR (propensity score pooled weighted proportion difference: –9.2%; 95% CI: –13.0 to –5.4; p<0.0001) (63,66).

When the choice of surgical AVR or TAVR is being made in an individual patient at intermediate surgical risk, other factors, such as vascular access, comorbid cardiac and noncardiac conditions that affect risk of either approach, expected functional status and survival after AVR, and patient values and preferences, must be considered. The choice of mechanical or bioprosthetic surgical AVR (Section 11 of this focused update) versus a TAVR is an important consideration and is influenced by durability considerations, because durability of transcatheter valves beyond 3 and 4 years is not yet known (65). TAVR has not been studied in patients with severe asymptomatic AS who have an intermediate or low surgical risk. In these patients, frequent clinical monitoring for symptom onset is appropriate, as discussed in Section 2.3.3 in the 2014 VHD guideline. The specific choice of a balloon-expandable valve or self-expanding valve depends on patient anatomy and other considerations (41,57).

<table>
<thead>
<tr>
<th>IIb</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percutaneous aortic balloon dilation may be considered as a bridge to surgical AVR or TAVR for symptomatic patients with severe AS.</td>
<td>2014 recommendation remains current.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III: No Benefit</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (61).</td>
<td>2014 recommendation remains current.</td>
</tr>
</tbody>
</table>
Figure 1. Choice of TAVR Versus Surgical AVR in the Patient With Severe Symptomatic AS

AS indicates aortic stenosis; AVR, aortic valve replacement; and TAVR, transcatheter aortic valve replacement.

7. Mitral Regurgitation

7.2. Stages of Chronic MR

In chronic secondary MR, the mitral valve leaflets and chords usually are normal (Table 2 in this focused update; Table 16 from the 2014 VHD guideline). Instead, MR is associated with severe LV dysfunction due to coronary artery disease (ischemic chronic secondary MR) or idiopathic myocardial disease (nonischemic chronic secondary MR). The abnormal and dilated left ventricle causes papillary muscle displacement, which in turn results in leaflet tethering with associated annular dilation that prevents adequate leaflet coaptation. There are instances in which both primary and secondary MR are present. The best therapy for chronic secondary MR is not clear because MR is only 1 component of the disease, with clinical outcomes also related to severe LV systolic dysfunction, coronary disease, idiopathic myocardial disease, or other diseases affecting the heart muscle. Thus, restoration of mitral valve competence is not curative. The optimal criteria for defining severe secondary MR have been controversial. In patients with secondary MR, some data suggest that, compared with primary MR, adverse outcomes are associated with a smaller calculated effective regurgitant orifice, possibly because of the fact that a smaller regurgitant volume may still represent a large regurgitant fraction in the presence of compromised LV systolic function (and low total stroke volume) added to the effects of elevated filling pressures. In addition, severity of secondary MR may increase over time because of the associated progressive LV systolic dysfunction and dysfunction due to adverse remodeling of the left ventricle. Finally, Doppler methods for calculations of effective regurgitant orifice area by the flow convergence method may underestimate severity because of the crescentic shape of the regurgitant orifice, and multiple parameters must be used to determine the severity of MR (67,68). Even so, on the basis of the criteria used for determination of
“severe” MR in RCTs of surgical intervention for secondary MR (69-72), the recommended definition of severe secondary MR is now the same as for primary MR (effective regurgitant orifice $\geq 0.4$ cm$^2$ and regurgitant volume $\geq 60$ mL), with the understanding that effective regurgitant orifice cutoff of $>0.2$ cm$^2$ is more sensitive and $>0.4$ cm$^2$ is more specific for severe MR. However, it is important to integrate the clinical and echocardiographic findings together to prevent unnecessary operation when the MR may not be as severe as documented on noninvasive studies.
Table 2. Stages of Secondary MR (Table 16 in the 2014 VHD Guideline)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Valve Anatomy</th>
<th>Valve Hemodynamics*</th>
<th>Associated Cardiac Findings</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At risk of MR</td>
<td>• Normal valve leaflets, chords, and annulus in a patient with coronary disease or cardiomyopathy</td>
<td>• No MR jet or small central jet area &lt;20% LA on Doppler • Small vena contracta &lt;0.30 cm</td>
<td>• Normal or mildly dilated LV size with fixed (infarction) or inducible (ischemia) regional wall motion abnormalities • Primary myocardial disease with LV dilation and systolic dysfunction</td>
<td>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy</td>
</tr>
<tr>
<td>B</td>
<td>Progressive MR</td>
<td>• Regional wall motion abnormalities with mild tethering of mitral leaflet • Annular dilation with mild loss of central coaptation of the mitral leaflets</td>
<td>• ERO &lt;0.40 cm²† • Regurgitant volume &lt;60 mL • Regurgitant fraction &lt;50%</td>
<td>• Regional wall motion abnormalities with reduced LV systolic function • LV dilation and systolic dysfunction due to primary myocardial disease</td>
<td>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy</td>
</tr>
<tr>
<td>C</td>
<td>Asymptomatic severe MR</td>
<td>• Regional wall motion abnormalities and/or LV dilation with severe tethering of mitral leaflet • Annular dilation with severe loss of central coaptation of the mitral leaflets</td>
<td>• ERO ≥0.40 cm²† • Regurgitant volume ≥60 mL • Regurgitant fraction ≥50%</td>
<td>• Regional wall motion abnormalities with reduced LV systolic function • LV dilation and systolic dysfunction due to primary myocardial disease</td>
<td>Symptoms due to coronary ischemia or HF may be present that respond to revascularization and appropriate medical therapy</td>
</tr>
<tr>
<td>D</td>
<td>Symptomatic severe MR</td>
<td>• Regional wall motion abnormalities and/or LV dilation with severe tethering of mitral leaflet • Annular dilation with severe loss of central coaptation of the mitral leaflets</td>
<td>• ERO ≥0.40 cm²† • Regurgitant volume ≥60 mL • Regurgitant fraction ≥50%</td>
<td>• Regional wall motion abnormalities with reduced LV systolic function • LV dilation and systolic dysfunction due to primary myocardial disease</td>
<td>HF symptoms due to MR persist even after revascularization and optimization of medical therapy • Decreased exercise tolerance • Exertional dyspnea</td>
</tr>
</tbody>
</table>

*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.†The measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO because of the crescentic shape of the proximal convergence.

2D indicates 2-dimensional; ERO, effective regurgitant orifice; HF, heart failure; LA, left atrium; LV, left ventricular; MR, mitral regurgitation; and TTE, transthoracic echocardiogram.
### 7.3. Chronic Primary MR

#### 7.3.3. Intervention: Recommendations

<table>
<thead>
<tr>
<th>Recommendations for Primary MR Intervention</th>
<th>Comment/Rationale</th>
<th>COR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitral valve surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and LVEF greater than 30% (73-75).</td>
<td>2014 recommendation remains current.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Mitral valve surgery is recommended for asymptomatic patients with chronic severe primary MR and LV dysfunction (LVEF 30% to 60% and/or left ventricular end-systolic diameter [LVESD] ≥40 mm, stage C2) (76-82).</td>
<td>2014 recommendation remains current.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Mitral valve repair is recommended in preference to MVR when surgical treatment is indicated for patients with chronic severe primary MR limited to the posterior leaflet (83-99).</td>
<td>2014 recommendation remains current.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Mitral valve repair is recommended in preference to MVR when surgical treatment is indicated for patients with chronic severe primary MR involving the anterior leaflet or both leaflets when a successful and durable repair can be accomplished (84,89,95,100-104).</td>
<td>2014 recommendation remains current.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Concomitant mitral valve repair or MVR is indicated in patients with chronic severe primary MR undergoing cardiac surgery for other indications (105).</td>
<td>2014 recommendation remains current.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Mitral valve repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved LV function (LVEF &gt;60% and LVESD &lt;40 mm) in whom the likelihood of a successful and durable repair without residual MR is greater than 95% with an expected mortality rate of less than 1% when performed at a Heart Valve Center of Excellence (101,106-112).</td>
<td>2014 recommendation remains current.</td>
<td>IIa</td>
<td>B</td>
</tr>
<tr>
<td>Mitral valve surgery is reasonable for asymptomatic patients with chronic severe primary MR (stage C1) and preserved LV function (LVEF &gt;60% and LVESD &lt;40 mm) with a progressive increase in LV</td>
<td>NEW: Patients with severe MR who reach an EF ≤60% or LVESD ≥40 have already developed LV systolic function.</td>
<td>IIa</td>
<td>C-LD</td>
</tr>
</tbody>
</table>
There is concern that the presence of MR leads to progressively more severe MR (“mitral regurgitation begets mitral regurgitation”). The concept is that the initial level of MR causes LV dilatation, which increases stress on the mitral apparatus, causing further damage to the valve apparatus, more severe MR and further LV dilatation, thus initiating a perpetual cycle of ever-increasing LV volumes and MR. Longstanding volume overload leads to irreversible LV dysfunction and a poorer prognosis. Patients with severe MR who develop an EF ≤60% or LVESD ≥40 have already developed LV systolic dysfunction (112-115). One study has suggested that for LV function and size to return to normal after mitral valve repair, the left ventricular ejection fraction (LVEF) should be >64% and LVESD <37 mm (112). Thus, when longitudinal follow-up demonstrates a progressive decrease of EF toward 60% or a progressive increase in LVESD approaching 40 mm, it is reasonable to consider intervention. Nonetheless, the asymptomatic patient with stable LV dimensions and excellent exercise capacity can be safely observed (116).

<table>
<thead>
<tr>
<th>Level</th>
<th>Code</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B</td>
<td>Mitral valve repair is reasonable for asymptomatic patients with chronic severe nonrheumatic primary MR (stage C1) and preserved LV function (LVEF &gt;60% and LVESD &lt;40 mm) in whom there is a high likelihood of a successful and durable repair with 1) new onset of AF or 2) resting pulmonary hypertension (pulmonary artery systolic arterial pressure &gt;50 mm Hg) (111,117-123).</td>
</tr>
<tr>
<td>IIa</td>
<td>C</td>
<td>Concomitant mitral valve repair is reasonable in patients with chronic moderate primary MR (stage B) when undergoing cardiac surgery for other indications.</td>
</tr>
<tr>
<td>IIb</td>
<td>C</td>
<td>Mitral valve surgery may be considered in symptomatic patients with chronic severe primary MR and LVEF less than or equal to 30% (stage D).</td>
</tr>
<tr>
<td>IIb</td>
<td>B</td>
<td>Transcatheter mitral valve repair may be considered for severely symptomatic patients (NYHA class III to IV) with chronic severe primary MR (stage D) who have favorable anatomy for the repair procedure and a reasonable life expectancy but who have a prohibitive surgical risk because of severe comorbidities and remain severely symptomatic despite optimal GDMT for heart failure (HF) (124).</td>
</tr>
<tr>
<td>III:</td>
<td>B</td>
<td>MVR should not be performed for the treatment of isolated severe primary MR limited to less than one half of the posterior leaflet unless mitral valve repair has been attempted and was unsuccessful (84,89,90,95).</td>
</tr>
</tbody>
</table>

2014 recommendation remains current.
**7.4. Chronic Secondary MR**

**7.4.3. Intervention: Recommendations**

Chronic severe secondary MR adds volume overload to a decompensated LV and worsens prognosis. However, there are only sparse data to indicate that correcting MR prolongs life or even improves symptoms over an extended time. Percutaneous mitral valve repair provides a less invasive alternative to surgery but is not approved for clinical use for this indication in the United States (70,72,125-127). The results of RCTs examining the efficacy of percutaneous mitral valve repair in patients with secondary MR are needed to provide information on this patient group (128,129).

AF indicates atrial fibrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; EF, ejection fraction; ERO, effective regurgitant orifice; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; MV, mitral valve; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; and Rx, therapy.
### Recommendations for Secondary MR Intervention

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C</td>
<td>Mitral valve surgery is reasonable for patients with chronic severe secondary MR (stages C and D) who are undergoing CABG or AVR.</td>
<td>2014 recommendation remains current.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>It is reasonable to choose chordal-sparing MVR over downsized annuloplasty repair if operation is considered for severely symptomatic patients (NYHA class III to IV) with chronic severe ischemic MR (stage D) and persistent symptoms despite GDMT for HF (69,70,125,127,130-139).</td>
<td>NEW: An RCT has shown that mitral valve repair is associated with a higher rate of recurrence of moderate or severe MR than that associated with mitral valve replacement (MVR) in patients with severe, symptomatic, ischemic MR, without a difference in mortality rate at 2 years’ follow-up.</td>
</tr>
</tbody>
</table>

#### In an RCT of mitral valve repair versus MVR in 251 patients with severe ischemic MR, mortality rate at 2 years was 19.0% in the repair group and 23.2% in the replacement group (p=0.39) (70). There was no difference between repair and MVR in LV remodeling. The rate of recurrence of moderate or severe MR over 2 years was higher in the repair group than in the replacement group (58.8% versus 3.8%, p<0.001), leading to a higher incidence of HF and repeat hospitalizations in the repair group (70). The high mortality rate at 2 years in both groups emphasizes the poor prognosis of secondary MR. The lack of apparent benefit of valve repair over valve replacement in secondary MR versus primary MR highlights that primary and secondary MR are 2 different diseases (69,125,127,130-139).

| IIb  | B    | Mitral valve repair or replacement may be considered for severely symptomatic patients (NYHA class III to IV) with chronic severe secondary MR (stage D) who have persistent symptoms despite optimal GDMT for HF (125,127,130-140). | 2014 recommendation remains current.                                                |
| IIb  | B-R  | In patients with chronic, moderate, ischemic MR (stage B) undergoing CABG, the usefulness of mitral valve repair is uncertain (71,72). | MODIFIED: LOE updated from C to B-R. The 2014 recommendation supported mitral valve repair in this group of patients. An RCT showed no clinical benefit of mitral repair in this population of patients, with increased risk of postoperative complications. |

#### In an RCT of 301 patients with moderate ischemic MR undergoing CABG, mortality rate at 2 years was 10.6% in the group undergoing CABG alone and 10.0% in the group undergoing CABG plus mitral valve repair (HR in the combined-procedure group = 0.90; 95% CI: 0.45 to 1.83; p=0.78) (71). There was a higher rate of moderate or severe residual MR in the CABG-alone group (32.3% versus 11.2%; p<0.001), even though LV reverse remodeling was similar in both groups (71). Although rates of hospital readmission and overall serious adverse events were similar in the 2 groups, neurological events and...
supraventricular arrhythmias were more frequent with combined CABG and mitral valve repair. Thus, only weak evidence to support mitral repair for moderate secondary MR at the time of other cardiac surgery is currently available (71,72).

11. Prosthetic Valves

11.1. Evaluation and Selection of Prosthetic Valves

11.1.2. Intervention: Recommendations

<p>| Recommendations for Intervention of Prosthetic Valves |</p>
<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-LD</td>
<td>The choice of type of prosthetic heart valve should be a shared decision-making process that accounts for the patient's values and preferences and includes discussion of the indications for and risks of anticoagulant therapy and the potential need for and risk associated with reintervention (141-146).</td>
<td>MODIFIED: LOE updated from C to C-LD. In choosing the type of prosthetic valve, the potential need for and risk of “reoperation” was updated to risk associated with “reintervention.” The use of a transcatheter valve-in-valve procedure may be considered for decision making on the type of valve, but long-term follow-up is not yet available, and some bioprosthetic valves, particularly the smaller-sized valves, will not be suitable for a valve-in-valve replacement. Multiple other factors to be considered in the choice of type of valve for an individual patient; these factors are outlined in the text. More emphasis has been placed on shared decision making between the caregiver and patient.</td>
</tr>
</tbody>
</table>

The choice of valve prosthesis in an individual patient is based on consideration of several factors, including valve durability, expected hemodynamics for a specific valve type and size, surgical or interventional risk, the potential need for long-term anticoagulation, and patient values and preferences (147-149). Specifically, the trade-off between the potential need for reintervention for bioprosthetic structural valve deterioration and the risk associated with long-term anticoagulation should be discussed in detail with the patient (142-145). Some patients prefer to avoid repeat surgery and are willing to accept the risks and inconvenience of lifelong anticoagulant therapy. Other patients are unwilling to consider long-term VKA therapy because of the inconvenience of monitoring, the attendant dietary and medication interactions, and the need to restrict participation in some types of athletic activity. Several other factors must be taken into consideration in a decision about the type of valve prosthesis, including other comorbidities (Table 3). Age is important because the incidence of structural deterioration of a bioprosthesis is greater in younger patients, but the risk of bleeding from anticoagulation is higher in older patients (142,143,150,151). A mechanical valve might be a prudent choice for patients for whom a second
surgical procedure would be high risk (i.e., those with prior radiation therapy or a porcelain aorta). In patients with shortened longevity and/or multiple comorbidities, a bioprosthesis would be most appropriate. In women who desire subsequent pregnancy, the issue of anticoagulation during pregnancy is an additional consideration (Section 13 in the 2014 VHD guideline). The availability of transcatheter valve-in-valve replacement is changing the dynamics of the discussion of the trade-offs between mechanical and bioprosthetic valves, but extensive long-term follow-up of transcatheter valves is not yet available, and not all bioprostheses are suitable for a future valve-in-valve procedure (152-154). A valve-in-valve procedure will always require insertion of a valve smaller than the original bioprosthesis, and patient–prosthesis mismatch is a potential problem, depending on the size of the initial prosthesis. Irrespective of whether a mechanical valve or bioprosthesis is placed, a root enlargement should be considered in patients with a small annulus to ensure that there is not an initial patient–prosthesis mismatch.

<table>
<thead>
<tr>
<th>I</th>
<th>C</th>
<th>A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is contraindicated, cannot be managed appropriately, or is not desired.</th>
<th>2014 recommendation remains current.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>An aortic or mitral mechanical prosthesis is reasonable for patients less than 50 years of age who do not have a contraindication to anticoagulation (141,149,151,155-157).</td>
<td>MODIFIED: LOE updated from B to B-NR. The age limit for mechanical prosthesis was lowered from 60 to 50 years of age.</td>
</tr>
</tbody>
</table>

Patients <50 years of age at the time of valve implantation incur a higher and earlier risk of bioprosthetic valve deterioration (141,149,151,155-157). Overall, the predicted 15-year risk of needing reoperation because of structural deterioration is 22% for patients 50 years of age, 30% for patients 40 years of age, and 50% for patients 20 years of age, although it is recognized that all bioprostheses are not alike in terms of durability (151). Anticoagulation with a VKA can be accomplished with acceptable risk in the majority of patients <50 years of age, particularly in compliant patients with appropriate monitoring of International Normalized Ratio (INR) levels. Thus, the balance between valve durability versus risk of bleeding and thromboembolic events favors the choice of a mechanical valve in patients <50 years of age, unless anticoagulation is not desired, cannot be monitored, or is contraindicated. (See the first Class I recommendation for additional discussion).

| IIa   | B-NR               | For patients between 50 and 70 years of age, it is reasonable to individualize the choice of either a mechanical or bioprosthetic valve prosthesis on the basis of individual patient factors and preferences, after full discussion of the trade-offs involved (141-145,157-160). | MODIFIED: Uncertainty exists about the optimum type of prosthesis (mechanical or bioprosthetic) for patients 50 to 70 years of age. There are conflicting data on survival benefit of mechanical versus bioprosthetic valves in this age group, with equivalent stroke and thromboembolic outcomes. Patients receiving a mechanical valve incur greater risk of... |

See Online Data Supplement 20 (Updated From 2014 VHD Guideline)
bleeding, and those undergoing bioprosthetic valve replacement more often require repeat valve surgery.

Uncertainty and debate continue about which type of prosthesis is appropriate for patients 50 to 70 years of age. RCTs incorporating most-recent-generation valve types are lacking. Newer-generation tissue prostheses may show greater freedom from structural deterioration, specifically in the older individual, although a high late mortality rate in these studies may preclude recognition of valve dysfunction (147,149-151,161). The risks of bleeding and thromboembolism with mechanical prostheses are now low, especially in compliant patients with appropriate INR monitoring. Observational and propensity-matched data vary, and valve-in-valve technology has not previously been incorporated into rigorous decision analysis. Several studies have shown a survival advantage with a mechanical prosthesis in this age group (142,157-159). Alternatively, large retrospective observational studies have shown similar long-term survival in patients 50 to 69 years of age undergoing mechanical versus bioprosthetic valve replacement (143-145,160). In general, patients with mechanical valve replacement experience a higher risk of bleeding due to anticoagulation, whereas individuals who receive a bioprosthetic valve replacement experience a higher rate of reoperation due to structural deterioration of the prosthesis and perhaps a decrease in survival (142,143,145-160,162). Stroke rate appears to be similar in patients undergoing either mechanical or bioprosthetic AVR, but it is higher with mechanical than with bioprosthetic MVR (142-145,157). There are several other factors to consider in the choice of type of valve prosthesis (Table 3). Ultimately, the choice of mechanical versus bioprosthetic valve replacement for all patients, but especially for those between 50 and 70 years of age, is a shared decision-making process that must account for the trade-offs between durability (and the need for reintervention), bleeding, and thromboembolism (143,145-160,162).

| IIa | B | A bioprosthesis is reasonable for patients more than 70 years of age (163-166). | 2014 recommendation remains current. |
| IIb | C | Replacement of the aortic valve by a pulmonary autograft (the Ross procedure), when performed by an experienced surgeon, may be considered for young patients when VKA anticoagulation is contraindicated or undesirable (167-169). | 2014 recommendation remains current. |

Table 3. Factors Used for Shared Decision Making About Type of Valve Prosthesis

<table>
<thead>
<tr>
<th>Favor Mechanical Prosthesis</th>
<th>Favor Bioprosthesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;50 y</td>
<td>Age &gt;70 y</td>
</tr>
<tr>
<td>• Increased incidence of structural deterioration with bioprosthesis (15-y risk: 30% for age 40 y, 50% for age 20 y)</td>
<td>• Low incidence of structural deterioration (15-y risk: &lt;10% for age &gt;70 y)</td>
</tr>
<tr>
<td>• Lower risk of anticoagulation complications</td>
<td>• Higher risk of anticoagulation complications</td>
</tr>
<tr>
<td>Patient preference (avoid risk of reintervention)</td>
<td>Patient preference (avoid risk and inconvenience of anticoagulation and absence of valve sounds)</td>
</tr>
<tr>
<td>Low risk of long-term anticoagulation</td>
<td>High risk of long-term anticoagulation</td>
</tr>
<tr>
<td>Compliant patient with either home monitoring or close access to INR monitoring</td>
<td>Limited access to medical care or inability to regulate VKA</td>
</tr>
<tr>
<td>Other indication for long-term anticoagulation (e.g., AF)</td>
<td>Access to surgical centers with low reoperation mortality rate</td>
</tr>
</tbody>
</table>

© 2017 by the American Heart Association, Inc., and the American College of Cardiology Foundation
High-risk reintervention (e.g., porcelain aorta, prior radiation therapy)

Small aortic root size for AVR (may preclude valve-in-valve procedure in future).

AF indicates atrial fibrillation; AVR, aortic valve replacement; INR, International Normalized Ratio; and VKA, vitamin K antagonist.

11.2. Antithrombotic Therapy for Prosthetic Valves

11.2.1. Diagnosis and Follow-Up

Effective oral antithrombotic therapy in patients with mechanical heart valves requires continuous VKA anticoagulation with an INR in the target range. It is preferable to specify a single INR target for each patient and to recognize that the acceptable range includes 0.5 INR units on each side of this target. A specific target is preferable because it reduces the likelihood of patients having INR values consistently near the upper or lower boundary of the range. In addition, fluctuations in INR are associated with an increased incidence of complications in patients with prosthetic heart valves, so patients and caregivers should strive to attain the specific INR value (170,171). The effects of VKA anticoagulation vary with the specific drug, absorption, various foods, alcohol, other medications, and changes in liver function. Most of the published studies of VKA therapy used warfarin, although other coumarin agents are used on a worldwide basis. In clinical practice, a program of patient education and close surveillance by an experienced healthcare professional, with periodic INR determinations, is necessary. Patient monitoring through dedicated anticoagulation clinics results in lower complication rates than those seen with standard care and is cost effective because of lower rates of bleeding and hemorrhagic complications (172,173). Periodic direct patient contact and telephone encounters (174) with the anticoagulation clinic pharmacists (175,176) or nurses are equally effective in reducing complication rates (177). Self-monitoring with home INR measurement devices is another option for educated and motivated patients.

11.2.2. Medical Therapy: Recommendations

| Recommendations for Antithrombotic Therapy for Patients with Prosthetic Heart Valves |
|-----------------|-----------------|-----------------|
| COR | LOE | Recommendations | Comment/Rationale |
| I | A | Anticoagulation with a VKA and INR monitoring is recommended in patients with a mechanical prosthetic valve (178-183). | 2014 recommendation remains current. |
| I | B | Anticoagulation with a VKA to achieve an INR of 2.5 is recommended for patients with a mechanical bileaflet or current-generation single-tilting disc AVR and no risk factors for thromboembolism (178,184-186). | 2014 recommendation remains current. |
Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in patients with a mechanical AVR and additional risk factors for thromboembolic events (AF, previous thromboembolism, LV dysfunction, or hypercoagulable conditions) or an older-generation mechanical AVR (such as ball-in-cage) (178).

Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in patients with a mechanical MVR (178,187,188).

Aspirin 75 mg to 100 mg daily is recommended in addition to anticoagulation with a VKA in patients with a mechanical valve prosthesis (178,189,190).

Aspirin 75 mg to 100 mg per day is reasonable in all patients with a bioprosthetic aortic or mitral valve (178,191-194).

Anticoagulation with a VKA to achieve an INR of 2.5 is reasonable for at least 3 months and for as long as 6 months after surgical bioprosthetic MVR or AVR in patients at low risk of bleeding (195-197).

MODIFIED: LOE updated from C to B-NR.
Anticoagulation for all surgical tissue prostheses was combined into 1 recommendation, with extension of the duration of anticoagulation up to 6 months. Stroke risk and mortality rate are lower in patients who receive anticoagulation for up to 6 months after implantation of a tissue prosthesis than in those who have do not have anticoagulation. Anticoagulation for a tissue prosthesis is also supported by reports of valve thrombosis for patients undergoing bioprosthetic surgical AVR or MVR, a phenomenon that may be warfarin responsive.

Many patients who undergo implantation of a surgical bioprosthetic MVR or AVR will not require life-long anticoagulation. However, there is an increased risk of ischemic stroke early after operation, particularly in the first 90 to 180 days after operation with either a bioprosthetic AVR or MVR (198-205). Anticoagulation early after valve implantation is intended to decrease the risk of thromboembolism until the prosthetic valve is fully endothelialized. The potential benefit of anticoagulation therapy must be weighed against the risk of bleeding. In a nonrandomized study, patients with a bioprosthetic MVR who received anticoagulation had a lower rate of thromboembolism than those who did not receive therapy with VKA (2.5% per year with anticoagulation versus 3.9% per year without anticoagulation; p=0.05) (193). Even with routine
anticoagulation early after valve surgery, the incidence of ischemic stroke within the first 30 postoperative days was higher after replacement with a biological prosthesis (4.6%±1.5%) than after mitral valve repair (1.5%±0.4%) or replacement with a mechanical prosthesis (1.3%±0.8%; p<0.001) (206). Small RCTs have not established a convincing net benefit of anticoagulation after implantation of a bioprosthetic AVR (205,207); however, a large observational Danish registry demonstrated a lower risk of stroke and death with VKA extending up to 6 months, without a significantly increased bleeding risk (197). Concern has also been raised about a higher-than-recognized incidence of bioprosthetic valve thrombosis leaflets after surgical valve replacement (196). Thus, anticoagulation with an INR target of 2.5 may be reasonable for at least 3 months and perhaps for as long as 6 months after implantation of a surgical bioprosthetic MVR or AVR in patients at low risk of bleeding. Compared with oral anticoagulation alone, the addition of dual-antiplatelet therapy results in at least a 2- to 3-fold increase in bleeding complications, and the recommendations on triple therapy should be followed (208).

IIb B-R

A lower target INR of 1.5 to 2.0 may be reasonable in patients with mechanical On-X AVR and no thromboembolic risk factors (209).

NEW: A lower target INR was added for patients with a mechanical On-X AVR and no thromboembolic risk factors treated with warfarin and low-dose aspirin. A single RCT of lower- versus standard-intensity anticoagulation in patients undergoing On-X AVR showed equivalent outcomes, but the bleeding rate in the control group was unusually high.

See Online Data Supplement 6.

In patients without risk factors who receive a mechanical On-X aortic heart valve (On-X Life Technologies Inc., Austin, Texas), a lower INR target of 1.5 to 2.0 (in conjunction with aspirin 81 mg daily) may be considered for long-term management, beginning 3 months after surgery. Warfarin dosing is targeted to an INR of 2.5 (range 2.0 to 3.0) for the first 3 months after surgery (209). This is based on a single RCT of lower- versus standard-intensity anticoagulation in patients undergoing On-X AVR, showing equivalent outcomes. The control arm did have a bleeding rate of 3.2% per patient-year (209).

IIb B-NR

Anticoagulation with a VKA to achieve an INR of 2.5 may be reasonable for at least 3 months after TAVR in patients at low risk of bleeding (203,210,211).

NEW: Studies have shown that valve thrombosis may develop in patients after TAVR, as assessed by multidetector computerized tomographic scanning. This valve thrombosis occurs in patients who received antiplatelet therapy alone but not in patients who were treated with VKA.

See Online Data Supplement 6.

Several studies have demonstrated the occurrence of prosthetic valve thrombosis after TAVR, as assessed by multidetector computerized tomography, which shows reduced leaflet motion and hypo-attenuating opacities. The incidence of this finding has varied from 7% to 40%, depending on whether the patients are from a clinical trial or registry and whether some patients received anticoagulation with VKA (203,210,211). Up to 18% of patients with a thrombus formation developed clinically overt obstructive
valve thrombosis (210). A post-TAVR antithrombotic regimen without warfarin seems to predispose patients to the development of valve thrombosis (203,210). The utility of the DOACs in this population is unknown at this time.

### 11.3. Bridging Therapy for Prosthetic Valves

#### 11.3.1. Diagnosis and Follow-Up

The management of patients with mechanical heart valves for whom interruption of anticoagulation therapy is needed for diagnostic or surgical procedures should take into account the type of procedure; bleeding risk; patient risk factors; and type, location, and number of heart valve prostheses.

#### 11.3.2. Medical Therapy: Recommendations

<table>
<thead>
<tr>
<th>Recommendations for Bridging Therapy for Prosthetic Valves</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>I C</td>
<td></td>
<td></td>
<td>Continuation of VKA anticoagulation with a therapeutic INR is recommended in patients with mechanical heart valves undergoing minor procedures (such as dental extractions or cataract removal) where bleeding is easily controlled.</td>
<td>2014 recommendation remains current.</td>
</tr>
<tr>
<td>I C</td>
<td></td>
<td></td>
<td>Temporary interruption of VKA anticoagulation, without bridging agents while the INR is subtherapeutic, is recommended in patients with a bileaflet mechanical AVR and no other risk factors for thrombosis who are undergoing invasive or surgical procedures.</td>
<td>2014 recommendation remains current.</td>
</tr>
<tr>
<td>IIa C-LD</td>
<td></td>
<td></td>
<td>Bridging anticoagulation therapy during the time interval when the INR is subtherapeutic preoperatively is reasonable on an individualized basis, with the risks of bleeding weighed against the benefits of thromboembolism prevention, for patients who are undergoing invasive or surgical</td>
<td>MODIFIED: COR updated from I to IIa, LOE updated from C to C-LD. RCTs of bridging anticoagulant therapy versus no bridging therapy for patients with AF who do not have a mechanical heart valve have shown higher risk of bleeding without a</td>
</tr>
</tbody>
</table>

See Online Data Supplement 21
Nishimura, et al.
2017 AHA/ACC Focused Update on VHD

(Updated From 2014 VHD Guideline) procedures with a 1) mechanical AVR and any thromboembolic risk factor, 2) older-generation mechanical AVR, or 3) mechanical MVR (199,214,215).

change in incidence of thromboembolic events. This may have implications for bridging anticoagulation therapy for patients with prosthetic valves.

“Bridging” therapy with either intravenous unfractionated heparin or low-molecular-weight heparin has evolved empirically to reduce thromboembolic events during temporary interruption of oral anticoagulation in higher-risk patients, such as those with a mechanical MVR or AVR and additional risk factors for thromboembolism (e.g., AF, previous thromboembolism, hypercoagulable condition, older-generation mechanical valves [ball-cage or tilting disc], LV systolic dysfunction, or >1 mechanical valve) (214).

When interruption of oral VKA therapy is deemed necessary, the agent is usually stopped 3 to 4 days before the procedure (so the INR falls to <1.5 for major surgical procedures) and is restarted postoperatively as soon as bleeding risk allows, typically 12 to 24 hours after surgery. Bridging anticoagulation with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin is started when the INR falls below the therapeutic threshold (i.e., 2.0 or 2.5, depending on the clinical context), usually 36 to 48 hours before surgery, and is stopped 4 to 6 hours (for intravenous unfractionated heparin) or 12 hours (for subcutaneous low-molecular-weight heparin) before the procedure.

There are no randomized comparative-effectiveness trials evaluating a strategy of bridging versus no bridging in adequate numbers of patients with prosthetic heart valves needing temporary interruption of oral anticoagulant therapy, although such studies are ongoing. The evidence used to support bridging therapy derives from cohort studies with poor or no comparator groups (214,215). In patient groups other than those with mechanical heart valves, increasing concerns have surfaced that bridging therapy exposes patients to higher bleeding risks without reducing the risk of thromboembolism (199). Accordingly, decisions about bridging should be individualized and should account for the trade-offs between thrombosis and bleeding.

IIa C Administration of fresh frozen plasma or prothrombin complex concentrate is reasonable in patients with mechanical valves receiving VKA therapy who require emergency noncardiac surgery or invasive procedures. 2014 recommendation remains current.
11.6. Acute Mechanical Prosthetic Valve Thrombosis

11.6.1. Diagnosis and Follow-Up: Recommendation

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>B-NR</td>
<td>Urgent evaluation with multimodality imaging is indicated in patients with suspected mechanical prosthetic valve thrombosis to assess valvular function, leaflet motion, and the presence and extent of thrombus (216-222).</td>
<td>MODIFIED: LOE updated to B-NR. Multiple recommendations for imaging in patients with suspected mechanical prosthetic valve thrombosis were combined into a single recommendation. Multimodality imaging with transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), fluoroscopy, and/or computed tomography (CT) scanning may be more effective than one imaging modality alone in detecting and characterizing valve thrombosis. Different imaging modalities are necessary because valve function, leaflet motion, and extent of thrombus should all be evaluated.</td>
</tr>
</tbody>
</table>

Obstruction of mechanical prosthetic heart valves may be caused by thrombus formation, pannus ingrowth, or a combination of both (216). The presentation can vary from mild dyspnea to severe acute pulmonary edema. Urgent diagnosis, evaluation, and therapy are indicated because rapid deterioration can occur if there is thrombus causing malfunction of leaflet opening. The examination may demonstrate a stenotic murmur and muffled closing clicks, and further diagnostic evaluation is required. TTE and/or TEE should be performed to examine valve function and the status of the left ventricle (216). Leaflet motion should be visualized with TEE (particularly for a mitral prosthesis) or with CT or fluoroscopy (for an aortic prosthesis) (217-223). Prolonged periods of observation under fluoroscopy or TEE may be required to diagnose intermittent obstruction. The presence and quantification of thrombus should be evaluated by either TEE or CT (217,223). Differentiation of valve dysfunction due to thrombus versus fibrous tissue ingrowth (pannus) is challenging because the clinical presentations are similar. Thrombus is more likely with a history of inadequate anticoagulation, a more acute onset of valve dysfunction, and a shorter time between surgery and symptoms. Mechanical prosthetic valve thrombosis is diagnosed by an abnormally elevated gradient across the prosthesis, with either limited leaflet motion or attached mobile densities consistent with thrombus, or both. Vegetations from IE must be excluded. If obstruction is present with normal leaflet motion and no thrombus, either patient–prosthesis mismatch or pannus formation is present (or both). Thrombus formation on the valve in the absence of obstruction can also occur and is associated with an increased risk of embolic events.
11.6.3. Intervention: Recommendation

<table>
<thead>
<tr>
<th>Recommendation for Mechanical Prosthetic Valve Thrombosis Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td>I</td>
</tr>
</tbody>
</table>

See Online Data Supplement 7 and 7A.

Mechanical left-sided prosthetic valve obstruction is a serious complication with high mortality and morbidity and requires urgent therapy with either fibrinolytic therapy or surgical intervention. There has not been an RCT comparing the 2 interventions, and the literature consists of multiple case reports, single-center studies, multicenter studies, registry reports, and meta-analyses—with all the inherent problems of differing definitions of initial diagnosis, fibrinolytic regimens, and surgical expertise (224-235) (Data Supplement 7A). The overall 30-day mortality rate with surgery is 10% to 15%, with a lower mortality rate of <5% in patients with NYHA class I/II symptoms (225,226,232-234). The results of fibrinolytic therapy before 2013 showed an overall 30-day mortality rate of 7% and hemodynamic success rate of 75% but a thromboembolism rate of 13% and major bleeding rate of 6% (intracerebral hemorrhage, 3%) (224-230). However, recent reports using an echocardiogram-guided slow-infusion low-dose fibrinolytic protocol have shown success rates >90%, with embolic event rates <2% and major bleeding rates <2% (231,235). This fibrinolytic therapy regimen can be successful even in patients with advanced NYHA class and larger-sized thrombi. On the basis of these findings, the writing group recommends urgent initial therapy for prosthetic mechanical valve thrombosis resulting in symptomatic obstruction, but the decision for surgery versus fibrinolysis is dependent on individual patient characteristics that would support the recommendation of one treatment over the other, as shown in Table 4, as well as the experience and capabilities of the institution. All factors must be taken into consideration in a decision about therapy, and the decision-making process shared between the caregiver and patient. Final definitive plans should be based on the initial response to therapy.

Table 4. Fibrinolysis Versus Surgery for Prosthetic Valve Thrombosis

<table>
<thead>
<tr>
<th>Favor Surgery</th>
<th>Favor Fibrinolysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Readily available surgical expertise</td>
<td>No surgical expertise available</td>
</tr>
<tr>
<td>Low surgical risk</td>
<td>High surgical risk</td>
</tr>
<tr>
<td>Contraindication to fibrinolysis</td>
<td>No contraindication to fibrinolysis</td>
</tr>
<tr>
<td>Recurrent valve thrombosis</td>
<td>First-time episode of valve thrombosis</td>
</tr>
</tbody>
</table>
11.7. Prosthetic Valve Stenosis

Surgical reoperation to replace the stenotic prosthetic heart valve has been the mainstay treatment modality. Although it is associated with acceptable mortality and morbidity in the current era, it remains a serious clinical event and carries a higher risk than the initial surgery. Reoperation is usually required for moderate-to-severe prosthetic dysfunction (structural and nonstructural), dehiscence, and prosthetic valve endocarditis. Reoperation may also be needed for recurrent thromboembolism, severe intravascular hemolysis, severe recurrent bleeding from anticoagulant therapy, and thrombosed prosthetic valves. In 2015, catheter-based therapy with transcatheter valve-in-valve emerged as an acceptable alternative to treat high- and extreme-risk patients with bioprosthetic aortic valve stenosis (stenosis, insufficiency, or combined) in the absence of active IE (154).

Symptomatic prosthetic valve stenosis secondary to thrombosis is observed predominantly with mechanical valves. Mechanical prosthetic valve thrombosis and its treatment are discussed in Section 11.6. Bioprosthetic valve thrombosis can result in thromboembolic events or obstruction. In a pooled analysis from 3 studies including 187 patients who underwent either TAVR or bioprosthetic surgical AVR, reduced leaflet motion was noted on 4-dimensional volume-rendered CT imaging in 21% of patients (203). In this small cohort, therapeutic anticoagulation with warfarin was associated with lower incidence of reduced leaflet motion than that associated with dual antiplatelet therapy, as well as more restoration of leaflet motion on follow-up CT imaging. Subclinical leaflet thrombosis was identified as the likely cause on the basis of advanced and characteristic imaging findings (203). As outlined by the U.S. Food and Drug Administration, most cases of reduced leaflet motion (which occurs in 10% to 40% of TAVR patients and 8% to 12% of surgical AVR patients) were discovered by advanced imaging studies in asymptomatic patients (236). The diagnosis of bioprosthetic valve thrombosis remains difficult, with most suspected bioprosthetic valve thrombosis based on increased transvalvular gradients.

In some patients, the size of the prosthetic valve that can be implanted results in inadequate blood flow to meet the metabolic demands of the patient, even when the prosthetic valve itself is functioning normally. This situation, called patient–prosthesis mismatch (defined as an indexed effective orifice area \( \leq 0.85 \text{ cm}^2/\text{m}^2 \) for aortic valve prostheses), is a predictor of a high transvalvular gradient, persistent LV hypertrophy, and an increased rate of cardiac events after AVR (237,238). The impact of a relatively small valve area is most...
noticeable with severe patient–prosthesis mismatch, defined as an indexed orifice area <0.65 cm²/m². Patient–prosthesis mismatch is especially detrimental in patients with reduced LVEF and may decrease the likelihood of resolution of symptoms and improvement in LVEF. Patient–prosthesis mismatch can be avoided or reduced by choice of a valve prosthesis that will have an adequate indexed orifice area, determined by the patient’s body size and annular dimension. In some cases, annular enlargement or other approaches may be needed to allow implantation of an appropriately sized valve or avoidance of a prosthetic valve. With bileaflet mechanical valves, patterns of blood flow are complex, and significant pressure recovery may be present; this may result in a high velocity across the prosthesis that should not be mistaken for prosthetic valve stenosis or patient–prosthesis mismatch, particularly in those with small aortic diameters.

### 11.7.3. Intervention: Recommendation

<table>
<thead>
<tr>
<th>Recommendations for Prosthetic Valve Stenosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>**COR</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>IIa</td>
</tr>
</tbody>
</table>

There are no medical therapies known to prevent or treat bioprosthetic valve degeneration. However, bioprosthetic valve thrombosis may present with slowly progressive stenosis months to years after implantation. Small, nonrandomized studies support the use of VKAs to treat patients with bioprosthetic valve thrombosis after both surgical AVR and TAVR (203,242-246). In a retrospective single-center report of 31 patients with bioprosthetic valve thrombosis who were initially treated with either a VKA or surgery/thrombolysis, VKA-treated patients had 87% thrombus resolution and experienced hemodynamic and clinical improvement comparable to surgery/thrombolysis, with no complications (244). Notably, in that case series, the peak incidence of bioprosthetic valve thrombosis occurred 13 to 24 months after implantation, with the longest interval being 6.5 years (244). Surgery or thrombolysis may still be needed for patients who are hemodynamically unstable or have advanced and refractory HF, large mobile thrombus, or high risk of embolism. At present, the DOACs have not been adequately studied, nor has the U.S. Food and Drug Administration approved them for prophylaxis or treatment of prosthetic valve thrombosis.

IIa | B-NR | For severely symptomatic patients with bioprosthetic aortic valve stenosis judged by the heart team to be at high or prohibitive risk of reoperation, and in whom improvement in hemodynamics is anticipated, a transcatheter | NEW: Registries and case series have reported on the short-term outcomes and complication rates in patients with bioprosthetic AS |
The VIVID (Valve-In-Valve International Data) Registry is the largest registry to date examining outcomes of the transcatheter valve-in-valve procedure in 459 patients, of whom about 40% had isolated stenosis and 30% had combined regurgitation and stenosis (154). Within 1 month after the valve-in-valve procedure, 7.6% of patients died, 1.7% had a major stroke, and 93% of survivors experienced good functional status (NYHA class I/II). The overall 1-year survival rate was 83.2% (154). In nonrandomized studies and a systematic review comparing outcomes and safety of the transcatheter valve-in-valve procedure with repeat surgical AVR, the valve-in-valve procedure was found to have similar hemodynamic outcomes, lower stroke risk, and reduced bleeding risk as compared with repeat surgery (248). No data are available yet on the durability and long-term outcomes after transcatheter valve-in-valve procedures. There are also unique clinical and anatomic challenges, requiring experienced operators with an understanding of the structural and fluoroscopic characteristics of the failed bioprosthetic valve. An anticipated hemodynamic improvement from the transcatheter valve-in-valve procedure occurs only in patients with larger-sized prostheses, because a smaller-sized valve will always be placed within a failing bioprosthesis. In 2015, the U.S. Food and Drug Administration approved the transcatheter heart valve-in-valve procedure for patients with symptomatic heart disease due to stenosis of a surgical bioprosthetic aortic valve who are at high or greater risk for open surgical therapy (as judged by a heart team, including a cardiac surgeon) (249). The transcatheter aortic valve-in-valve procedure is not currently approved to treat para-prosthetic valve regurgitation or for failed/degenerated transcatheter heart valves; and it is contraindicated in patients with IE. Transcatheter valve-in-valve implantation has also been successfully performed for failed surgical bioprostheses in the mitral, pulmonic, and tricuspid positions.

### 11.8. Prosthetic Valve Regurgitation

#### 11.8.3. Intervention: Recommendations

<table>
<thead>
<tr>
<th>Recommendations for Prosthetic Valve Regurgitation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COR</strong></td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>Hha</td>
</tr>
</tbody>
</table>

See Online Data Supplement 23 (Updated From 2014 VHD Guideline)
Bioprosthetic valve degeneration can result in regurgitation due to leaflet calcification and noncoaptation or leaflet degeneration with a tear or perforation. Even in asymptomatic patients with severe bioprosthetic regurgitation, valve replacement is reasonable because of the risk of sudden clinical deterioration if further leaflet tearing occurs (241). The increased risk of a repeat operation must always be taken into consideration. The type of valve prosthesis and method of replacement selected for a patient undergoing reoperation depend on the same factors as those for patients undergoing a first valve replacement.

### Recommendations

<table>
<thead>
<tr>
<th>Level</th>
<th>Grade</th>
<th>Procedure Description</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B</td>
<td>Percutaneous repair of paravalvular regurgitation is reasonable in patients with prosthetic heart valves and intractable hemolysis or NYHA class III/IV HF who are at high risk for surgery and have anatomic features suitable for catheter-based therapy when performed in centers with expertise in the procedure (252-254).</td>
<td>2014 recommendation remains current.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>For severely symptomatic patients with bioprosthetic aortic valve regurgitation judged by the heart team to be at high or prohibitive risk for surgical therapy, in whom improvement in hemodynamics is anticipated, a transcatheter valve-in-valve procedure is reasonable (154,247,248).</td>
<td>NEW: Registries and case series of patients have reported on the short-term outcomes and complication rates for patients with bioprosthetic aortic regurgitation who have undergone transcatheter valve-in-valve replacement.</td>
</tr>
</tbody>
</table>

The VIVID (Valve-In-Valve International Data) Registry is the largest registry to date examining outcomes of the transcatheter valve-in-valve procedure in 459 patients, of whom 30% had severe prosthetic valve regurgitation and 30% had combined regurgitation and stenosis (154). Within 1 month after the valve-in-valve procedure, 7.6% of patients died, 1.7% had a major stroke, and 93% of survivors experienced good functional status (NYHA class I/II). The overall 1-year survival rate was 83.2% (154). In nonrandomized studies and a systematic review comparing outcomes and safety of the transcatheter valve-in-valve procedure with repeat surgical AVR, the valve-in-valve procedure was found to have similar hemodynamic outcomes, lower stroke risk, and reduced bleeding risk as compared with repeat surgery (248). No data are available yet on the durability and long-term outcomes after transcatheter valve-in-valve procedures. There are also unique clinical and anatomic challenges requiring experienced operators with an understanding of the structural and fluoroscopic characteristics of the failed bioprosthetic valve. The use of transcatheter valve-in-valve procedures to treat bioprosthetic valve regurgitation should be applied only to patients with larger-sized prostheses for whom hemodynamic improvement is anticipated. The transcatheter aortic valve-in-valve procedure is not currently approved to treat paraprosthetic valve regurgitation or failed/degenerated transcatheter heart valves, and it is contraindicated in patients with IE. Transcatheter valve-in-valve implantation has also been successfully performed for failed surgical bioprostheses in the mitral, pulmonic, and tricuspid positions.
# 12. Infective Endocarditis

## 12.2. Infective Endocarditis

### 12.2.3. Intervention: Recommendations

<table>
<thead>
<tr>
<th>Recommendations for IE Intervention</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COR</strong></td>
<td><strong>LOE</strong></td>
</tr>
<tr>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>IIa</td>
<td>B</td>
</tr>
<tr>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>IIa</td>
<td>B</td>
</tr>
<tr>
<td>IIb</td>
<td>B</td>
</tr>
<tr>
<td>IIb</td>
<td>B-NR</td>
</tr>
</tbody>
</table>
Delaying valve surgery for at least 4 weeks may be considered for patients with IE and major ischemic stroke or intracranial hemorrhage if the patient is hemodynamically stable (286).

**NEW:** In patients with extensive neurological damage or intracranial hemorrhage, cardiac surgery carries a high risk of death if performed within 4 weeks of a hemorrhagic stroke.

Patients with hemorrhagic stroke and IE have a prohibitively high surgical risk for at least 4 weeks after the hemorrhagic event. One multicenter observational study (286) showed wide variation in patient deaths when those who underwent surgery within 4 weeks of a hemorrhagic stroke were compared with those whose surgery was delayed until after 4 weeks (75% versus 40%, respectively). The percentage of new bleeds postoperatively was 50% in patients whose surgery was performed in the first 2 weeks, 33% in patients whose surgery was performed in the third week, and 20% in patients whose surgery was performed at least 21 days after the neurological event (286).

<table>
<thead>
<tr>
<th><strong>IIb</strong></th>
<th>B-NR</th>
</tr>
</thead>
<tbody>
<tr>
<td>See Online Data Supplement 24 (Updated From 2014 VHD Guideline)</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (January 2016)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals by Section*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick A. Nishimura <em>(Co-Chair)</em></td>
<td>Mayo Clinic, Division of Cardiovascular Disease—Judd and Mary Morris Leighton Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Catherine M. Otto <em>(Co-Chair)</em></td>
<td>University of Washington Division of Cardiology—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert O. Bonow</td>
<td>Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Blase A. Carabello</td>
<td>East Carolina University, Brody School of Medicine, East Carolina Heart Institute—Chief Cardiology Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● Edwards Lifesciences (DSMB)†</td>
<td>● Medtronic†</td>
<td>None</td>
<td>3.2.4, 7.3.3, 7.4.3, and 11.1.</td>
</tr>
<tr>
<td>John P. Erwin III</td>
<td>Texas A&amp;M College of Medicine, Baylor Scott and White Health—Senior Staff Cardiologist, Clinical Professor and Chair of Internal Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lee A. Fleisher</td>
<td>University of Pennsylvania, Department of Anesthesiology—Professor of Anesthesiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hani Jneid</td>
<td>Baylor College of Medicine—Associate Professor of Medicine, Director of Interventional Cardiology Research; The Michael E. DeBakey VA Medical Center—Director of Interventional Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael J. Mack</td>
<td>The Heart Hospital Baylor Plano—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>● Abbott Vascular ● Edwards Lifesciences</td>
<td>None</td>
<td>3.2.4, 7.3.3, 7.4.3, and 11.1.</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Relationships</td>
<td>Pfizer</td>
<td>Medtronic</td>
<td>Edwards LifeScience</td>
<td>Thrasos (Steering Committee)</td>
<td>Section Numbers</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>-----------</td>
<td>--------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Christopher J. McLeod</td>
<td>Mayo Clinic, Division of Cardiovascular Disease—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Patrick T. O’Gara</td>
<td>Brigham and Women’s Hospital—Professor of Medicine; Harvard Medical School—Director of Clinical Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Vera H. Rigolin</td>
<td>Northwestern University Feinberg School of Medicine—Professor of Medicine; Northwestern Memorial Hospital—Medical Director, Echocardiography Laboratory</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Thoralf M. Sundt III</td>
<td>Massachusetts General Hospital—Chief, Division of Cardiac Surgery, Harvard Medical School—Professor of Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Edwards LifeScience—Partner trial (PI)</td>
<td>Medtronic—Perigon trial (PI)</td>
<td>3.2.4, 7.3.3, 7.4.3, and 11.1.</td>
<td></td>
</tr>
<tr>
<td>Annemarie Thompson</td>
<td>Duke University Medical Center—Department of Anesthesiology, Professor of Anesthesiology; Residency Program Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text guideline.

†No financial benefit.

‡Significant relationship.

ACC indicates American College of Cardiology; AHA, American Heart Association; Partner, Placement of Aortic Transcatheter Valve; Perigon, Pericaldial Surgical Aortic Valve Replacement; and VA, Veterans Affairs.
Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (September 2016)

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salvatore P. Costa</td>
<td>Official Reviewer—AHA</td>
<td>Dartmouth-Hitchcock Medical Center; Section of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Federico Gentile</td>
<td>Official Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines Lead Reviewer</td>
<td>Centro Medico Diagnostico—Director, Cardiovascular Disease</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lawrence G. Rudski</td>
<td>Official Reviewer—ACC Board of Governors</td>
<td>Jewish General Hospital, McGill University—Professor of Medicine; Integrated Cardiovascular Sciences Program—Director</td>
<td>None</td>
<td>None</td>
<td>Medtronic*</td>
<td>Sanofi/Genzyme*</td>
<td>GE Healthcare*</td>
<td>None</td>
</tr>
<tr>
<td>John J. Ryan</td>
<td>Official Reviewer—AHA</td>
<td>University of Utah Health Sciences Center—Division of Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis</td>
<td>None</td>
</tr>
<tr>
<td>David Adams</td>
<td>Organizational Reviewer—AATS</td>
<td>Mount Sinai Medical Center; Department of Cardiovascular Surgery—Professor and System Chair</td>
<td>None</td>
<td>None</td>
<td>Medtronic*</td>
<td>NeoChord</td>
<td>Edwards Lifesciences*</td>
<td>None</td>
</tr>
<tr>
<td>Joseph E. Bavaria</td>
<td>Organizational Reviewer—STS</td>
<td>Hospital of the University of Pennsylvania; Division of Cardiovascular Surgery—Vice Chief; Thoracic Aortic Surgery Program—Director;</td>
<td>None</td>
<td>None</td>
<td>CytoSorbents</td>
<td>Edwards Lifesciences</td>
<td>Edwards Lifesciences*</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Institution/Position</td>
<td>Conflict of Interest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wael A. Jaber</td>
<td>Organizational Reviewer—ASE, Cleveland Clinic Foundation, Cardiovascular Medicine, Cardiovascular Imaging Core Laboratory—Director</td>
<td>None, None, None, Edwards Lifesciences, None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stanton Sherman</td>
<td>Organizational Reviewer—SCA, Brigham and Women’s Hospital, Cardiac Anesthesia Division—Director, Harvard Medical School—Professor</td>
<td>None, None, None, None, None, Philips Healthcare, National Board of Echocardiography†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molly Szerlip</td>
<td>Organizational Reviewer—SCAI, The Heart Group—Interventional Cardiologist; The Heart Hospital Baylor Plano—Medical Director, Inpatient and Outpatient Valve Program</td>
<td>Edwards Lifesciences, Medtronic, Edwards Lifesciences†, None, None, Edwards Lifesciences, Medtronic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim K. Birtcher</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines, University of Houston College of Pharmacy—Clinical Professor</td>
<td>Jones &amp; Bartlett Learning, None, None, None, None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vera Bittner</td>
<td>Content Reviewer—ACC Prevention of Cardiovascular Disease Section Leadership Council, University of Alabama at Birmingham—Professor of Medicine; Section Head, General Cardiology, Prevention and Imaging</td>
<td>Eli Lilly, ABIM*, Alabama ACC, Alabama ACP, None, None, Amgen, AstraZeneca*, Bayer Healthcare*, DalCor*, Pfizer, Sanofi-aventis*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Institution</td>
<td>Financial Relationships</td>
<td>Reclassified Financial Relationships</td>
<td>Other Relationships</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------</td>
<td>-------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>James Fang</td>
<td>Content Reviewer</td>
<td>University of Utah School of Medicine—Chief of Cardiovascular Medicine; University of Utah Health Care—Director, Cardiovascular Service Line</td>
<td>Accordia</td>
<td>None</td>
<td>Actelion (DSMB)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CardioKinetix</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NIH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael S. Firstenberg</td>
<td>Content Reviewer—ACC Surgeons’ Council</td>
<td>The Summa Health System—Thoracic and Cardiac Surgery</td>
<td>Allmed*</td>
<td>None</td>
<td>Grisfols</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Johnson &amp; Johnson</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Maquet Cardiovascular*</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annetteine Gelijns</td>
<td>Content Reviewer</td>
<td>Mount Sinai Medical Center, Population Health Science and Policy—Professor and System Chair</td>
<td>None</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Samuel Gidding</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Nemours/Alfred I. duPont Hospital for Children—Chief, Division of Pediatric Cardiology</td>
<td>FH Foundation†</td>
<td>None</td>
<td>FH Foundation†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>International FH Foundation†</td>
<td>None</td>
<td>NIH*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul A. Grayburn</td>
<td>Content Reviewer</td>
<td>Baylor Heart and Vascular Institute—Director of Cardiology Research</td>
<td>Abbott Vascular*</td>
<td>None</td>
<td>Abbott Vascular†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tendyne</td>
<td>None</td>
<td>Boston Scientific†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medtronic†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tendyne†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Valtech Cardio†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard Grimm</td>
<td>Content Reviewer—ACC Heart Failure and Transplant Section</td>
<td>Cleveland Clinic Foundation, Department of Cardiovascular Medicine—Medical Director of Echo Lab</td>
<td>Abbott Laboratories</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2017 by the American Heart Association, Inc., and the American College of Cardiology Foundation
<table>
<thead>
<tr>
<th>Leadership Council</th>
<th>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</th>
<th>Mount Sinai Medical Center—Professor of Medicine</th>
<th>AstraZeneca</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan L. Halperin</td>
<td>Content Reviewer—ACC Surgeons’ Council</td>
<td>Dartmouth Hitchcock Medical Center—Attending Cardiac Surgeon; Cardiac Surgical Research—Director; The Dartmouth Institute—Assistant Professor of Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alex Iribarne</td>
<td>Content Reviewer</td>
<td>University of Wisconsin-Madison—Professor of Medicine, Cardiovascular Medicine Division</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Craig January</td>
<td>Content Reviewer</td>
<td>UT Southwestern Medical Center—Associate Professor of Internal Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>José Joglar</td>
<td>Content Reviewer</td>
<td>Mayo Clinic—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kyle W. Klarich</td>
<td>Content Reviewer</td>
<td>Emory University, Division of Cardiology—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gautam Kumar</td>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>Texas Tech University Health Sciences Center at El Paso—President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Richard Lange</td>
<td>Content Reviewer</td>
<td>Texas Tech University Health Sciences Center at El Paso—President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Susan T. Laing</td>
<td>Content Reviewer—ACC Heart Failure and Transplant</td>
<td>UT Health Science Center at Houston (UT Health)—Professor of Medicine, Division of Cardiology,</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Nishimura, et al.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017 AHA/ACC Focused Update on VHD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section Leadership Council</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associate Chief; Director of Echocardiography</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glenn Levine</th>
<th>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</th>
<th>Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Lindman</td>
<td>Content Reviewer</td>
<td>Washington University School of Medicine in St. Louis, Cardiovascular Division—Associate Professor of Medicine</td>
<td>Roche Diagnostics</td>
<td>None</td>
<td>None</td>
<td>AHA Clinical Research Grant*</td>
<td>NIH*</td>
</tr>
<tr>
<td>D. Craig Miller</td>
<td>Content Reviewer</td>
<td>Stanford University Medical Center—Cardiothoracic Surgeon</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td>Abbott Laboratories</td>
<td>None</td>
</tr>
<tr>
<td>Stefano Nistri</td>
<td>Content Reviewer</td>
<td>CMSR Veneto Medica—Chief, Cardiology Service</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Edwards Lifesciences*</td>
<td>None</td>
</tr>
<tr>
<td>Philippe Pibarot</td>
<td>Content Reviewer</td>
<td>Université Laval—Professor of Medicine; Canada Research in Valvular Heart Diseases—Chair</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Cardiac Phoenix*</td>
<td>None</td>
</tr>
</tbody>
</table>

*Denotes financial relationship with one or more manufacturers of medical devices, pharmaceuticals, or suppliers of related services.
<table>
<thead>
<tr>
<th>Name</th>
<th>Content Reviewer</th>
<th>Institution</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hartzell V. Schaff</td>
<td>Content Reviewer</td>
<td>Mayo Clinic—Professor of Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Allan Schwartz</td>
<td>Content Reviewer</td>
<td>Columbia University Medical Center—Chief, Division of Cardiology, Vice Chair of Department of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Karen Stout</td>
<td>Content Reviewer</td>
<td>University of Washington—Director, Adult Congenital Heart Disease Program, Professor, Internal Medicine and Pediatrics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Rakesh Suri</td>
<td>Content Reviewer</td>
<td>Cleveland Clinic Foundation—Professor of Surgery, Department of Thoracic and Cardiovascular Surgery</td>
<td>Sorin† Abbott</td>
<td>None</td>
<td>None</td>
<td>St. Jude Medical</td>
<td>St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vinod Thourani</td>
<td>Content Reviewer</td>
<td>Emory University School of Medicine, Division of Cardiothoracic Surgery—Professor of Surgery; Structural Heart and Valve Center of the Emory Heart and Vascular Center—Co-Director; Emory University Hospital Midtown—Chief of Cardiothoracic Surgery</td>
<td>Edwards Lifesciences, St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>Abbott Medical, Boston Scientific†, Edwards Lifesciences†, Medtronic†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>E. Murat Tuzcu</td>
<td>Content Reviewer</td>
<td>Cleveland Clinic Abu Dhabi—Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Andrew Wang</td>
<td>Content Reviewer</td>
<td>Duke University Medical Center—Professor of Metabolics*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

© 2017 by the American Heart Association, Inc., and the American College of Cardiology Foundation
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution/Position</th>
<th>Significant Interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. Samuel Wann</td>
<td>Content Reviewer</td>
<td>Columbia St. Mary's Cardiovascular Physicians—Clinical Cardiologist</td>
<td>United Healthcare</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• ACP*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Edwards Lifesciences</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Medtronic</td>
</tr>
<tr>
<td>Frederick Welt</td>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>University of Utah Health Sciences Center, Division of Cardiology—Director, Interventional Cardiology</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Athersys</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Capricor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• CardioKinetix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Renova Therapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Siemens</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Teva Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Washington University</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to [http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy](http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy) for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.
†No financial benefit.

AAFP indicates American Academy of Family Physicians; AATS, American Association for Thoracic Surgery; ABIM, American Board of Internal Medicine; ACC, American College of Cardiology; ACP, American College of Physicians; AHA, American Heart Association; ASE, American Society of Echocardiography; CSE, Canadian Society of Echocardiography; DSMB, data safety monitoring board; FH, familial hyperlipidemia; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; SCA, Society of Cardiovascular Anesthesiologists; STS, Society of Thoracic Surgeons; UT, University of Texas; and WVU, West Virginia University.
Appendix 3. Abbreviations

AF = atrial fibrillation
AS = aortic stenosis
AVR = aortic valve replacement
CABG = coronary artery bypass graft surgery
CI = confidence interval
CT = computed tomography
DOACs = direct oral anticoagulants
EF = ejection fraction
GDMT = guideline-directed management and therapy
HF = heart failure
HR = hazard ratio
IE = infective endocarditis
INR = International Normalized Ratio
LV = left ventricular
LVEF = left ventricular ejection fraction
LVESD = left ventricular end-systolic diameter
MR = mitral regurgitation
MS = mitral stenosis
MVR = mitral valve replacement
NYHA = New York Heart Association
RCT = randomized controlled trial
TAVR = transcatheter aortic valve replacement
VHD = valvular heart disease
VKA = vitamin K antagonist
References


by guest on September 1, 2017 http://circ.ahajournals.org/ Downloaded from


121:584-92.

120:1904-11; discussion 12.

119:310:609-16.


114:50-8.


111:5:282-5.


104:5:282-5.


101:584-92.

100:101:584-92.


Nishimura, et al.
2017 AHA/ACC Focused Update on VHD


Chan KL. Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. CMAJ. 2002; 167:19-24.


### Author Relationships With Industry and Other Entities (Comprehensive)—2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (January 2016)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Nishimura (Co-Chair)</td>
<td>Mayo Clinic, Division of Cardiovascular Disease—Judd and Mary Morris Leighton Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Catherine M. Otto (Co-Chair)</td>
<td>University of Washington Division of Cardiology—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert O. Bonow</td>
<td>Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• NHLBI—PROMISE trial (DSMB) • Harvard Clinical Research Institute—DAPT trial (DSMB)</td>
<td>• Gilead • JAMA (Editor)</td>
<td>None</td>
</tr>
<tr>
<td>Blase A. Carabello</td>
<td>East Carolina University, Brody School of Medicine, East Carolina Heart Institute—Chief Cardiology Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Edwards Lifesciences (DSMB)†</td>
<td>• Medtronic†</td>
<td>None</td>
</tr>
<tr>
<td>John P. Erwin III</td>
<td>Texas A&amp;M College of Medicine, Baylor Scott and White Health—Senior Staff Cardiologist, Clinical Professor and Chair of Internal Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• DCRI;NIH • Eli Lilly* • TIMI Trialist Group*</td>
<td>None</td>
</tr>
<tr>
<td>Lee Fleisher</td>
<td>University of Pennsylvania, Department of Anesthesiology—Professor of Anesthesiology</td>
<td>• Blue Cross/Blue Shield Association—Medical Advisory Panel to the Technology Evaluation Center</td>
<td>None</td>
<td>None</td>
<td>• Johns Hopkins Medical Institutions</td>
<td>• Association of University Anesthesiologists† • Foundation for Anesthesia Education and Research†</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Institution and Role</td>
<td>National Quality Forum</td>
<td>None</td>
<td>None</td>
<td>NIH</td>
<td>NIH</td>
<td>None</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>------</td>
<td>------</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
</tr>
<tr>
<td>Hani Jneid</td>
<td>Baylor College of Medicine—Associate Professor of Medicine, Director of Interventional Cardiology Research; The Michael E. DeBakey VA Medical Center—Director of Interventional Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael Mack</td>
<td>The Heart Hospital Baylor Plano—Director</td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Chris McLeod</td>
<td>Mayo Clinic, Division of Cardiovascular Disease—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick O’Gara</td>
<td>Brigham and Women’s Hospital—Professor of Medicine; Harvard Medical School—Director of Clinical Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH</td>
<td>NIH</td>
<td>None</td>
</tr>
<tr>
<td>Vera Rigolin</td>
<td>Northwestern University Feinberg School of Medicine—Professor of Medicine; Northwestern Memorial Hospital—Medical Director, Echocardiography Laboratory</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Gilead Sciences</td>
<td>Pfizer</td>
<td>None</td>
</tr>
<tr>
<td>Thoralf M. Sundt III</td>
<td>Massachusetts General Hospital—Chief, Division of Cardiac Surgery, Harvard Medical School—Professor of Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Edwards LifeScience—Partner trial (PI)</td>
<td>Thrasos (Steering Committee)*</td>
<td>Defendant, Myocardial protection, 2014</td>
</tr>
<tr>
<td>Annemarie Thompson</td>
<td>Duke University Medical Center—Department of Anesthesiology, Professor of Anesthesiology; Residency Program Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.
†No financial benefit.

AATS indicates American Associate Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; CORAL, Cardiovascular Outcomes in Renal Atherosclerotic Lesions; DAPT, dual antiplatelet therapy; DSMB, data safety monitoring board; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health, PROMISE, Prospective Multicenter Imaging Study for Evaluation of Chest Pain; TRANSLATE-ACS, Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome and VA, Veterans Affairs.
# Table of Contents

Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of IE (Section 2.4) .......................................................... 2
Data Supplement 2. RCTs for IE (Section 2.4) ................................................................................................................................. 3
Data Supplement 3. RCTs Comparing Anticoagulation for AF in Patients With VHD (Section 2.4.3) .............................................................. 4
Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Anticoagulation for AF in Patients With VHD (Section 2.4.3) .............................................................. 4
Data Supplement 9. (Updated From 2014 Guideline) Choice of Intervention in Symptomatic Adults With Severe AS (Stage D): RCTs of Surgical Versus TAVR or Medical Therapy (Section 3.2.4) .............................................................. 7
Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of TAVR (Section 3.2.4) .............................................................. 4
Data Supplement 17. (Updated From 2014 Guideline) Primary MR—Evidence for Intervention (Section 7.3.3) .......................................................................................................................... 9
Data Supplement 18. (Updated From 2014 Guideline) Secondary MR—Evidence for Intervention (7.4.3) ...................................................................................................................................................... 12
Data Supplement 19. (Updated From 2014 Guideline) Clinical Outcomes With Bioprosthetic and Mechanical Valves (Section 11.1.2) .................................................................................................................. 14
Data Supplement 6. Antithrombotic Therapy for Prosthetic Valves (Section 11.2.2) ........................................................................................................ 22
Data Supplement 20. (Updated From 2014 Guideline) Bridging Anticoagulation Therapy for Mechanical Heart Valves (Section 11.3.2) ............................................................................................................. 26
Data Supplement 7. Prosthetic Valve Thrombosis (Section 11.6) ....................................................................................................................... 28
Data Supplement 21. (Updated From 2014 Guideline) Selective Studies of VKA in Patients with Bioprosthetic Valve Thrombosis (Section 11.7.3) ................................................................................................. 36
Data Supplement 8. Selective Studies of VKA in Patients with Bioprosthetic Valve Thrombosis (Section 11.7.3) ................................................................................................. 36
Data Supplement 9. Clinical Outcomes With VIV Procedures (Sections 11.7.3 and 11.8.3) ........................................................................... 38
Data Supplement 22. (Updated From 2014 Guideline) Selective Studies on Surgical and Catheter-based Closure for Paravalvular Regurgitation (Section 11.8.3) .............................................................................................................. 44
Data Supplement 24. (Updated From 2014 Guideline) Selective Studies on Surgical and Catheter-based Closure for Paravalvular Regurgitation (Section 11.8.3) .............................................................................................................. 44
Data Supplement 23. (Updated From 2014 Guideline) Selective Studies on Surgical and Catheter-based Closure for Paravalvular Regurgitation (Section 11.8.3) .............................................................................................................. 44

## References

1. indicates primary; 2°, secondary; ACC, American College of Cardiology; AF, atrial fibrillation; AHA, American Heart Association; AKI, acute kidney injury; AMI, acute myocardial infarction; AP, antibiotic prophylaxis; AS, aortic stenosis; ASA, acetylsalicylic acid; AR, aortic regurgitation; AV, aortic valve; AVA, aortic valve area; AVR, aortic valve replacement; BHV, bioprosthetic heart valve; BPVT, bioprosthetic valve thrombosis; CABG, coronary artery bypass graft; CAD, coronary artery disease; CI, confidence interval; CT, computed tomography; CTA, computed tomography angiography; CV, cardiovascular; DAPT, dual antiplatelet therapy; dx, diagnosis; EF, ejection fraction; ERO, effective regurgitant orifice; heart failure; HR, hazard ratio; HF, FDA, U.S. Food and Drug Administration; HTN, hypertension; Hx, history; IE, infective endocarditis; INR, international normalized ratio; IV, intravenous; LV, left ventricle; LVEF, left ventricular ejection fraction; LVESEd, left ventricular end-systolic dimension; MAPE, major adverse prosthesis-related events; MCV, Medtronic CoreValve; MDCT, multidetector computed tomography; MHV, mechanical heart valve; MI, myocardial infarction; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVR, mitral valve repair; N/A, not available; NICE, National Institute for Health and Care Excellence; NVE, native valve endocarditis; NYHA, New York Heart Association; NS, nonsignificant; NSAID, nonsteroidal anti-inflammatory drug; NOAC, novel anticoagulant; OR, odds ratio; ∆P, mean transaortic pressure gradient; PAP, pulmonary artery pressure; pt, patient; PVL, paravalvular leak; PVR, paravalvular regurgitation; PVT, pulmonary valve thrombosis; RCT, randomized controlled trial; RR, relative risk; Rx, prescription; QoL, quality of life; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, Stroke Prevention in Atrial Fibrillation; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TEE, transesophageal echocardiography; THV, transcatheter heart valve; TIA, transient ischemic attack; TTE, transthoracic echocardiography; VARC, Valvular Academic Research Consortium; VIV: valve-in-valve; VHD, valvular heart disease; VKA, vitamin K antagonist Vmax; and aortic valve maximum velocity.

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.
### Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of IE (Section 2.4)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (p values; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mackie AS, et al., 2016 (1) 26868840</td>
<td>Study type: Retrospective; Size: n=9,431 pts with IE hospitalizations</td>
<td>Inclusion criteria: IE Hospitalizations Exclusion criteria: N/A</td>
<td>1st endpoint: Incidence of IE of hospitalizations per 10 million Results: There was no difference in the rates of hospitalization for IE before and after publication of the revised recommendations</td>
<td>• This retrospective study examined the incidence of IE hospitalizations before and after the 2007 AHA prophylaxis guidelines publication • The rate of IE hospitalizations increased before/after implementation • 2007 AHA recommendations had no impact on incidence rates of hospitalization for IE</td>
</tr>
<tr>
<td>Dayer MJ, et al., 2015 (2) 25467569</td>
<td>Study type: Retrospective secular trend study: relationship AP vs. none on IE incidence; Size: Cases reported per 10 million people per mo</td>
<td>Inclusion criteria: Single dose IE prophylaxis all pts w/IE dx Exclusion criteria: N/A</td>
<td>1st endpoint: IE dx at discharge/death and number of Rx of IE prophylaxis Results: • Decrease IE Prophylaxis; • Increase IE incidence</td>
<td>• AP has fallen and incidence of IE has increased since 2008 NICE guidelines</td>
</tr>
<tr>
<td>Glenny AM, et al., 2013 (3) 24108511</td>
<td>Study type: Meta-analysis; Size: Only 1 study met criteria for inclusion</td>
<td>Inclusion criteria: RCT, cohort, case control Exclusion criteria: Guidelines, editorial discussion</td>
<td>1st endpoint: Development of IE, mortality Results: Only 1 study met criteria</td>
<td>• There remains no evidence to determine whether AP is effective or ineffective</td>
</tr>
<tr>
<td>Sherman-Weber S, et al., 2004 (4) 18762934</td>
<td>Study type: Retrospective literature review; Size: n=659 pts</td>
<td>Inclusion criteria: Single-center heart transplant hospitalization with IE Exclusion criteria: N/A</td>
<td>1st endpoint: N/A Results: Between 1993-Feb. 2004, 10 pts had endocarditis</td>
<td>• Endocarditis is substantially more common in heart transplant recipients than in general populations. Central venous catheter access and multiple endomyocardial biopsies appear to predispose to infection</td>
</tr>
<tr>
<td>Gillinov AM, et al., 2002 (5) 12078774</td>
<td>Study type: Retrospective review; Size: n=22 pts</td>
<td>Inclusion criteria: 22 pts with endocarditis of a previously repaired MV Exclusion criteria: N/A</td>
<td>1st endpoint: N/A Results: 15 had repeat MV operations; 7 were treated with antibiotics</td>
<td>N/A</td>
</tr>
<tr>
<td>Karavas AN, et al., 2002 (6) 13358402</td>
<td>Study type: Retrospective review of MV repairs; Size: n=1,275 pts</td>
<td>Inclusion criteria: MV repairs at a single institution Exclusion criteria: N/A</td>
<td>1st endpoint: Endocarditis (non-recurrent) of previously repaired MV Results: 9 of 1,275 pts developed endocarditis after MV repair: all required excision of the annuloplasty ring</td>
<td>N/A</td>
</tr>
<tr>
<td>Duval X, et al.,</td>
<td>Study type: Survey; Size: Pts 25–85 y of age; French</td>
<td>Inclusion criteria: Pts 25–85 y of age; French</td>
<td>1st endpoint:</td>
<td>A large no. of pts would need prophylaxis to</td>
</tr>
</tbody>
</table>
### Exclusion criteria:

- N/A

### Results:

- The results were extrapolated to general French population.
- Risk of developing IE in unprotected procedure:
  - 1 in 10,700 for prosthetic valve predisposing cardiac conditions
  - 1 in 54,300 for native valve predisposing cardiac conditions
- Risk of developing IE in protected procedures:
  - 1 in 150,000

- The results cannot be generalized to general population

### Study Type: Observational case control

**Size:** n=273 cases (238 native valve infections, 35 prosthetic valve infections)

### Inclusion criteria:

- Subjects with community acquired IE discharged within 3 mo and matched community residents

### Exclusion criteria:

- IE due to IV drug abuse, <18 y of age, hospital acquired IE

**1° endpoint:** N/A

**Results:**

- Dental treatment not more common in cases compared to controls (adjusted OR: 0.8, 95% CI: 0.4–1.5)
- Cases with Hx of MV prolapse OR: 19.4; congenital heart disease OR: 6.7, valvular surgery OR: 74.6, rheumatic fever OR: 13.4; heart murmur OR: 4.2
- Prophylaxis dental therapy was significantly low (p=0.03) in cases with cardiac lesions as compared to controls.

### Relevant 2° Endpoint (if any): Cardiac valvular abnormalities associated with IE more than the dental treatment

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, p values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouget FK, et al., 2015; (9) 25758845</td>
<td><strong>Aim:</strong> To assess the impact of AP on bacteremia <strong>Study type:</strong> Double-blind, randomized, placebo-controlled <strong>Size:</strong> n=290 pts</td>
<td>Inclusion criteria: 2008 cohort urgent care presentation for tooth extraction. <strong>Exclusion criteria:</strong> &lt;10 teeth antibiotic use within 2 wk. Need for AP based on practice guidelines active viral disease, Immunocompromised, poorly-controlled systemic disease penicillin allergy, fever, cellulitis, chewing/tooth brushing within 1 h.</td>
<td>Intervention: • Tooth brushing (n=98 pts) • Single tooth extraction with AP (n=96 pts) <strong>Comparator:</strong> Single tooth extraction with placebo</td>
<td><strong>1° endpoint:</strong> Bacteremia 32% brushing 33% amoxicillin 60% placebo</td>
<td>• Given frequency of IE causing bacteremia during a tooth brushing; recommend RCT to determine efficacy of prophylaxis for dental procedure; recommend good dental hygiene.</td>
</tr>
<tr>
<td>Lockhart PB, et al., 2008; (10) 1851739</td>
<td><strong>Aim:</strong> To compare the incidence, duration, type and extent of endocarditis related bacteremia and to determine <strong>Inclusion criteria:</strong> Subjects in need for tooth extraction <strong>Exclusion criteria:</strong></td>
<td></td>
<td>Intervention: • Tooth brushing group (98) • Extraction with amoxicillin group (96)</td>
<td><strong>1° endpoint:</strong> 32/96 bacterial species identified cause IE. Cumulative incidence from 6 blood draws</td>
<td>• The results cannot be generalized to general public • Tooth brushing and single tooth-extractions seem to be similar in terms of</td>
</tr>
</tbody>
</table>
the impact of AP on single tooth extraction.

**Study type:** RCT

**Size:** n=290 pts

Use of systematic antibiotics within previous 2 wk; on AP; active viral disease; immunocompromised; systemic disease with bad prognosis; Hx of penicillin allergy; 100.5°F temp; facial cellulitis; and handling of the gingival tissues within 1 h before the study.

- Extraction with Placebo group (96)
- Tooth brushing: 23%; extraction-amoxicillin: 33% and extraction-placebo: 60%; p<0.0001
- Amoxicillin resulted in decrease of positive cultures (p=0.05)

1° Safety endpoint (if relevant): N/A

at risk individuals for IE

---

**Data Supplement 3. RCTs Comparing Anticoagulation for AF in Patients With VHD (Section 2.4.3)**

<table>
<thead>
<tr>
<th>Study Acronym</th>
<th>Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, p values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| ARISTOTLE     | Avezum A, et al., 2015 (11) | **Aim:** Apixaban vs. warfarin in pts with VHD  
**Study type:** Sub-analysis of prospective, multicenter, randomized  
**Size:** n=4,808 pts (26.4%) had a Hx of VHD (all types of VHD, except severe MS) | **Inclusion criteria:**  
- Pts with VHD, including AS, AR, mild MS, MR, tricuspid stenosis, tricuspid regurgitation, valve repair, or bioprosthetic valve replacement  
**Exclusion criteria:**  
- Clinically significant MS  
- Indications for oral anticoagulation other than AF  
- Planned use of concomitant high-dose ASA (≥165 mg/d) or DAPT | **Intervention:** Apixaban  
**Comparator:** Warfarin | **1° endpoint:** Stroke or systemic embolism  
**Safety endpoint:** Major bleeding as defined by the International Society on Thrombosis and Haemostasis  
- VHD pts in this subgroup of Aristotle (n=4,808) were older, more prior MI and bleeding; and higher CHADS2 scores  
- Pts with VHD experienced similar benefit with anticoagulation  
- Apixaban was associated with less bleeding |
| ROCKET AF     | Breithardt G, et al., 2014 (12) | **Aim:** Assess outcomes of pts with VHD in ROCKET-AF Rivaroxaban vs. Warfarin  
**Study type:** Sub-analysis of prospective, multicenter, randomized  
**Size:** n=2,003 pts (14.1%) had VHD | **Inclusion criteria:**  
- Nonvalvular AF (with no MS, no heart valve prosthesis, and no valvular disease requiring surgery)  
**Exclusion criteria:**  
- Hemodynamically significant mitral valve stenosis.  
- Prosthetic heart valve  
- Annuloplasty with or without prosthetic ring  
- Planned invasive procedure with potential for uncontrolled bleeding | **Intervention:** Rivaroxaban  
**Comparator:** Warfarin | **1° endpoint:** Composite of all stroke (both ischaemic and haemorrhagic) and systemic embolism  
**Safety endpoint:** Major or non-major bleeding or intracranial hemorrhage  
- Risk of stroke is similar to pts without VHD  
- Efficacy of rivaroxaban vs. warfarin was similar in pts with and without significant valvular disease |
NASPEAF
Perez-Gomez F, et al., 2004 (13) 15489085

**Aim:** To evaluate the safety and efficacy of combining antiplatelet and moderate intensity anticoagulation therapy in pts with AF

**Study type:** Multicenter RCT

**Size:** n=1,209 pts, 13 hospitals

**Inclusion criteria:**
- Pts with chronic or documented paroxysmal AF

**Exclusion criteria:**
- Low-risk pts according to SPAF III stratification
- Pts <60 y of age
- Mechanical valve prosthesis,
- Stroke in the previous 6 mo
- Serum creatinine over 3 mg/dl,
- Alcoholism or drug addiction,
- Severe uncontrolled HTN
- Diffuse arteriosclerosis,
- Indication for NSAIDs or indication/contraindication for antiplatelet or anticoagulant therapy

**Intervention:**
- The high-risk group pts either had anticoagulation (acenocoumarol) with a target INR of 2–3 or the combination therapy with a target INR of 1.4–2.4.

**Comparator:**
- The intermediate-risk group had 3 arms:
  - Oral anticoagulation (acenocoumarol) to a target INR of 2–3
  - Triflusal 600 mg daily, or a combination of both with a target INR of 1.25–2.

**1° endpoint:**
- Composite of vascular death, TIA, and nonfatal stroke or systemic embolism, (whichever event came first)
- 1° outcome was lower in the combined therapy than in the anticoagulant arm in both the intermediate (HR: 0.33; 95% CI: 0.12–0.91; p=0.02) and the high-risk group (HR: 0.51; 95% CI: 0.27–0.96; p=0.03).

**Safety endpoint:** N/A

RE-LY Sub-analysis
Ezekowitz, et al 2016 (14) 27496855

**Aim:** Compare pts with and without any valve disease and to compare warfarin or dabigatran

**Study type:** Post hoc analysis

**Size:** n=3,950 pts with any VHD

**Inclusion criteria:**
- VHD and AF

**Exclusion criteria:**
- Prosthetic heart valves, significant MS, and VHD requiring intervention

**Intervention:**
- Warfarin

**Comparator:**
- Dabigatran

**1° endpoint:**
- The presence of VHD did not influence comparison of dabigatran at either dose with warfarin in terms of stroke or systemic embolism, major bleed, death, or intracranial hemorrhage.

**Safety endpoint:** N/A

- The combination of antiplatelet and anticoagulation therapy significantly decreased vascular events compared to anticoagulation only and was safe in AF pts

- The baseline characteristics of pts with VHD reflected a higher CV risk than those of pts without VHD
## Data Supplement 4. Nonrandomized Trials, Observational Studies, and/or Registries of Anticoagulation for AF in Patients With VHD (Section 2.4.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (p values; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion</th>
<th>Comment(s)</th>
</tr>
</thead>
</table>
| Noseworthy PA, et al., 2016 (15)     | Study type: Retrospective analysis of administrative claims data to compare effectiveness and safety of NOACs with warfarin in pts with AF and VHD | **Study type:** Retrospective analysis of administrative claims data to compare effectiveness and safety of NOACs with warfarin in pts with AF and VHD  
**Inclusion criteria:** Pts with VHD and AF  
**Exclusion criteria:** N/A  
**Study Size:** n=20,158 NOAC-treated pts with VHD | **1st endpoint:** N/A  
**Results:** N/A | Combining rheumatic and nonrheumatic MS, NOACs trended toward lower risk of stroke (HR: 0.52 95% CI: 0.15–1.81, p=0.31) and major bleeding (HR: 0.77 95% CI: 0.41–1.43, p=0.40).  
Pts with AS or AR or MR both stroke or systemic embolism and major bleeding were significantly lower in NOACs compared to warfarin | |
| Olesen, et al., 2011 (16) 21282258 | Study type: Nationwide cohort study  
**Study type:** Nationwide cohort study  
**Size:** n=121,280 pts; 73,538 included in analysis  
**Inclusion criteria:** Nonvalvular AF  
**Exclusion criteria:** No previous diagnoses of MV or AV disease, and no MV or AV surgery | **Study type:** Nationwide cohort study  
**Size:** n=121,280 pts; 73,538 included in analysis  
**Inclusion criteria:** Nonvalvular AF  
**Exclusion criteria:** No previous diagnoses of MV or AV disease, and no MV or AV surgery | **1st endpoint:** To evaluate the individual risk factors composing the CHADS2 score and the CHA2DS2-VASc score and to calculate the capability of the schemes to predict thromboembolism.  
**Results:**  
• In pts at low risk, 1.67 per 100 person y (95% CI:1.47–1.89)  
• In pts at intermediate risk, 4.75 per 100 person y (95% CI:4.45–5.07)  
• CHA2DS2-VASc performed better than CHADS2 in predicting pts at high risk and low risk |  |
| Petty, et al., 2000 (17) 11062286 | Study type: Cohort/epidemiological  
**Study type:** Cohort/epidemiological  
**Size:** n=729 pts  
**Inclusion criteria:** Echocardiographic dx of MS (n=19), MR (n=528), AS (n=140), and AR (n=106) between 1985 and 1992  
**Exclusion criteria:** N/A | **Study type:** Cohort/epidemiological  
**Size:** n=729 pts  
**Inclusion criteria:** Echocardiographic dx of MS (n=19), MR (n=528), AS (n=140), and AR (n=106) between 1985 and 1992  
**Exclusion criteria:** N/A | **1st endpoint:** Rates and determinants of cerebrovascular events in pts with VHD pts.  
**Results:** Risk of CVA and death among pts with valve disease was significantly higher than significantly higher than the corresponding age- and sex-adjusted rates for the community  
• Independent predictors of CVA were age, AF, and severe AS.  
• AS was associated with rates of CVA similar to those for MS and was an independent determinant of CVA events after adjustment for age and AF (RR:3.5) |  |
### PARTNER COHORT A (high-surgical risk)

- **Study**
  - Smith et al 2011 21639811
  - Kodali, et al. 2012 22443479
  - Mack, et al. 2015 25788234

- **Aim of Study**
  - To show that TAVR is not inferior to SAVR

- **Study Type**
  - RCT

- **Study Groups (N)**
  - TAVR 348 vs. SAVR 351

- **Patient Population**
  - Severe symptomatic calcific AS defined as AVA <0.8 cm² plus a ΔP≥40 mm Hg or Vmax≥4.0 m/s with NYHA class II-IV symptoms.

- **Major Endpoints**
  - All-cause death (intention-to-treat analysis): TAVR 3.4% vs. SAVR 6.5% p-value 0.07
  - 1 y* 24.2% vs. 26.8% p-value 0.44
  - 2 y 33.9% vs. 35.0% p-value 0.78
  - 5 y 67.8% vs. 62.4% p-value 0.76

- **Exclusions**
  - were bicuspid aortic valve, AMI, significant CAD, LVEF<20%, aortic annulus <18 or >25 mm, severe AR or MR, TIA within 6 mo, or severe renal insufficiency

### PARTNER COHORT B (inoperable)

- **Study**
  - Kapadia, et al 2015 25788231
  - Leon, et al 2010 20961243
  - Makkar, et al 2012 22443478

- **Aim of Study**
  - Compare TAVR to medical Rx in inoperable pts with severe symptomatic AS

- **Study Type**
  - RCT

- **Study Groups (N)**
  - TAVR in 179 vs. standard medical therapy in 179 (including BAV in 150 (84%)

- **Patient Population**
  - Severe symptomatic calcific AS defined as AVA <0.8 cm² plus a ΔP≥40 mm Hg or Vmax≥4.0 m/s with NYHA class II-IV symptoms.

- **Inoperable**
  - due to coexisting conditions with predicted ≥50% risk of death within 30 d of intervention or a serious irreversible condition.

- **Exclusions**
  - were bicuspid aortic valve, AMI, significant CAD, LVEF<20%, aortic annulus <18 or >25 mm, severe AR or MR, TIA within 6 mo, or severe renal insufficiency
Core Valve (high surgical risk)

Adams, et al 2014 24678937 (24)

Deeb et al, 2016 27050187 (25)

Compare TAVR and SAVR in pts at high surgical risk

RCT

TAVR with self-expanding Core Valve prosthesis in 390 vs. SAVR in 357. Mean age 83.2 y. Men 52.7%

Mean STS-PROM score 7.4%

Severe symptomatic calcific AS defined as AVA ≤0.8 cm², or indexed AVA ≤0.5 cm²/m² and either a ΔP >40 mm Hg or Vmax>4.0 m/s with NYHA class II-IV symptoms.

High surgical risk defined as ≥15% risk of death by 30 d after the procedure and a risk or death or irreversible complications <50% within 30 d of procedure

Exclusions were valve sizing mismatch, inadequate access vessels, bicuspid aortic valve, significant CAD, or compliance issues.

All-cause death at 1 y:

TAVR 14.2% vs. SAVR 19.1% (p<0.001 for non inferiority and p=0.04 for superiority).

All-cause death or stroke at 3 y:

TAVR 37.3% vs. SAVR 46.7% (p=0.006).

PARTNER 2 COHORT A

Leon, et al. 2016 27040324 (26)

To compare surgical AVR and TAVR in an intermediate risk cohort

RCT

TAVR 1011 pts vs. SAVR 1021 pts

TAVR was transfemoral in 76.3% and transapical in 23.7%

Severe symptomatic calcific AS defined as AVA <0.8 cm² plus a ΔP>40 mm Hg or Vmax≥4.0 m/s with NYHA class II-IV symptoms.

Intermediate surgical risk defined as ≥24% risk of death by 30 d after the procedure. An STS score ≥8% was the upper limit of enrolled pts. Pts with an STS score <4% were enrolled if other conditions indicating increased risk. Mean STS score was 5.8%.

Exclusions were bicuspid aortic valve, AMI, significant CAD, LVEF<20%, aortic annulus <18 or >25 mm, severe AR or MR, TIA within 6 mo, or severe renal insufficiency

1° endpoint-cause death or disabling stroke at 2 y: HR: 0.89 (95% CI: 0.73–1.09; p=0.25).

All-cause death at 2 y:

TAVR 16.7% vs. SAVR 18.0%

Disabling Stroke

TAVR 6.2% vs. SAVR 6.4%

Transfemoral TAVR vs SAVR:

HR: 0.79; 95% CI: 0.62–1.00; p=0.05

Transthoracic TAVR vs SAVR:

HR: 1.21; 95% CI: 0.84–1.74; p=0.31

NOTION (severe symptomatic AS with low-surgical risk)

Thyregod HG, et al. 27005980 (27)

Compare outcomes with TAVR and SAVR in pts at low surgical risk

RCT

TAVR with self-expanding Core Valve prosthesis in 145 vs. SAVR in 135

Mean age: 79.12 y. Men: 53.2%

STS-PROM score <4 in 81.8%

Severe symptomatic calcific AS in pts over age 70 y with no significant coronary disease. Severe AS defined as AVA <1.0 cm² or indexed AVA ≤0.6 cm²/m² plus a ΔP >40 mm Hg or Vmax>4.0 m/s with NYHA class II-IV symptoms.

Also include asymptomatic severe AS (n=10) if severe LV hypertrophy, decreasing LVEF or new onset AF present.

Exclusions were expected survival <1 y, other severe valve disease, significant coronary disease, previous cardiac surgery, MI or stroke within 30 d, severe renal or pulmonary disease.

Composite endpoint: Death from any cause, stroke, or MI at 1 y.

TAVR 13.1% vs. SAVR 16.3% ( -3.2% absolute difference, p=0.43 for superiority).

Major complications at 30 d:

TAVR 5.6% vs. SAVR 1.5% (p=0.10)

Major bleeding at 30 d: TAVR 29.5% vs. SAVR 36.7% (p=0.03)

AKI: TAVR 0.7% vs. SAVR 6.7% (p=0.01)

Permanent pacing implantation:

TAVR 22.3% vs. SAVR 11.3% (p<0.001)

New-onset AF or worsening AF at 30 d: TAVR 16.9% vs. SAVR 57.8% (p<0.001).
Horstkotte, et al 1988 3042404 (28)  
Compare outcomes with symptomatic vs. asymptomatic severe AS  
Retrospective  
n=35 pts  
Severe symptomatic AS refused AVR. AVA 0.4–0.8 cm²  
Mean interval from symptom onset to death: 4.5 y for angina (n=18), 2.6 y for syncope (n=13), <1 y for HF (n=20)  
Mortality reached 100% at: 10 y for angina, 5 y for syncope, 2.4 y for HF  
There were 3 sudden deaths before symptom onset

Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of TAVR (Section 3.2.4)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (P values; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion</th>
<th>Comment(s)</th>
</tr>
</thead>
</table>
| Popma, et al. 2014 (29) 24657685     | Study type: Prospective, multicenter  
Size: n=506 pts recruited; n=489 pts who underwent attempted treatment with CoreValve THV  
Inclusion criteria:Pts with symptomatic sever AS with prohibitive risk for surgery  
Exclusion criteria: N/A | **1° endpoint:** All-cause mortality or major stroke at 12 mo, compared to a pre-specified objective performance goal  
Results: All-cause mortality or stroke was 26.0% vs. 43.0% objective performance goal (p<0.0001) | • TVR with self-expanding bio prosthesis was found to be safe for pts with symptomatic severe AS with prohibitive risk for surgery |
| Thourani, et al. 2016 (30) 27053442  | Study type: Observational  
Size: n=1,077 pts at 51 sites  
Inclusion criteria: Pts receiving TAVR with the SAPIEN 3 valve compared to intermediate risk pts treated with surgical valve replacement in the PARTNER 2A trial.  
Exclusion criteria: N/A | **1° endpoint:** All-cause mortality, stroke, reintervention, and aortic valve regurgitation 1 y following plantation.  
Results: TAVR was noninferior (9·2%; 90% CI: -12.4–6; p<0.0001) and superior (-9·2%, 95% CI: -13.0 – -5.4; p<0.0001) to surgical valve replacement. | • TAVR with SAPIEN 3 was associated with lower all-cause mortality, strokes, and aortic valve regurgitation at 1 y compared with surgical valve replacement of the PARTNER 2A trial. |

Data Supplement 17. (Updated From 2014 Guideline) Primary MR—Evidence for Intervention (Section 7.3.3)

<table>
<thead>
<tr>
<th>Study Name, Author, Year</th>
<th>Aim of Study</th>
<th>Study Type</th>
<th>Study Size (N)</th>
<th>Study Intervention Group (n)</th>
<th>Study Comparator Group (n)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gillinov, et al. 2010 (32) 20667334</td>
<td>Assess impact of symptoms on outcomes</td>
<td>Retrospective propensity-matched</td>
<td>n=4,253 pts</td>
<td>MVR</td>
<td>NYHA all class</td>
<td>Even NYHA class II preoperative symptoms impaired late survival.</td>
</tr>
<tr>
<td>Reference</td>
<td>Study Title</td>
<td>Study Design</td>
<td>n</td>
<td>Procedure</td>
<td>Outcome Measures</td>
<td>Results</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>--------------</td>
<td>---</td>
<td>-----------</td>
<td>------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Rosenhek, et al. 2006 (33) 16651470</td>
<td>Assess outcome with watchful waiting</td>
<td>Prospective</td>
<td>n=132 pts</td>
<td>Watchful waiting for severe MR</td>
<td>N/A</td>
<td>Survival for watchful waiting identical to age normal population, but triggers for surgery occurred early after enrollment in 50%.</td>
</tr>
<tr>
<td>Kang, et al. 2009 (34) 19018506</td>
<td>Assess outcome with watchful waiting</td>
<td>Prospective</td>
<td>n=447 pts</td>
<td>Mitral surgery</td>
<td>Early surgery vs. watchful waiting</td>
<td>Early surgery appeared superior, but several unoperated pts refused surgery despite presence of triggers.</td>
</tr>
<tr>
<td>Tribouilloy, et al. 2009 (36) 19909877</td>
<td>Assess impact of LVESD on outcome</td>
<td>Retrospective</td>
<td>n=739 pts</td>
<td>Mitral surgery</td>
<td>LVESD &lt;40 vs. ≥40</td>
<td>LVESD &gt;40 mm nearly doubled late mortality risk.</td>
</tr>
<tr>
<td>Enriquez-Sarano, et al. 2005 (37) 15745978</td>
<td>Assess impact of MR severity</td>
<td>Prospective</td>
<td>n=450 pts</td>
<td>N/A</td>
<td>ERO of different sizes</td>
<td>ERO &gt;0.4 cm² nearly tripled mortality, but mortality was reduced by surgery.</td>
</tr>
<tr>
<td>Ghoresi 2011 (38) 21962906</td>
<td>Assess impact of pulmonary HTN on outcome</td>
<td>Retrospective</td>
<td>n=873 pts</td>
<td>Mitral surgery</td>
<td>Preoperative-pulmonary HTN of various degrees</td>
<td>5-y survival 88% for PAP &lt;40 vs. 52% PAP &gt;60.</td>
</tr>
<tr>
<td>Goldman, et al. 1987 (39) 3624663</td>
<td>Compare LV function after replace vs. repair</td>
<td>Prospective</td>
<td>n=18 pts</td>
<td>Mitral surgery</td>
<td>Repair vs. replacement</td>
<td>LVEF fell following replacement, but not repair.</td>
</tr>
<tr>
<td>David, et al. 1984 (40) 6492840</td>
<td>Compare outcome with and without chordal presentation</td>
<td>Prospective</td>
<td>n=27 pts</td>
<td>Mitral surgery</td>
<td>MV surgery with and without chordal preservation</td>
<td>LVEF decreased without preservation, but was maintained with preservation.</td>
</tr>
<tr>
<td>Rozich, et al. 1992 (41) 1451243</td>
<td>Examined LVEF</td>
<td>Retrospective</td>
<td>n=15 pts</td>
<td>Mitral surgery</td>
<td>Chordal preservation vs. destruction</td>
<td>Afterload increased following chordal destruction, but decreases following preservation.</td>
</tr>
<tr>
<td>David, et al. 2013 (42) 22458614</td>
<td>Assess long-term Outcome of MV repair</td>
<td>Retrospective</td>
<td>n=804 pts</td>
<td>Mitral repair</td>
<td>Normal population</td>
<td>Predicted Reduced survival for class II pts; 6% re-op rate at 20 y, 91% freedom from severe MR; 70% freedom from even moderate MR.</td>
</tr>
<tr>
<td>Tribouilloy, et al 2011 (43) 21821606</td>
<td>Assess predictors of post op LV function</td>
<td>Retrospective</td>
<td>n=355 pts</td>
<td>Mitral surgery</td>
<td>Postoperative EF</td>
<td>Preop EF of 0.64 and an LVESD of &lt;37 mm predicted a normal post-op EF.</td>
</tr>
<tr>
<td>Reference</td>
<td>Study Title</td>
<td>Study Type</td>
<td>n</td>
<td>Procedure</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------------------------------------------</td>
<td>------------------</td>
<td>-----</td>
<td>--------------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>Suri, et al. 2016 (44)</td>
<td>Assess Durability of MV repair</td>
<td>Retrospective</td>
<td>1,218</td>
<td>Mitral repair</td>
<td>Repair Durability</td>
<td></td>
</tr>
<tr>
<td>Vassileva, et al. 2013 (45)</td>
<td>Assess survival after MV surgery</td>
<td>Retrospective</td>
<td>47,279</td>
<td>Mitral surgery</td>
<td>Repair vs. replacement</td>
<td></td>
</tr>
<tr>
<td>Dillon, et al. 2015 (47)</td>
<td>Assess repair durability in Rheumatic Disease</td>
<td>Retrospective</td>
<td>366</td>
<td>Mitral surgery</td>
<td>Repair in Rheumatic vs Nonrheumatic MR</td>
<td></td>
</tr>
<tr>
<td>Feldman, et al. 2015 (48)</td>
<td>5-y follow-up of Percutaneous MV repair</td>
<td>Prospective RCT</td>
<td>279</td>
<td>Mitral repair</td>
<td>Percutaneous vs Surgical Repair</td>
<td></td>
</tr>
<tr>
<td>Girgioni, et al. 2008 (49)</td>
<td>Outcome of repair vs. replacement</td>
<td>Prospective</td>
<td>394</td>
<td>Mitral surgery</td>
<td>Repair vs. replacement vs. nonsurgery</td>
<td></td>
</tr>
<tr>
<td>Gillinov, et al. 2008 (50)</td>
<td>Outcome of repair vs. replacement</td>
<td>Retrospective</td>
<td>328</td>
<td>N/A</td>
<td>Repair vs. replacement propensity</td>
<td></td>
</tr>
<tr>
<td>Weiner, et al. 2014 (51)</td>
<td>Assess effect of experience in repair on outcome</td>
<td>Retrospective</td>
<td>1,054</td>
<td>Mitral repair</td>
<td>Early experience vs late</td>
<td></td>
</tr>
<tr>
<td>Enrique Serano, et al. 2015 (52)</td>
<td>Assess effect of timing of surgical correction of MR on outcome</td>
<td>Retrospective stratification</td>
<td>1,512</td>
<td>Mitral surgery correction</td>
<td>Surgical indication class I triggers (HF symptoms, EF &lt;60%, end-systolic diameter ≥40 mm vs. class II (AF or pulmonary HTN) vs. early class III (combination of severe MR and high probability of valve repair)). Operative mortality highest with Class I (1.1% vs. 0% and 0%, p=0.016). Long-term survival was lower with Class I (15-y 42% ± 2%; adjusted HR: 1.89 (95% CI: 1.53, 2.34), p&lt;.0001) and Class II-EarlyT (15-y 53% ± 4%, adjusted HR: 1.39 (95% CI: 1.04, 1.84), p=0.027) vs. Class II-EarlyT (15-y 70% ± 3%, p&lt;0.0001).</td>
<td></td>
</tr>
</tbody>
</table>
Examine early changes in LV size and function after MV repair or replacement

**Suri, et al. 2008 (53)**
18692655

Rate of valve repair increased from 78% to 92%. At early echocardiography (mean, 5 d postop), significant decreases in LVEF (mean: 28.8) and LVESD (mean, 27.5). Magnitude of early decline in EF was similar in pts who had MVR and MV replacement.

Assess predictors and long-term survival of latent LV dysfunction

**Quintana, et al. 2014 (54)**
26179130

Pts with absence of LV dysfunction had significant and immediate greater enlargement in systolic dimension and decrease in right ventricular systolic pressure. EF recovered to preop levels (>60%) in only one third of pts with postrepair EF<50% vs. two thirds of those with an EF of ≥50% (p<0.001). The overall survival at 5, 10, and 15 y of follow-up was 95%, 85%, and 70.8%, respectively. Postop EF <40% conferred a 70% increase in the hazard of late death: adjusted HR: 1.74 (95% CI: 1.03, 2.92), p=0.037

To assess the tempo of MR progression, predictors of MR progression, incidence of de novo LV dysfunction, and predictors of LV dysfunction

**Suri, et al. 2011 (55)**
21257316

- The likelihood of MR progression was higher in those with greater baseline MR grade (mild/mild-moderate 44/124 (31%) vs. moderate/moderate-severe 35/60 (58%) p=0.0008).
- LV deterioration occurred even in the absence of MR progression
- Multivariable modeling revealed that LVEDD was the only independent predictor OR: 1.15; 95% CI: 1.08, 1.23; p=0.0001 of greater MR progression with time.

---

**Data Supplement 18. (Updated From 2014 Guideline) Secondary MR—Evidence for Intervention (7.4.3)**

<table>
<thead>
<tr>
<th>Study Name, Author, Year</th>
<th>Aim of Study</th>
<th>Study Type</th>
<th>Study Size (N)</th>
<th>Study Intervention Group (n)</th>
<th>Study Comparator Group (n)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kang, et al 2006 (56)</td>
<td>Outcome surgery in moderate-to-severe ischemic MR</td>
<td>Retrospective</td>
<td>n=107 pts</td>
<td>CABG + repair</td>
<td>CABG</td>
<td>Higher operative mortality with CABG and MV repair vs CABG alone (12% vs. 2%) but similar 5 y survival (88% vs 87%)</td>
</tr>
<tr>
<td>Rossi, et al 2011 (57)</td>
<td>Impact of on outcome</td>
<td>Retrospective</td>
<td>n=1,256 pts</td>
<td>None</td>
<td>Impact of SMR on HF</td>
<td>After adjusting for LVEF and other factors-SMR, increased mortality by 2-fold</td>
</tr>
<tr>
<td>Wu, et al 2005 (58)</td>
<td>Impact of surgery on moderate-severe MR</td>
<td>Retrospective</td>
<td>n=126 pts</td>
<td>Surgery with mitral annuloplasty</td>
<td>Med Rx</td>
<td>No survival advantage to MV annuloplasty</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Year</td>
<td>Cell</td>
<td>Study Design</td>
<td>n</td>
<td>Intervention</td>
<td>Comparator</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>------</td>
<td>--------------</td>
<td>---</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>Mihaljevic, et al.</td>
<td>2007 (59)</td>
<td></td>
<td>Retrospective</td>
<td>290 pts</td>
<td>CABG+MV surgery</td>
<td>CABG</td>
</tr>
<tr>
<td>Benedetto, et al.</td>
<td>2009 (60)</td>
<td></td>
<td>Meta-analysis</td>
<td>2,479 pts</td>
<td>CAGB+MV surgery</td>
<td>CABG</td>
</tr>
<tr>
<td>Fattouch, et al.</td>
<td>2009 (61)</td>
<td></td>
<td>Randomized prospective</td>
<td>102 pts</td>
<td>CABG+repair</td>
<td>CABG</td>
</tr>
<tr>
<td>Deja, et al.</td>
<td>2012 (62)</td>
<td></td>
<td>Randomized to radial vs. surgery</td>
<td>104 pts</td>
<td>CABG+repair</td>
<td>CABG</td>
</tr>
<tr>
<td>Nombela-Franco, et al.</td>
<td>2014 (63)</td>
<td></td>
<td>Summarize the effect of TAVR on MR</td>
<td>&gt;1,000</td>
<td>TAVR</td>
<td>MR before and after TAVR</td>
</tr>
<tr>
<td>Smith PK, et al.</td>
<td>2014 (64)</td>
<td></td>
<td>Randomized prospective</td>
<td>301 pts</td>
<td>CABG</td>
<td>CABG+Repair</td>
</tr>
<tr>
<td>Michler, et al.</td>
<td>2016 (65)</td>
<td></td>
<td>Randomized prospective</td>
<td>301 pts</td>
<td>CABG</td>
<td>CABG+Repair</td>
</tr>
<tr>
<td>Acker, et al.</td>
<td>2014 (66)</td>
<td></td>
<td>Randomized prospective</td>
<td>251 pts</td>
<td>repair</td>
<td>Replacement</td>
</tr>
<tr>
<td>Goldstein, et al.</td>
<td>2016 (67)</td>
<td></td>
<td>Randomized prospective</td>
<td>251 pts</td>
<td>repair</td>
<td>Replacement</td>
</tr>
<tr>
<td>Author, Year</td>
<td>Study Size</td>
<td>Methods</td>
<td>Patient Population</td>
<td>Follow-Up</td>
<td>Outcomes</td>
<td>Study Limitations</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>---------</td>
<td>--------------------</td>
<td>-----------</td>
<td>----------</td>
<td>------------------</td>
</tr>
<tr>
<td>Hammermeister, et al 2000 (68)</td>
<td>575 pts undergoing isolated AVR (394) or MVR (181) at 13 VA medical centers (1977–1982)</td>
<td>RCT</td>
<td>Isolated AVR or MVR. Concurrent CABG performed in 39% of AVR and 36% of MVR pts. Women, contraindications to VKA anticoagulation, requirement for antiplatelet therapy, valve size AVR or endocarditis.</td>
<td>15 y</td>
<td>• AVR, all-cause mortality at 15 y was lower for MHV vs. BHV: (66±3% [mean±SE] vs. 79±3%; p=0.02) No difference for MVR. 1° valve failure was significantly greater with a BHV vs. MHV valve, both for AVR (23±5% vs. 0±0%; p=0.0001) and MVR (44±8% vs. 5±4%; p=0.0002). 1° valve failure nearly always (93%) occurred in pts &lt;65 y. • AVR reoperation was higher after BHV vs. MHV (29±5% vs. 10±3%; p=0.004). No statistically significant difference for MVR.</td>
<td>Pts receiving mechanical MVR were older and had more HTN than those with a bioprosthetic MVR.</td>
</tr>
<tr>
<td>Oxenham, et al. 2003 (69)</td>
<td>541 pts undergoing MVR (261), AVR (211), or both (61) 1975–1979</td>
<td>RCT</td>
<td>Mean age 53.9 (10.6) y. 56% female. Additional valve procedures or not eligible for VKA anticoagulation.</td>
<td>20 y</td>
<td>• No difference in overall survival (Bjork-Shiley vs. porcine prosthesis [mean (SEM)]: 25.0 (2.7)% vs. 22.6 (2.7)%, log rank test p=0.39. • Combined endpoint of death and reoperation occurred in 23.5 (2.6)% with BHV vs. 6.7 (1.6)% with MHV (log rank test; p&lt;0.0001). • Major bleeding was more common in pts with MHV (40.7 [5.4]% vs. 27.9 [8.4]% after 20 y; p=0.008), with NS difference in major embolism or endocarditis.</td>
<td>Older generation valve types.</td>
</tr>
<tr>
<td>Stassano, et al. 2009 (70)</td>
<td>310 pts undergoing AVR 1995–2003</td>
<td>RCT</td>
<td>Age 55–70 y Other valve surgery. Contraindication to VKA anticoagulation</td>
<td>Mean 106±28 mo</td>
<td>• No survival difference at 13 y between BHV and MHV groups. • Valve failures and reoperations were more frequent in the BHV group compared with the MHV group (p=0.0001 and p=0.0003, respectively). • No differences in the linearized rate of thromboembolism, bleeding, endocarditis, and MAPE between the MHV and BHV valve groups.</td>
<td>Power may not be adequate to detect a clinically-meaningful difference at longer follow-up.</td>
</tr>
<tr>
<td>Khan, et al 2001 (71)</td>
<td>Initial AVR in 1389 pts, MVR in 915 pts, 1976–2001 at a single medical center.</td>
<td>Retrospective, observational</td>
<td>Age 64.5±12.9 y for MHV Age 72.0±12.6 y for BHV Homografts, combined MHV and BHV procedure, any previous valve surgery</td>
<td>20 y</td>
<td>• Freedom from reoperation at 15 y for AVR was 67±4.8% for BHV and 99±0.5% for MVH. For MVR, freedom from reoperation was 52±5.7% for BHV and 93±3.2% for MVH. • Survival at 15 y (BHV vs. MHV, p=NS for all): • AVR in pts &lt;65 y (55±5.9 vs. 61±5.3%), AVR in pts &gt;65 y (17±3.4 vs. 17±3.9%), • MVR in pts &lt;65 y (32±5.5 vs. 51±5.4%), MVR in pts &gt;65 y (12±3.5 vs. 18±3.8%)</td>
<td>Not prospective, not randomized. Concurrent CABG in 50%.</td>
</tr>
</tbody>
</table>
Chan, et al., 2006

<table>
<thead>
<tr>
<th>Study Authors</th>
<th>Year</th>
<th>Sample Size</th>
<th>Study Design</th>
<th>Age</th>
<th>Comparison</th>
<th>Follow-up</th>
<th>Valve-related Mortality</th>
<th>Valve-related Reoperation</th>
<th>Valve-related Morbidity</th>
<th>Actual Freedom from Valve-related Reoperation</th>
<th>Actual Freedom from Valve-related Morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kulik, et al., 2006</td>
<td>659 pts age 50–65 y with initial AVR or MVR</td>
<td>Prospective, observational</td>
<td>AVR in 388 (MHV 306, BHV 48), MVR in 236 (MHV 188, BHV 48)</td>
<td>Enrolled only if survived perioperative period. Valve repair excluded.</td>
<td>Mean 5.1±4.1 y; maximum 18.3 y</td>
<td>Freedom from 1st endpoint MAPE at 10 y (reoperation, endocarditis, major bleeding, or thromboembolism):</td>
<td>AVR MHV 70±4.1% vs. BHV 41.0±30.3% (p=0.55) MVR MHV 53.2±8.8% vs. BHV 61.2±9.2% (p=0.04)</td>
<td>Multivariate analysis did not identify valve type as an independent risk factor for MAPE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruel, et al., 2007</td>
<td>567 pts undergoing AVR or MVR</td>
<td>Retrospective observational</td>
<td>Age &lt;60 y. First heart valve operation.</td>
<td>N/A</td>
<td>Mean survivor follow-up, 24.0±3.1 y</td>
<td>Survival in AVR: no difference between BHV vs. MHV (HR:0.95, 95% CI: 0.7–1.3); Survival in MVR: no difference between BHV or MHV (HR: 0.9, 95% CI: 0.5–1.4); Long-term survival worse in MVR than AVR (HR: 1.4, 95% CI: 1.1–1.8); Reoperation in 89% of BHV AVR and 84% of BHV MVR (older generation devices) with reoperative mortality 4.3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>van Geldorp, et al., 2009</td>
<td>Bioprosthetic AVR=2,860 (73%) vs. mechanical AVR=1,074 (27%)</td>
<td>Bioprosthetic AVR: mean age=70 y, mean follow-up=6.1 y, CABG=47% vs. Mechanical AVR: mean age=58 y, mean follow-up=8.5 y, CABG=28%</td>
<td>Bioprosthetic AVR: mean follow-up=6.1 y. Mechanical AVR: mean follow-up=8.5 y</td>
<td>N/A</td>
<td>Bioprosthetic AVR: mean follow-up=6.1 y. Mechanical AVR: mean follow-up=8.5 y</td>
<td>Simulated events for a 60-y man undergoing AVR, favors a BP vs. MP: life-expectancy: 11.9 vs. 12.2 y, event-free survival: 9.8 vs. 9.3 y, reoperation-free: 10.5 vs. 11.9 y, reoperation risk: 25% vs. 3%, risk of bleeding: 12% vs. 41%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Badhwar, et al., 2012</td>
<td>172 pts undergoing isolated AVR or MVR (2003–2007)</td>
<td>Prospective, nonrandomized, matched pairs for BP vs. MP</td>
<td>Mean age 56.2±9.6 y (range, 24–72 y).</td>
<td>Limited 5-y survival based on comorbidity</td>
<td>Median follow-up 4.0 y</td>
<td>At a median 4-y follow-up, thromboembolism was 0.77% for MP and 0.78% for BP (p=NS); There was a survival benefit of mechanical prostheses at 7.5 y Noninferiority to bioprosthetic AVR for bleeding and thromboembolic complications.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>206 pts undergoing AVR (2000–2009)</th>
<th>Retrospective cohort analysis, with propensity matching of 103 BP to 103 MP</th>
<th>Age &lt;60 y. AVR with or without concurrent CABG, aortic root surgery, mitral or additional valve replacement.</th>
<th>Median follow-up 33±24 mo (2–120 mo)</th>
<th>• Overall survival was worse with BHV (90.3% vs. MHV=98%, p&lt;0.038; HR:0.243, 0.054–0.923)</th>
<th>Concurrent CABG in 49.9%, 14% were reoperations</th>
</tr>
</thead>
</table>

### Chang YP, et al. 2014

| 4,253 pts s/p AVR with MHV or BHV in New York state (1997-2004) BHV: 1466 pts (34.5%) MHV: 2787 pts (65.5%) Propensity score matching: 1001 pt pairs. | Retrospective with propensity matching | 50-69 y of age with 1st isolated AVR | Overall survival was worse with BHV (90.3% vs. MHV=98%, p<0.038; HR:0.243, 0.054–0.923) | Freedom from valve related complication complications was similar: BHV=54.5% vs. MHV=51.6%, p=NS |
|---------------------------------------------|-------------------------------------|----------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------|

### Kaneko T, et al. 2014

<table>
<thead>
<tr>
<th>768 pts &lt;65 y of age old s/p MVR January 1991 to June 2012 MHV: 627 pts BHV: 141 pts Propensity score matching: 125 matched pairs</th>
<th>Retrospective with propensity matching</th>
<th>Age &lt;65 s/p MVR</th>
<th>The median follow-up: 7 y MHV: 8 y BHV: 3 y</th>
<th>Long-term survival for propensity matched group: MHV: 13.7+/-0.7 y BHV: 11.3+/-1.0 y p&lt;0.004</th>
<th>Retrospective single-center Relatively short median follow-up</th>
</tr>
</thead>
</table>

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Participants</th>
<th>Methods</th>
<th>Findings</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>McClure 2014</td>
<td>(B0) 24521965</td>
<td>1701 pts aged &lt;65 y who underwent AVR between 1992 and 2011. BHV (2nd generation stented), n=769. MHV (bi-leaflet), n=932.</td>
<td>Retrospective, Stepwise logistic regression, propensity score identified subset of 361 evenly matched pairs.</td>
<td>Concomitant valve, coronary or ventricular procedures. Ross procedure Homograft or stentless bioprosthetic AVR.</td>
<td>Median follow-up for entire cohort 8 y (14484 pt-y). Median follow-up for matched pairs 6.5 y. For matched cohort: 30-d mortality: 1.9% BHV vs. 1.4% MHV (p=0.77). Survival at 5, 10, 15 and 18 y for BHV vs. MHV: 89% vs. 88%, 78% vs. 79%, 65% vs. 75% and 60% vs 51% (p=0.75). Freedom from reoperation at 18 y: 55% BHV vs. 95% MHV (p=0.002). Freedom from major bleeding 78% MHV vs. 98% BHV (p=0.002). No difference in stroke rates.</td>
</tr>
<tr>
<td>Du 2014</td>
<td>(B1) 25221895</td>
<td>Pts &gt;65 y of age in Medicare data base who underwent AVR between July 1, 2006 and December 31, 2011. MHV, n=19190. BHV, n=47263.</td>
<td>Retrospective analysis. Mixed-effects model adjusting for physician and hospital random effects to estimate ORs of early mortality for MHV vs BHV.</td>
<td>Medicare beneficiaries enrolled in Parts A, B and D for 6 mo before AVR. Age &gt;65 y of age Mean, 77 y of age. 45% of study population underwent concurrent CABG.</td>
<td>Up to 365 d after surgery: OR death on d of surgery MHV vs. BHV 1.61 (95% CI: 1.27–2.04; p&lt;0.001); RR: 1.60. NNT: 290. OR death within 30 d surgery MHV vs. BHV 1.18 (1.09–1.28), p&lt;0.001. NNT 121. No difference between MHV and BHV d 31–365 after surgery. Consistent findings in subgroup analyses of pts undergoing AVR + CABG but not in subgroup undergoing isolated AVR.</td>
</tr>
<tr>
<td>Bourguignon 2015A</td>
<td>(B2) 25583467</td>
<td>2,659 pts who underwent AVR with the CE-Perimount BHV valve (1984-2008) at a single center.</td>
<td>Retrospective, observational.</td>
<td>Mean age 70.7 +/- 10.4 y of age (range 16–91 y of age) Age &lt;60 y of age: 383 (13%).</td>
<td>Multiple valve replacement Mean followup 6.7 +/- 4.8 y (0–24.6 y). Actuarial survival rates 10 y: 52.4% ± 1.2%; 15 y: 31.1% ± 1.4%; 20 y: 14.4% ± 1.7%. Freedom from reoperation from structural valve deterioration: 60 y or less:15 y:70.8% ± 4.1%; 20 y:38.1% ± 5.6%; 60-70 y: 15 y:82.7% ± 2.9%; 20 y: 59.6% ± 7.6% Over 70 y: &gt;15 y:98.1% ± 0.8%. Expected valve durability is 19.7 y for the entire cohort.</td>
</tr>
</tbody>
</table>
Bourguignon 2014B
(83)
24667021

450 pts who underwent MVR with the CE-Perimount BHV valve (1984-2011) at a single center
Retrospective, observational
Mean age 68±/10.4 y (22-89 y)
Multiple valve replacement
Mean followup 7.2 ±/5.1 y(0 –24.8 y)
- 20 actuarial survival rate including early deaths was 16.9% ±/3.9%.
- Valve-related actuarial survival rate was 82.4% ± 9.0%.
- 20 y actuarial freedom from complications was thromboembolism, 83.9% ±/7.6%; hemorrhage, 90.2% ±/10.8%; endocarditis, 94.8% ±/1.4%; structural valve deterioration, 23.7% ±/6.9%; and explanation for structural valve deterioration, 40.5% ±/8.0%.
- The expected valve durability was 16.6 y for the entire cohort (11.4, 16.6, and 19.4 y for pts aged <60, 60 to 70, and >70 y, respectively).

Bourguignon 2015C
(84)
26187006

373 pts <60 y of age underwent AVR with CE-Perimount BHV valve (1984-2008) at a single center
Retrospective, observational
Mean age 51.0 ±9.2 Median age 54 (47–57.5) Range: 16-60 y
Multiple valve replacement
Mean follow-up was 8.6+/5.9 y.
- Actuarial survival rates: 78.1% ± 2.6%, 65.6% ± 3.5%, and 46.8% ± 6.0% after 10, 15, and 20 y
- Actuarial freedom from reoperation rates attributable to structural valve deterioration at 10, 15, and 20 y: 88.3% ± 2.4%, 70.8% ± 4.1%, and 38.1% ± 5.6%

Chikwe, 2015
(85)
25871669

795 (23.2%) BHV
2638 (76.8%)
Propensity matching: 664 pairs
Retrospective, observational
Mean age: Whole group: 60.1 +/5.8 BHV: 61.2 ±/5.9
MHV: 59.7 ±/5.7
Out-of-state residency, prior replacement of any valve, concomitant valve replacement, concomitant valve repair, cCABG surgery, or thoracic aortic surgery
Median duration was 8.2 y(range, 0-16.8 y).
- Actuarial 15-y survival in propensity matched group:
  • MHV: 57.5% (95% CI: 50.5–64.4%) BHV: 59.9% (95% CI: 54.8–65.0%) HR:0.95 [95% CI: 0.79–1.15], p=0.62;
  • Stroke 15 y in propensity matched group:
    • MHV: 14.0%; 95% CI: 9.5–18.6%) BHV: 6.8%; 95% CI: 4.5–8.8%)
    • HR: 1.62 [95% CI: 1.10–2.39], p=0.01.
  • Bleeding 15 y in propensity matched group:
    • MHV: 14.9%; 95% CI: 11.0–18.7%) BHV: 9.0%; 95% CI: 6.4–11.5%)
    • HR: 1.50 [95% CI: 1.05–2.16], p=0.03,
  • Reoperation at 15 y in propensity matched group:
    • MHV: 5.0%; 95% CI: 3.1–6.9% BHV:11.1%; 95% CI: 7.6–14.6% HR: 0.59 [95% CI: 0.37–0.94], p=0.03

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.
| Glaser 2015 (86) | 4,545 pts 50–69 y old s/p 1°, isolated AVR in Sweden from January 1, 1997 to December 31, 2013
MHV: 2713 pts  
BHV: 1832 pts  
Propensity matching: 1099 pairs | Retrospective, observational | Mean age (y)  
Whole group: 61.4+/-5.3  
MHV: 59.9+/- 5.1  
BHV: 63.7 +/- 4.7 | Prior cardiac surgery or a concomitant procedures | FU for whole group:  
Mean: 7.3 +/- 4.7y  
Max: 17.2 y  
FU for MHV:  
Mean 8.8 +/- 4.6y  
Max: 17.2 y  
FU for BHV:  
Mean 5.0+/-3.7 y  
Max: 17.2 y | • Greater long-term survival in MHV vs. BHV  
• HR: for bioprosthetic vs. mechanical valves  
• Overall unadjusted analysis: HR: 1.67; 95% CI: 1.44–1.94  
Overall multivariable adjusted model: HR: 1.30; 95% CI: 1.09–1.56  
Propensity score-matched cohort: HR: 1.34; 95% CI: 1.09 – 1.66; P = 0.006)  
• Propensity score-matched pts aged 50–59 y: survival greater in MHV:  
HR: 1.67; 95% CI: 1.06–2.61; p=0.026, n=574).  
• Propensity score-matched pts aged 60–69 y: no survival difference in MHV vs. BHV:  
HR: 1.08; 95% CI: 0.85 – 1.36; p=0.539, n=1502).  
• 2° endpoints: Propensity score matched cohort:  
• MVH: Stroke: 5.8%; Reoperation: 2.2%; Major bleeding: 9.6%; CV death: 5.2%  
• BHV: HR: bioprosthetic vs. mechanical valves  
• Stroke : 6.1%  
HR: 1.04 (95% CI: 0.72–1.50)  
Reoperation: 5.2%  
HR: 2.36 95% CI: 1.42–3.94)  
Major bleeding: 4.9%  
HR:0.49 (95% CI: 0.34–0.70)  
CV death: 5.1%  
HR:1.00 (95% CI: 0.67–1.50)  
• 2° endpoints: Overall Cohort:  
• MVH: Stroke: 7.6%;  
Reoperation: 3.1%; Major bleeding: 9.9%; CV death: 5.4%  
• BHV: Stroke: 5.1%  
HR: 0.97 (95% CI: 0.72–1.31)  
Reoperation: 4.1 %  
HR: 2.07 (95% CI: 1.38–3.11)  
Major bleeding: 4.0%  
HR: 0.53 (95% CI: 0.39–0.74)  
CV death: 4.0%  
HR: 1.26 (95% CI: 0.87–1.81).  |
| Isaacs 2015 (87) | All pts>18 y old who underwent AVR in NIS database.  
767,375 implanted valves | Observational | Median age: 74 y for pts receiving BHV  
Median age: 67 y for pts receiving MHV.  
Pts who underwent a simultaneous valve annuloplasty, valve repair, or mitral or tricuspid valve replacement were excluded.  
All pts aged >18 y in the National Inpatient Sample who received an AVR between 1998 and 2011 were studied | All pts aged >18 y in the National Inpatient Sample who received an AVR between 1998 and 2011 were studied | • 767,375 implanted valves.  
BHV increased from 37.7% in 1998-2001 to 63.6% in 2007-2011.  
• Use of bioprosthetic valves increased across all age groups, most markedly in pts age 55 to 64 y. | Retrospective Relative short follow-up |
De Vincentiis 2008 (88)

345 consecutive pts who underwent AVR from 5/1991-4/2005 at a single institution

BHV: 200 pts (58%)

MHV: 145 (42%)

Retrospective

Mean age 82+/-1 2 y (range 80-92)

Age <80 y

Mean follow-up was 40 +/-33 mo (range, 1 to 176 mo);

• In hospital mortality:
  Total group: 7.5%
  BHV: 8.5%
  MHV: 6.2% (P=0.536)

• Late FU:
  Total group: 61% at 5 y
  21% at 10 y
  6% at 14 y

• The NYHA functional class improvement
  BHV: 3.3 0.7 to 1.2 0.5 (p=0.001)
  MVH: 3.2 0.6 to 1.2 0.5

• Survival by type of prosthesis was significantly higher with mechanical prostheses (log-rank p 0.03).

• Freedom from cerebrovascular events (thromboembolic/hemorrhagic) at 5 and 10 y:
  BHV: 92% and 77%; MHV: 89% and 62%

Vicchio 2008 (89)


BHV: 68 pts

MHV: 92 pts

121 pts were alive at follow-up and answered the QoL questionnaire

BHV: 62 pts

MHV: 98 pts

Retrospective

Mean age of 82.3 2.3 y of age (range, 80 to 90 y of age)

BHV: 82.9 +/12.7 y

MHV:81.8+/-1.8 y

Age <80 y

3.4 +/-2.8 y (range, 6 mo to 14.4 y),

• Total hospital mortality: 8.8%
  BHV: 10.3%; 7.6% (p=0.75)
  Survival at 1, 3, 5 and 8 y:
  BHV: 86.4% +/-0.04%, 76.9% +/-0.06%, 58.1% +/-0.1%, and 46.5% +/-0.14%
  MHV: 91.3% +/-0.03%, 88.6% +/-0.03%, 81.6% +/-0.05%, and 70% +/-0.076% (p 0.025)

• QOL scores comparable between BHV and MHV

Dvir D, et al., 2012 (90)

202 pts with degenerated bioprosthetic valves from 38 cardiac centers. Bioprosthest mode of failure was stenosis (n=85, 42%), regurgitation (n=68, 34%) or combined stenosis and regurgitation (n=49, 24%). Implanted devices: Corevalve: n=124

Edwards: n=78

Global valve-in-valve Registry

Retrospective collection of data from cases performed before registry initiation, and prospective data collection after that time.

Mean y of age 77.7 +/- 10.4

All pts in the registry were included

Procedural success and 30-d FU

One yr FU in 87 pts

• Procedural success: 93.1% cases
  Adverse procedural outcomes: Device malposition: 15.3% Coronary obstruction: 3.5%
  30-d FU: All-cause mortality: 8.4% NYHA class III: 83.7%
  1 y FU in 87 pts; 85.8% survival

Short-term FU

Very few pts in late followup

Small sample size

Bias towards healthier pts receiving MHV

Retrospective
<table>
<thead>
<tr>
<th>Study</th>
<th>Authors</th>
<th>Year</th>
<th>Number and Description</th>
<th>Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dvir D, et al.</td>
<td>2014 (91)</td>
<td>25005653</td>
<td>459 pts with degenerated bioprosthetic valves undergoing valve-in-valve implantation between 2007 and May 2013 in 55 centers. Modes of BHV failure: Stenosis (n=181 [39.4%]), regurgitation (n=139 [30.3%]). Combined (n=139 [30.3%]).</td>
<td>Multinational valve-in-valve registry from 55 countries. Data collected retrospectively for cases performed before registry initiation and prospectively thereafter.</td>
<td>Mean age All: 77.6 +/-9.8 Mean age stenosis: 78.8 +/-7.8 Mean age regurgitation: 77.1 +/-10.6 Mean age self-expandible: 77.6 +/-10 Mean age balloon expandible: 77.6 +/-9.7</td>
</tr>
<tr>
<td>McClure RS, et al.</td>
<td>2014 (80)</td>
<td>24521965</td>
<td>n=1,701 pts &lt;65 y referred for isolated AVR (769 received a stented bioprosthetic valve; 932 received a mechanical valve)</td>
<td>Propensity-matched cohort, retrospective single center observational study</td>
<td>Mean age ≤65 y undergoing an isolated AVR with a bileaflet mechanical or stented bioprosthesis.</td>
</tr>
<tr>
<td>Repack 2016 (92)</td>
<td>26389590</td>
<td>N= 146 pts; to assess postoperative QOL in pts with either mechanical or bioprosthetic valves for aortic root repair</td>
<td>Prospective, observational</td>
<td>Pts who underwent aortic root repair with either mechanical (65.1%) or bioprosthetic (34.9%) and completed the QoL survey</td>
<td>Pts who did not complete QoL survey</td>
</tr>
<tr>
<td>Study Acronym; Author; Year Published</td>
<td>Aim of Study; Study Type; Study Size (N)</td>
<td>Patient Population</td>
<td>Study Intervention (# patients) / Comparator (# patients)</td>
<td>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</td>
<td>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>------------------------------------------</td>
<td>--------------------</td>
<td>----------------------------------------------------------</td>
<td>-------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>PROACT Puskas J 2014 (93) 24512654</td>
<td>Aim: To assess the efficacy and safety of less intensive anticoagulation (INR 1.5–2.0) in high-risk pts receiving an On-X AVR</td>
<td>Study type: RCT Size: n=375 pts</td>
<td>Intervention (test group): Warfarin targeted to INR 1.5-2.0 Comparator (control group): Warfarin targeted to INR 2.0–3.0 All pts received ASA 81 mg Randomization at 3 mo post-operatively All pts were treated with warfarin targeted to INR 2.0–3.0 plus ASA 81 mg daily for first 3 post-operative mo</td>
<td>1° endpoint: The 1° endpoints mandated by the FDA included major bleeding events, minor bleeding events, total bleeding events, TIA, hemorrhagic stroke, nonhemorrhagic stroke, any neurologic event, peripheral TE, any TE, valve thrombosis, TE and thrombosis, major event (major bleeding, any TE, valve thrombosis), death (cardiac, noncardiac, valve-related, and all-cause)</td>
<td>• The 2° endpoints included endocarditis, hemolysis, hemolytic anemia, PVL, structural and nonstructural dysfunction, postoperative NYHA class and echocardiographic Hemodynamics. • Comments: TTR 63.8% test group (INR 1.5–2.) vs. 69.8% control group (INR 2.0–3.0) • Mean INR 1.89 +/- 0.50 for test group vs. 2.5±0.64 control group (p&lt;0.0001) 14 (3.7%) of pts had AF • Unblinded</td>
</tr>
<tr>
<td>AREVA Acar, et al. 1996 (94) 8901659</td>
<td>Aim: To compare moderate oral anticoagulation (INR 2.0–3.0) to higher intensity anticoagulation (INR 3.0–4.5) following single- MV replacement (Omnicarbon or St. Jude)</td>
<td>Study type: RCT Size: n=433 pts (380 pts received treatment)</td>
<td>Intervention: INR of 2.0–3.0 (n=188 pts) Comparator: INR of 3.0–4.5 (n=192 pts)</td>
<td>1° endpoint: Thromboembolic, hemorrhagic events, mortality, endocarditis, withdrawal from oral anticoagulant therapy Safety endpoint (if relevant): None</td>
<td>• Major and minor bleeding events were significantly lower in the INR 2.0–3.0 group vs. the INR 3.0–4.5 group. • NS difference in thromboembolic event rates in the 2.0–3.0 group compared to the 3.0–4.5 group</td>
</tr>
<tr>
<td>Reference</td>
<td>Aim</td>
<td>Study type</td>
<td>Size</td>
<td>Inclusion criteria</td>
<td>Intervention and Comparator</td>
</tr>
<tr>
<td>-----------</td>
<td>-----</td>
<td>------------</td>
<td>------</td>
<td>--------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Hering 2005 (95) 15653962</td>
<td>To compare rates of thromboembolism and anticoagulation after MHV replacement.</td>
<td>RCT</td>
<td>n=2,735 pts</td>
<td>Pts undergoing St. Jude Medical AVR, MVR or combined AVR/MVR between July 1993 and May 1999</td>
<td>Group A: INR 3.0–4.5, Group B: INR 2.5–4.0, Group C: INR 2.0–3.5</td>
</tr>
<tr>
<td>Torella, 2010 (96) 20598989</td>
<td>To evaluate the safety of lower intensity oral anticoagulation following isolated mechanical AVR</td>
<td>RCT</td>
<td>n=396 pts</td>
<td>Low-risk pts following bileaflet mechanical AVR</td>
<td>Low- INR 1.5–2.5, Comparator: Conventional- INR 2.0–3.0</td>
</tr>
<tr>
<td>Mere, 2012 (97) 23188028</td>
<td>To assess the association of warfarin treatment with the risk of thromboembolic complications, bleeding incidents and CV death after bioprosthetic AVR</td>
<td>RCT</td>
<td>n=4,075 pts</td>
<td>Pts who had bioprosthetic AVR surgery performed between 1/1/1997 and 12/31/2009</td>
<td>Discontinued warfarin treatment, Comparator: Continued warfarin treatment</td>
</tr>
</tbody>
</table>

There was no significant difference in incidence of TEs and bleeding complications among the 3 groups.
Further study is needed of the intensity of anticoagulants in pts with SJM valve.

The mean INR was 1.94 ± 0.21 in the Low INR group and 2.1±0.25 in the Conventional INR group (p<0.001)
No difference in thromboembolic event rates
Total hemorrhagic events occurred in 6 pts in the low INR group vs. 16 pts in the conventional INR group (p=0.04)
The low INR is safe and feasible in low risk pts following bileaflet aortic mechanical valve replacement.

Discontinuation of warfarin within 3 mo of surgery was associated with significant increases in the risks of stroke, thromboembolism and CV death.
Discontinuation of warfarin within 90 to 179 d after surgery was associated with an increased risk of CV death,
### Brennan et al, 2012 (98) 22921973

**Aim:** To evaluate the risks and benefits of short-term anticoagulation in pts receiving an aortic valve bioprosthesis  
**Study type:** STS Adult Cardiac Database analysis  
**Size:** n=25,656

**Inclusion criteria:** Pts >65 y who had bioprosthetic AVR surgery performed between 2004–2006  
**Exclusion criteria:** Pts in whom clinical equipoise for anticoagulation was unlikely, including those with preoperative indication for warfarin, an indwelling mechanical valve, a predischarge contraindication to warfarin, a complication related to anticoagulation or those who died before hospital discharge

**Intervention and Comparator:**  
- **Group A:** ASA only  
- **Group B:** ASA and warfarin  
- **Group C:** Warfarin only

**1st endpoint:** Death, repeat hospitalization for embolic events or bleeding  
Among those receiving ASA-only, 3-mo adverse events were low (death, 3.0%; embolic events, 1.0%; bleeding events, 1.0%). Relative to ASA-only, those treated with warfarin plus ASA had a lower adjusted risk of death (RR: 0.80; 95% CI: 0.65–0.96) and embolic event (RR: 0.52; 95% CI: 0.35–0.75) but a higher risk of bleeding (RR: 2.80; 95% CI: 2.18–3.60). Relative to ASA-only, warfarin-only pts had a similar risk of death (RR: 1.01; 95% CI: 0.80–1.27), embolic events (RR: 0.95; 95% CI: 0.61–1.47), and bleeding (RR: 1.23; 95% CI: 0.85–1.79).

**Results:** BPVT is not uncommon and can occur several years after surgery.  
A combination of clinical and echocardiographic features can reliably diagnose BPVT

### Egbe AC1, et al. 2015 (99) 26610876

**Aim:** To determine the diagnostic features of BPVT  
**Study type:** Pathology database analysis  
**Size:** n=46 pts

**Inclusion criteria:** 46 of 397 consecutive cases of explanted bioprosthesis in the Mayo Clinic pathology database between 1997–2013 which were diagnosed as BPVT, matched 1:2 for age, sex and bioprosthesis position with pts whose valves were explanted for structural failure  
**Exclusion criteria:** Pts whose valves were explanted for structural failure

**Intervention and Comparator:** BPVT vs. structural deterioration of bioprosthesis  
**Results:** 46 cases of BPVT (11.6%; aortic 29, mitral 9, tricuspid 7, pulmonary 1), mean age 63 y, and 68% were male. 30 (65%) cases occurred >12 mo post-implantation; median bioprosthetic valve longevity was 24 mo (cases) vs. 108 mo (controls) (p<0.001). Independent predictors of BPVT were >50% increase in mean echo-Doppler gradient from baseline within 5 y (OR: 12.7), paroxysmal AF (OR: 5.19), subtherapeutic INR (OR: 7.37), increased cusp thickness (OR: 12.2), and abnormal cusp mobility (OR: 6.94). Presence of all 5 diagnostic features was predictive of BPVT with 76% sensitivity, 93% specificity, 85% positive predictive value, and 89% negative predictive value (p<0.001).

**Conclusion:** The condition resolved with therapeutic anticoagulation.

### Makkar RR, et al. 2015 (100) 26430963

**Aim:** To investigate the possibility of subclinical leaflet thrombosis in bioprosthetic AVs after TAVR and the effect of anticoagulation  
**Study type:** Analysis of 4D volume rendered CT scans from a clinical trial and 2 registries of TAVR

**Inclusion criteria:** Pts who had 4D volume rendered CT scans following TAVR implantation in a clinical trial and 2 registry studies  
**Exclusion criteria:** Pts with unusable scans (33 in clinical trial and 8 in registry studies)

**Intervention and Comparator:**  
- **Group A:** Initiated or continued anticoagulation  
- **Group B:** No anticoagulation

**Results:** Reduced leaflet motion was noted on CT in 22 of 55 pts (40%) in the clinical trial and 17 of 132 pts (13%) in the 2 registries. Reduced leaflet motion was detected among pts with multiple bioprosthesis types, including transcatheter and surgical bioprostheses. Therapeutic anticoagulation with warfarin, as compared with DAPT, was associated with a decreased incidence of reduced leaflet motion (0% and 55%, respectively, p=0.01 in the clinical trial; and 0% and 29%, respectively, p=0.04 in the pooled registries). In pts reevaluated with follow-up CT, the condition resolved with therapeutic anticoagulation.

**Conclusion:** Reduced aortic-valve leaflet motion was shown in pts with bioprosthetic AV following TAVR.
<table>
<thead>
<tr>
<th>Hansson NC et al.</th>
<th>2016 (101) 27580689</th>
</tr>
</thead>
</table>

**Aim:** To assess the incidence, potential predictors, and clinical implications of THV thrombosis as determined by contrast-enhanced MDCT after TAVR

**Study type:** Analysis of contrast enhanced MDCT scans from consecutive pts undergoing TAVR

| **Size:** n=405 pts |

**Inclusion criteria:** 460 consecutive pts who underwent TAVR at a single center between 2011-2016

**Exclusion criteria:** 55 pts who did not have contrast enhanced MDCT scans at 1-3 mo following TAVR

**Intervention and Comparator:**
- **Group A:** Treatment with warfarin
- **Group B:** No treatment with warfarin

**Results:** MDCT verified THV thrombosis in 28 of 405 (7%) pts. A total of 23 pts had subclinical THV thrombosis, whereas 5 (18%) pts experienced clinically overt obstructive THV thrombosis. The risk of THV thrombosis in pts who did not receive warfarin was higher compared with pts who received warfarin (10.7% vs. 1.8%; RR: 6.09; 95% CI: 1.86–19.84). A larger THV was associated with an increased risk of THV thrombosis (p=0.03). In multivariable analysis, a 29-mm THV (RR: 2.89; 95% CI: 1.44–5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68–17.7) independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of pts as documented by follow-up TEE and MDCT.

Pache et al 2016 (102) 26446193

**Aim:** To evaluate the frequency of early hypo-attenuated leaflet thickening of transcatheter AVs

**Study type:** Analysis of ECG gated dual source CTA angiography following TAVR at median of 5 d after implantation

| **Size:** n=156 pts |

**Inclusion criteria:** 249 pts who had TAVR at a single institution between 2014-2015

**Exclusion criteria:** Pts who had a contraindication for CTA due to acute renal failure, impaired renal function, missing consent, or inability to undergo a CTA examination (93 pts)

**Intervention and Comparator:**
- **Group A:** Presence of hypo-attenuated leaflet thickening
- **Group B:** Absence of hypo-attenuated leaflet thickening

**Results:** Hypo-attenuated leaflet thickening was found in 16 pts [10.3% (95% CI: 5.5%–15.0%)]. Hypo-attenuated leaflet thickening was not associated with clinical symptoms, but a small, albeit significant difference in mean pressure gradient at the time of CTA (11.6 ± 3.4 vs. 14.9 ± 5.3 mm Hg, p=0.026). Full anticoagulation led to almost complete resolution of hypo-attenuated leaflet thickening in 13 pts with follow-up CTA.

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.
### Data Supplement 21. *(Updated From 2014 Guideline)* Bridging Anticoagulation Therapy for Mechanical Heart Valves (Section 11.3.2)

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Study Type</th>
<th>Patient Population</th>
<th>Study Size and Comparator (N)</th>
<th>Outcomes</th>
<th>Study Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hammerstingl C, et al. 2007 (103)</td>
<td>Prospective, observational</td>
<td>Pts with MHV undergoing major surgery (n=25) or minor surgery (n=56), pacemaker implantation (n=21), or cardiac cath (n=34)</td>
<td>N/A</td>
<td>No thromboembolic (95% CI: 0–3.1%) complications. 1 major bleeding complication (0.86%; 95% CI: 0.02–4.7%). Minor bleeding in 10 pts (8.6%; 95% CI: 4.2–15.3%) at a mean of 5.4±1.4 d LMWH therapy.</td>
<td>Not randomized, no comparison group, relatively small study group.</td>
</tr>
<tr>
<td>Spyropoulos, et al. 2008 (104)</td>
<td>Observational, prospective, multicenter registry in USA, Canada</td>
<td>Adults undergoing elective surgery or invasive procedure with a mechanical valve on long-term VKA</td>
<td>Enrolled in another bridging study within 30 d. 73 with IV UFH (1,536±532 U/h) vs. 172 with SQ LMWH (76% enoxaparin 1 mg/kg bid, 13% dalteparin 100 U/kg bid, 4% tinzaparin 175 U/kg/d)</td>
<td>Major adverse event rates (5.5% vs. 10.3%; p=0.23) and major bleeds (4.2% vs. 8.8%; p=0.17) were similar in the LMWH and UFH groups, respectively; 1 arterial thromboembolic event occurred in each group. More LMWH-bridged pts were treated as out pts or discharged from the hospital in &lt;24 h (68.6% vs. 6.8%; p&lt;0.0001). Multivariate logistic analysis found no significant differences in major bleeds and major composite adverse events when compared to the UFH group.</td>
<td>Not randomized, bridging therapy chosen by clinician. The LMWH group was less likely to undergo major surgery (33.7% vs. 58.9%; p=0.0002) and cardiothoracic surgery (7.6% vs. 19.2%; p=0.008), and to receive intraprocedural anticoagulants or thrombolytics (4.1% vs. 13.7%; p=0.007)</td>
</tr>
<tr>
<td>Pengo, et al. 2009 (105)</td>
<td>Prospective inception cohort at 22 Italian centers, 2005–2007</td>
<td>Adults undergoing surgical or invasive procedures that required interruption of long-term VKA therapy</td>
<td>Body weight &lt;40 kg, Creatinine &gt;2.0 mg/dL, contraindication to LMWH, need for dual antiplatelet Rx</td>
<td>N=189 MHV valve pts (15% of total study size of 1,262). Bridging with 70 anti-Xa U/kg/bid for high-risk pts.</td>
<td>Only 15% had mechanical valves, no comparison group. Safety in pts with MHV valves has not been conclusively established.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any UFH N=99</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Population</td>
<td>Methods</td>
<td>Outcomes</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>------------</td>
<td>---------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Bu H, et al. 2009 (10)</td>
<td>Retrospective cohort study</td>
<td>173 pts on VKA anticoagulation for MHV (n=90) or for nonvalvular AF undergoing invasive or surgical procedures</td>
<td>Age &lt;18 y, Pregnancy, Hypercoagulable condition, bioprosthetic valve</td>
<td>No deaths or thromboembolic events at 2 mo. Major and minor bleeding rates were similar between the MHV and AF groups (3.2% and 2.9%, 14.5% and 13.2% respectively, p=NS).</td>
<td></td>
</tr>
<tr>
<td>Bleker, et al. 2012 (10)</td>
<td>Prospective cohort, single-center</td>
<td>Consecutive pts undergoing noncardiac surgery</td>
<td>Bioprosthetic valves, severe liver or renal disease, contraindication to heparin</td>
<td>Not randomized. Comparator group of AF may not require bridging. No sample size calculation for power of study.</td>
<td></td>
</tr>
<tr>
<td>Weiss, et al. 2013 (10)</td>
<td>Retrospective, single-center cohort study</td>
<td>Consecutive pts requiring postoperative bridging therapy after cardiac surgery during a 19 mo period</td>
<td>N/A</td>
<td>Not randomized, but well matched (first half of cohort received FD, second half HD) included only 100 (25.9% of total) pts with MHV, also included AF in 83.6%.</td>
<td></td>
</tr>
</tbody>
</table>

UFH or LMWH bridging used in high-risk pts (older AVR, any MVR, additional risk factors for TE). No bridging in isolated AVR pts. Minor Bleeding: Overall cumulative incidence of TE at 3 mo was 0.9%; all 1 wk of the procedure. No TE events VR with no bridging events occurred within in 53 pts with isolated A. 13 (6.1) 13 (5.4) 8 (8.1)
RCT, double-blind, placebo-controlled trial
Pts with chronic AF or flutter receiving warfarin therapy for at least 3 mo undergoing elective surgery
Mechanical heart valve, at least 1 CHADS2 risk factor cardiac, intracranial or intraspinal surgery.
N=1884; 950 with no bridging therapy. 934 assigned to bridging with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 d before the procedure until 24 h before the procedure and then for 5 to 10 d after the procedure.
The incidence of arterial thromboembolism was 0.4% in the no-bridging group and 0.3% in the bridging group (risk difference, 0.1 percentage points; 95% CI: −0.6 to 0.8; p=0.01 for noninferiority). The incidence of major bleeding was 1.3% in the no-bridging group and 3.2% in the bridging group (RR: 0.41; 95% CI: 0.20–0.78; p=0.005 for superiority).

Population excluded pts with MHV and was predominantly low risk for thromboembolism.

Study Acronym; Author; Year Published
Keuleers S, et al. 2011 (112) 21211605

Aim: to review the outcome of TT vs surgery for obstructive PVT
Study type: Single-center retrospective study
Size: n=30 pts with mechanical PVT (1 bioprosthesis)

Inclusion criteria: prosthetic valve dysfunction with thrombus present
Exclusion criteria: Patient Population: 81% women, mean age 59, NYHA Class IV 42%, all mitral

Intervention: tPA 10 mg then 90 mg over 2 h (13 pts)
Comparator: surgery (18 pts)

1° endpoint: Complete clinical response =complete hemodynamic response (normalization of gradient with complete leaflet opening on fluoroscopy) in absence of major complication
Results: Complete clinical response 62% partial response in 31% in obstructive. Size of thrombus not related to outcome.
Complications: 2 deaths at surgery, recurrence 31% in TT group with 1 death, other TT complications 1 CVA 1

Data Supplement 7. Prosthetic Valve Thrombosis (Section 11.6)
<table>
<thead>
<tr>
<th>Study Details</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>1st endpoint</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nagy A et al 2009 (113) 19567981</td>
<td>to assess effect of thrombus size, severity of symptoms and type of valve on success and complication rate of TT for PVT</td>
<td>obstructive – restricted leaflet motion with increased gradient, non-obstructive – thrombus on TEE</td>
<td>bolus and continuous infusion of SK, UK up to 72 h</td>
<td>N/A</td>
<td>complete clinical response = complete hemodynamic response (normalization of gradient with complete leaflet opening on fluoroscopy) in absence of major complication</td>
<td>Size of thrombus unrelated to success or complication rate. NYHA Class III/IV presentation vs III – no difference in success or complication rate of TT</td>
</tr>
<tr>
<td>Study type: Single-center retrospective study</td>
<td>Exclusion criteria:</td>
<td></td>
<td></td>
<td></td>
<td>• Conclusion: single-center study with loss of followup – cannot compare TT mortality vs surgical mortality as 2/3 had surgery after failed TT</td>
<td></td>
</tr>
<tr>
<td>Size: n=62 episodes in 55 pts identified by TEE</td>
<td>Patient Population: 61% women, mean age 56, NYHA Class III/IV 71% in obstructive, valve type (mitral 62), 52 obstructive 10 nonobstructive. Average thrombus area 1.06 cm² obstructive and 0.59 cm² in nonobstructive</td>
<td></td>
<td></td>
<td></td>
<td>• Comments: Intention to treat TT mortality 11% and surgical mortality 44% - overall TT mortality 6% and surgical mortality 26%</td>
<td></td>
</tr>
<tr>
<td>Lengyel M et al 2001 (114) 11603604</td>
<td>to compare the efficacy and safety of heparin vs TT vs surgery in pts with both obstructive and nonobstructive PVT</td>
<td>obstructive – restricted leaflet motion with increased gradient, nonobstructive – thrombus on TEE</td>
<td>Infusion of SK, UK up to 72 h</td>
<td>N/A</td>
<td>complete clinical response 73% partial response in 21% in obstructive. Size of thrombus not related to outcome.</td>
<td>• Conclusion: TT was best in both NYHA class III as well as NYHA class III/IV due to high risk surgery. Heparin ineffective in both obstructive and nonobstructive</td>
</tr>
<tr>
<td>Study type: Single-center retrospective study</td>
<td>Exclusion criteria: recurrent PVT or contraindication to TT</td>
<td></td>
<td></td>
<td></td>
<td>• Limitation: single-center without a standard process to decide therapy – cannot compare results of high mortality with surgery (29%) to mortality with TT (6%) as sicker pts in the surgery group</td>
<td></td>
</tr>
<tr>
<td>Size: 85 episodes in 59 pts identified by TEE</td>
<td>Patient Population: 58% women, mean age 53, NYHA Class III/IV 90% in obstructive, valve type (mitral 41 aortic 3), 54 obstructive 31 nonobstructive</td>
<td></td>
<td></td>
<td></td>
<td>• Comments: heparin alone inadequate in 82%, Authors state that TT is treatment of choice for all pts with PVT.</td>
<td></td>
</tr>
<tr>
<td>Karthikeyan G et al 2009 (115) 19738134</td>
<td>to compare the efficacy and safety of an accelerated infusion vs conventional infusion of SK in pts with PVT</td>
<td>obstructive – heparin or TT (SK or UK load with continuous infusion until successful) as initial therapy in 30 mitral and 2 aortic obstructive, surgery in 9 mitral and 1 aortic, Nonobstructive-heparin first</td>
<td>Intervention: Obstructive – heparin or TT, 4/43 CVA, 1/43 major bleed</td>
<td>N/A</td>
<td>complete clinical response 86% partial response in 9% with TT – heparin ineffective with both obstructive and no obstruction with half leading to obstruction</td>
<td>• Conclusion: no statistically significant difference in the outcome of the 2 infusion rates, although there was a trend toward more major bleeding in the accelerated infusion group</td>
</tr>
<tr>
<td>Study type: Randomized controlled prospective trial</td>
<td>Exclusion criteria:</td>
<td></td>
<td></td>
<td></td>
<td>• Limitation: underpowered to show a difference between the 2 groups. TEE was not performed.</td>
<td></td>
</tr>
<tr>
<td>Size: 120 pts entered into randomization for PVT</td>
<td>Patient Population: 44% women, mean age 33, NYHA Class III/IV 31%, valve type (mitral 79, aortic 30, both 11), all obstructive</td>
<td></td>
<td></td>
<td></td>
<td>• Comments: complete clinical response 74% in NYHA Class III and 24% on NYHA Class III/IV. Only randomized trial thus far with TT therapy, showing a lower success rate than prior studies</td>
<td></td>
</tr>
</tbody>
</table>

**Intervention:** 1st endpoint: complete clinical response = complete hemodynamic response (normalization of gradient with complete leaflet opening on fluoroscopy) in absence of major complication

**Comparator:** N/A

**Complications:** 3 deaths after surgery from failed TT, 4 deaths from complications of TT. 5 CVA, 1 TIA, 1 cerebral bleed, 2 major bleed, 2 embolic events.

**Limitsation:** Single-center without a standard process to decide therapy – cannot compare results of high mortality with surgery (29%) to mortality with TT (6%) as sicker pts in the surgery group.
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1° endpoint</th>
<th>Comparator</th>
<th>Results</th>
<th>Complications</th>
<th>Conclusion</th>
<th>Limitation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caceres-Loriga et al 2006 (116) 16622616</td>
<td>To determine the efficacy and safety of TT for PVT</td>
<td>Single-center retrospective review</td>
<td>69 consecutive pts with PVT</td>
<td>Consecutive pts presenting with left sided obstructive PVT and no contraindication to TT</td>
<td>Bolus and continuous infusion of SK up to 72 h</td>
<td>Complete hemodynamic response (normalization of gradient with complete leaflet opening on fluoroscopy)</td>
<td>N/A</td>
<td>Complete hemodynamic response 80.6%, partial response 8.3%, no response 11%</td>
<td><strong>4 deaths, 5 embolic complications (3 CVA and 5 TIA), 3 major hemorrhage (2 intracranial bleeding). 16% had recurrence in follow-up.</strong></td>
<td>Single-center retrospective study</td>
<td>Authors recommended TT as first line of therapy in all pts</td>
<td></td>
</tr>
<tr>
<td>Gupta et al 2000 (117) 11099995</td>
<td>To determine the short and long-term results of TT for PVT</td>
<td>Single-center retrospective review</td>
<td>110 consecutive pts with obstructive PVT</td>
<td>All pts presenting with left sided obstructive PVT and no contraindication to TT</td>
<td>Bolus and continuous infusion of SK up to 72 h</td>
<td>Complete hemodynamic response (normalization of gradient with complete leaflet opening on fluoroscopy)</td>
<td>N/A</td>
<td>Complete hemodynamic response 81.8%, partial response 10%, and no response 8.2%. 23% had recurrence in follow up.</td>
<td><strong>8 deaths, 21 embolic complications (6 CVA and 5 TIA), 9 major hemorrhage (5 intracranial bleeding).</strong></td>
<td>Single-center study with 10% lost to follow-up. TEE was not done in majority.</td>
<td>pts who died were primarily those with severe Class IV HF and 3 died within 2 h of infusion (not enough time for TT to work), of incomplete responders only 3/11 did well</td>
<td></td>
</tr>
<tr>
<td>Roudaut et al 2009 (118) 19427604</td>
<td>To define the efficacy and safety of thrombolysis vs surgery for PVT</td>
<td>Single-center retrospective review</td>
<td>210 pts; treated by TT (n=127 pts) or surgery (n=136 pts)</td>
<td>All pts at single institution treated for PVT</td>
<td>SK (49), UK (41), rTPA (37), combination (38)</td>
<td>Hemodynamic success (complete normalization of hemodynamics by echo and fluoroscopy)</td>
<td>Surgery with either valve replacement (106) or declotting pannus excision (30)</td>
<td>Hemodynamic success higher in surgery 89% vs TT group 71%</td>
<td>Mortality similar (10%) both groups, total complications (25% vs 11%) and embolic events (15% vs 0.7%) higher in TT vs surgery group</td>
<td>Single-center experience which changed over time – surgery the more preferred therapy with time</td>
<td>NYHA class at presentation was strongest predictor of late death. Long-term follow-up at 6 y– better outcome in terms of mortality and recurrence with surgery 76% of pts were subtherapeutic on their INR before presentation, 23% had temporary cessation of warfarin</td>
<td>Surgical had a higher success rate and lower complication rate than TT</td>
</tr>
</tbody>
</table>
Tong AT et al.
2004
(119) 14715187

**Aim:** To determine whether thrombus size can predict outcome of thrombolysis therapy for PVT

**Study type:** Registry of TEE performed prior to TT for PVT

**Size:** n=107 pts entered into registry

**Inclusion criteria:** Pts suspected of PVT obstruction or thrombus formation undergoing TEE prior to TT

**Exclusion criteria:**
- **Patient Population:** 107 pts from 14 centers, 71% women, mean age 54, valve type (19 mitral, 13 aortic, 15 tricuspid), NYHA Class III/IV 63%, 99 obstructive vs 14 nonobstructive

**Intervention:** Slow infusion SK (54%), UK (17%) or tPA (29%)

**Comparator:** N/A

**1° endpoint:** Complete hemodynamic success (hemodynamics to normal range), partial hemodynamic success (partial improvement in hemodynamics), clinical success (hemodynamic success without complication)

**Results:** Complete hemodynamic success 76%, partial hemodynamic success 8.6%, clinical success 74%

**Complications:** Overall complications in 17.8%. Death 5.6%, left sided embolic rate 14%, major complication of death, CVA, MI, cerebral bleed in 9.3%

**Conclusion:** Thrombus area >0.8cm2, Hx of stroke and NYHA Class III/IV was predictive of complications and poor outcome

**Limitation:** Registry study from 14 centers with strict inclusion criteria and differing thrombolytic regimens – a study more of the TEE predictors rather than outcome of thrombolysis

**Comments:** Soft mass increased success to 91% but still 75% success without soft mass

Thrombus size was an important predictor of complication even in Class III/IV pts

TROIA Trial.
Ozkan M, et al
2013
(120) 23489534

**Aim:** To identify the most effective and safest TEE-guided thrombolytic regimen for PVT.

**Study type:** Single-center, non-randomized, prospective

**Size:** 182 consecutive pts with 220 episodes of PVT

**Inclusion criteria:** Pts with obstructive PVT, nonobstructive PVT with recent thromboembolism, or a thrombus diameter of ≥10 mm

**Exclusion criteria:** Contraindication to TT, nonobstructive PVT with a thrombus diameter of <10 mm and no recent thromboembolism, prosthetic valve obstruction with no thrombus on TEE and normal prosthetic valve leaflet motion

**Patient population:** 182 pts, 71% female, mean age 43, 41% NYHA Class III/IV, valve type (84% mitral, 10% aortic), 48% obstructive, 52% nonobstructive

**Intervention:** Different thrombolysis regimens:
- **Group I:** Rapid streptokinase (16)
- **Group II:** Slow streptokinase (41)
- **Group III:** High dose tPA (12)
- **Group IV:** Half dose, bolus and slow tPA infusion (27)
- **Group V:** Low dose, non –bolus and slow tPA infusion (124)

**Comparator:** N/A

**1° endpoint:** Thrombolytic success
- Obstructive: Decrease gradient, 75% reduction in thrombus size and clinical improvement (complete all 3, partial <3)
- Nonobstructive: >75% reduction thrombus size

**Results:** Successful thrombolysis in 83.2% of cases (68.8%, 85.4%, 75.0%, 81.5%, 85.5% respectively; p<0.46)

**Complications:** Overall complication rate of 18.6%. Lower combined complication rate in Group V (10.5%) vs. other groups (24%-38%)

Absence of mortality in Group V. The predictors of combined mortality plus nonfatal major complications were any TT regimen other than Group V (OR group 1 through IV: 8.2, 3.8, 8.1 and 4.1 respectively; p<0.05 for each)

**Conclusion:** Low-dose nonbolus slow tPA infusion resulted in the highest success rate of thrombolysis and lowest combined complication rate.

**Limitation:** Single-center nonrandomized study with small number of pts in each group, included both obstructive and nonobstructive PVT

**Comments:** 64 pts who had a contraindication to thrombolysis or failed thrombolysis underwent surgery with a 27% mortality

Ozkum M et al.
2013
(121) 23812180

**Aim:** To evaluate the safety and efficacy of low-dose, slow infusion tPA activator for the treatment of PVT in pregnant women

**Inclusion criteria:** Pregnant pts. with obstructive and nonobstructive PVT with recent thromboembolism and thrombus diameter of >5mm and pts with asymptomatic mobile nonobstructive PVT with thrombus

**Intervention:** Low dose tPA – 25 mg over 6 h, repeat at 24 h

**Comparator:** N/A

**1° endpoint:** Thrombolytic success
- Obstructive: Decrease gradient, 75% reduction in thrombus size and clinical improvement (complete all 3, partial <3)
- Nonobstructive: >75% reduction thrombus size

**Result:** 100% thrombolytic success. (Obstructive PVT group thrombus area, mean, 1.7±1.2 cm²; range, 0.8–6

**Conclusion:** low dose slow infusion of tPA is an effective and safe regimen for PVT in pregnant women

**Limitation:** single-center nonrandomized trial with small number of pts.; included both obstructive and nonobstructive PVT
<table>
<thead>
<tr>
<th>Study type:</th>
<th>Single-center, nonrandomized, prospective (subgroup of TROIA trial)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size:</td>
<td>24 consecutive pregnant pts with 28 episodes of PVT (all mitral – 23 mechanical)</td>
</tr>
<tr>
<td>Diameter of thrombus:</td>
<td>≥10 mm</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>Pts. with contraindication to TT, asymptomatic non obstructive PVT with a thrombus diameter of &lt;10mm and no recent thromboembolism, pts with imminent abortion or placenta previa, pts with prosthetic valve obstruction with no thrombus on TEE and normal prosthetic valve leaflet motion</td>
</tr>
<tr>
<td>Patient population:</td>
<td>24 women during 25 pregnancies and 28 episodes PVT, mean age 29, mean gestational age 19 wk, NYHA class III/IV (50%) obstructive in 15 (all mitral), nonobstructive in 13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Single-center, nonrandomized, prospective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size:</td>
<td>114 consecutive pts with 120 episodes of PVT (113 mechanical PVT)</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>Pts with obstructive PVT, nonobstructive PVT with recent thromboembolism, or a thrombus diameter of ≥10 mm</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>Contraindication to TT, nonobstructive PVT with a thrombus diameter of &lt;10 mm and no recent thromboembolism, Prosthetic valve obstruction with no thrombus on TEE and normal prosthetic valve leaflet motion</td>
</tr>
<tr>
<td>Patient Population:</td>
<td>65% female, mean age 49, NYHA Class III/IV (35%), obstructive in 77 (23 aortic, 40 mitral 4 tricuspid, 2 double valve), nonobstructive in 43 (10)</td>
</tr>
</tbody>
</table>

| Intervention: | Low dose tPA – 25 mg over 6 h, repeat every 24 h |
| Comparator: | N/A |

<table>
<thead>
<tr>
<th>1st endpoint:</th>
<th>Thrombolytic success</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive:</td>
<td>Decrease gradient, 75% reduction in thrombus size and clinical improvement (complete all 3, partial &lt;3)</td>
</tr>
<tr>
<td>Nonobstructive:</td>
<td>&gt;75% reduction thrombus size</td>
</tr>
</tbody>
</table>

| Result: | Successful thrombolysis in 90%. Only independent predictor of unsuccessful result was higher NYHA Class. |

| Complications: | Total complications in 8 pts (6.7%) – death (0.8%), major complication (3.3%), minor complication (2.5%). – 1 stroke, 1 peripheral embolism and 4 hemorrhage |

| Conclusion: | Low dose nonbolus slow tPA infusion resulted in the high success rate of thrombolysis (90%) and low combined complication rate (embolism 1.7%, major bleed 1.7% minor bleed 1.7%) |

| Limitation: | Single-center nonrandomized study with small number of pts, included both obstructive and nonobstructive PVT. Only 4 pts were in NYHA Class IV |

| Comments: | Success rate 20% after first dose and required up to 8 doses, Median number sessions ≥2, median dose tPA = 64 mg |

PORMETEE Trial  Ozkun M et al 2015 (122) 26299240
<table>
<thead>
<tr>
<th>Study Authors, Year</th>
<th>Study Type</th>
<th>Aim</th>
<th>Inclusion Criteria</th>
<th>Intervention</th>
<th>1st Endpoint</th>
<th>Comparator</th>
<th>Results</th>
<th>Safety Endpoint</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbetseas, et al. 1998 (123) 9809956</td>
<td>Prospective observational</td>
<td>To determine the clinical and echocardiographic parameters to differentiate thrombus from pannus formation for obstructed mechanical prostheses</td>
<td>23 pts with 24 obstructed mechanical prostheses (surgical confirmation)</td>
<td>14 pts thrombus vs. 10 pts pannus</td>
<td>14 pts thrombus vs. 10 pts pannus</td>
<td>10 pts pannus</td>
<td>Pts with thrombus: Shorter duration of symptoms, Lower rate of anticoagulation. TEE soft mass: 92% of thrombus, 29% of pannus</td>
<td>Duration of symptoms and anticoagulation status and ultrasound intensity of mass can differentiate pannus from thrombus</td>
<td></td>
</tr>
<tr>
<td>Gunduz, et al. 2015 (124) 26659372</td>
<td>Observational</td>
<td>To determine the utility of MDCT to differentiate thrombus from pannus formation for obstructed mechanical prostheses</td>
<td>62 pts with mechanical prosthesis (thrombolysis success or surgical confirmation)</td>
<td>N/A</td>
<td>Definitive dx 37 pts: 22 thrombus and 17 pannus</td>
<td>N/A</td>
<td>Attenuation value of Hounsfield Units (HU) differentiated thrombus from pannus: HU &gt;145 units for differentiating thrombus from pannus; 87% sensitivity, 95% specificity</td>
<td>64 slice MDCT is helpful in differentiating pannus from thrombus in pts with mechanical prosthetic obstruction</td>
<td></td>
</tr>
<tr>
<td>Cianciulli, et al. 2005 (125) 16245506</td>
<td>Observational</td>
<td>To determine the benefit of cine-flouroscopy for mechanical prosthetic valve dysfunction</td>
<td>229 pts with mechanical valve prosthesis underwent Doppler echocardiography and fluoroscopy. n=221 prosthetic valves for analysis</td>
<td>N/A</td>
<td>Flouroscopy identified 87 single leaflet and 134 bileaflet prosthesis</td>
<td>N/A</td>
<td>Disk motion differentiated between normal and abnormal prosthetic function by opening angle: Normal 74 +/- 13 degree, Abnl 49 +/- 18 degree</td>
<td>Fluoroscopy is superior to echo in identifying disc motion, while Doppler allows measurement of gradient</td>
<td></td>
</tr>
<tr>
<td>Montorsi, et al. 2000 (126) 11078238</td>
<td>Observational; to evaluate the diagnostic efficacy of cine-flouroscopy, TTE and TEE</td>
<td>To determine the benefit of cine-flouroscopy for mechanical prosthetic valve dysfunction</td>
<td>consecutive pts with mechanical valves and suspected valve thrombosis</td>
<td>N/A</td>
<td>TEE is the gold standard for dx of prosthetic valve thrombosis when either fluoroscopy and TTE are nondiagnostic</td>
<td>N/A</td>
<td>TEE showed thrombus in 33% of Gp B TEE ruled out thrombus in Gp C</td>
<td>TEE is the gold standard for dx of prosthetic valve thrombosis when either fluoroscopy and TTE are nondiagnostic</td>
<td></td>
</tr>
</tbody>
</table>

**Inclusion Criteria:**
- LV dysfunction (n=8 pts)
- LV dysfunction (n=8 pts)
- LV dysfunction (n=8 pts)
- LV dysfunction (n=8 pts)
- LV dysfunction (n=8 pts)

**Results:**
- Thrombus detected in 33% of Gp B
- TEE showed thrombus in 33% of Gp B
- TEE ruled out thrombus in Gp C

**Safety Endpoint:**
- N/A
- N/A
- N/A
- N/A
- N/A

**Comparator:**
- N/A
- N/A
- N/A
- N/A
- N/A

**Intervention:**
- N/A
- N/A
- N/A
- N/A
- N/A

**Aim:**
- To determine the clinical and echocardiographic parameters to differentiate thrombus from pannus formation for obstructed mechanical prostheses
- To determine the utility of MDCT to differentiate thrombus from pannus formation for obstructed mechanical prostheses
- To determine the benefit of cine-flouroscopy for mechanical prosthetic valve dysfunction
- To determine the diagnostic efficacy of cine-flouroscopy, TTE and TEE

**Study Type:**
- Prospective observational
- Observational
- Observational
- Observational; to evaluate the diagnostic efficacy of cine-flouroscopy, TTE and TEE

**Study Size:**
- n=221
- n=221
- n=82
- n=82

**Study Authors:**
- Barbetseas, et al.
- Gunduz, et al.
- Cianciulli, et al.
- Montorsi, et al.
<table>
<thead>
<tr>
<th>Study type</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>1st endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observational; to evaluate the diagnostic accuracy of TTE and TEE for leaflet motion in pts with mechanical prosthesis</td>
<td>Pts with mechanical prosthesis for cardioversion or suspected valve dysfunction</td>
<td>N/A</td>
<td>N/A</td>
<td>TEE showed thrombus in 14% of Gp D</td>
<td>TEE is accurate for leaflet motion with MVR and but not for AVR</td>
</tr>
<tr>
<td>Observational; to evaluate the additive value of cardiac CT in suspected mechanical valve dysfunction</td>
<td>n=111 pts</td>
<td>N/A</td>
<td>N/A</td>
<td>Mitral prosthesis - TTE 85%, TEE 100%</td>
<td>Accuracy for leaflet motion: Mitral prosthesis – TTE 85%, TEE 100% Aortic prosthesis – TTE 13%, TEE 35%</td>
</tr>
<tr>
<td>Observational; to evaluate the additive value of cardiac CT in suspected mechanical valve dysfunction</td>
<td>Pts who underwent repeat AVR due to valve dysfunction</td>
<td>N/A</td>
<td>N/A</td>
<td>CT feasible in 23 pts.</td>
<td>CT was additive to TEE in determination of mechanical valve dysfunction</td>
</tr>
<tr>
<td>Observational; to evaluate the additive value of cardiac CT in suspected mechanical valve dysfunction</td>
<td>p=25 pts</td>
<td>N/A</td>
<td>N/A</td>
<td>In 11 of 13 pts with inconclusive TEE, CT identified pannus. Accuracy for pannus formation – 100% Accuracy for leaflet motion – 61%</td>
<td>Multidetector CT scan can identify causes of abnormal prosthesis function which are missed at echocardiography or fluoroscopy</td>
</tr>
<tr>
<td>Observational; to evaluate the additive value of cardiac CT in suspected mechanical valve dysfunction</td>
<td>Pts with prosthetic valves in whom obstruction was suspected but no cause found</td>
<td>N/A</td>
<td>N/A</td>
<td>CT identified morphologic etiology of obstruction in 8 of 13 pts, confirmed at surgery in 6 pts</td>
<td>Findings by CT: Sub-prosthetic substrate – 8 pts Leaflet motion restriction - 7 pts</td>
</tr>
</tbody>
</table>
## Data Supplement 7A. Prosthetic Valve Thrombosis (Section 11.6)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Name</th>
<th>Date</th>
<th>Episodes</th>
<th>Obstructive/ Nonobstructive</th>
<th>Complete success (%)</th>
<th>Partial success (%)</th>
<th>Overall Complication Rate (%)</th>
<th>Mortality (%)</th>
<th>Major Bleed (cerebral hemorrhage)(%)</th>
<th>Embolism (CVA/TIA) (%)</th>
<th>Recurrence (%)</th>
<th>Treatment</th>
<th>Type study</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT prior</td>
<td>Gupta</td>
<td>2000</td>
<td>110</td>
<td>110</td>
<td>81</td>
<td>10</td>
<td>27</td>
<td>7.3</td>
<td>9(4.5)</td>
<td>19(8.1)</td>
<td>25</td>
<td>SK</td>
<td>Single center</td>
<td>Compare heparin vs TT vs surgery</td>
</tr>
<tr>
<td>TT prior</td>
<td>Lengyl</td>
<td>2001</td>
<td>95</td>
<td>54/31</td>
<td>86</td>
<td>9</td>
<td>17</td>
<td>4.6</td>
<td>2.3</td>
<td>9.3</td>
<td></td>
<td>SK, UK, tPA</td>
<td>Single center</td>
<td>Thrombus size on TEE predictive of outcome</td>
</tr>
<tr>
<td>TT prior</td>
<td>Tong</td>
<td>2004</td>
<td>107</td>
<td>99/14</td>
<td>76</td>
<td>8.6</td>
<td>18</td>
<td>5.6</td>
<td>5.6 (1.9)</td>
<td>14 (5.6)</td>
<td></td>
<td>SK, UK, tPA</td>
<td>Registry</td>
<td>Compare surgical vs TT</td>
</tr>
<tr>
<td>TT prior</td>
<td>Caceres-origa</td>
<td>2006</td>
<td>68</td>
<td>68</td>
<td>80</td>
<td>3.6</td>
<td>22</td>
<td>5.9</td>
<td>4.4 (2.9)</td>
<td>7.4 (4.4)</td>
<td>16</td>
<td>SK</td>
<td>Single center</td>
<td>Compare with surgery - similar orally but higher complication rate with TT</td>
</tr>
<tr>
<td>TT prior</td>
<td>Roudaut</td>
<td>2009</td>
<td>127</td>
<td>115/12</td>
<td>71</td>
<td>17.3</td>
<td>25</td>
<td>11.8</td>
<td>4.7 (1.6)</td>
<td>15 (11)</td>
<td>24.7</td>
<td>SK, UK, tPA</td>
<td>Single center</td>
<td>No difference in accelerated dose aside from trend to increased bleeding</td>
</tr>
<tr>
<td>TT prior</td>
<td>Karthikeyan</td>
<td>2009</td>
<td>120</td>
<td>120</td>
<td>63</td>
<td>17</td>
<td>7.5</td>
<td>9.1 (4.1)</td>
<td>5.0</td>
<td></td>
<td></td>
<td>SK, UK, tPA</td>
<td>Randomeiz trial</td>
<td>Determine lack of effect of thrombus size on outcome</td>
</tr>
<tr>
<td>TT prior</td>
<td>Nagy</td>
<td>2009</td>
<td>62</td>
<td>52/10</td>
<td>77</td>
<td>21</td>
<td>18</td>
<td>11</td>
<td>4.8 (2)</td>
<td>13 (5.8)</td>
<td>11</td>
<td>SK, UK, tPA</td>
<td>Single center</td>
<td>Compare surgical vs TT</td>
</tr>
<tr>
<td>TT prior</td>
<td>Keuleers</td>
<td>2011</td>
<td>13</td>
<td>13</td>
<td>61</td>
<td>31</td>
<td>38</td>
<td>7.6</td>
<td>7.6</td>
<td>30 (15)</td>
<td></td>
<td>Convention al tPA</td>
<td>Low dose tPA safest and best</td>
<td></td>
</tr>
<tr>
<td>TT prior</td>
<td>Ozkun</td>
<td>2013</td>
<td>220</td>
<td>105/106</td>
<td>83</td>
<td>19</td>
<td>2.7</td>
<td>9 (3.1)</td>
<td>8 (6.8)</td>
<td></td>
<td></td>
<td>5 regimens</td>
<td>Single center</td>
<td>Overall surgical mortality related to</td>
</tr>
<tr>
<td>TT overall before 2013</td>
<td>75 +/- 8</td>
<td>14 +/- 8</td>
<td>22 +/- 6</td>
<td>7 +/- 3</td>
<td>6.3 +/- 2.3(2.8 +/- 1.0)</td>
<td>13.4 +/- 7.1 (8.1 +/- 3.4)</td>
<td>21 +/- 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>Deveri</td>
<td>1991</td>
<td>106</td>
<td>106</td>
<td>100</td>
<td>12.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Single center</td>
<td>Overall surgical mortality related to</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>Author, Year Published</td>
<td>Study Type/Design; Study Size</td>
<td>Patient Population</td>
<td>Endpoints and Results</td>
<td>Comment(s) / Summary/ Conclusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>----------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roudaut 2009</td>
<td>136 136 100</td>
<td>10.3 0.7 11.5</td>
<td>NYHA Class I-III (4.75) vs IV (17.5%)</td>
<td>Compare surgical vs TT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keuleers 2011</td>
<td>18 18 100</td>
<td>11 11</td>
<td>Compare surgical vs TT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karthikeyan 2013</td>
<td>446 446 100</td>
<td>13.5 1.4 1.6 7.1</td>
<td>Literature review</td>
<td>Surgical outcome from 7 studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang 2013</td>
<td>662 662 100</td>
<td>15 6 6</td>
<td>Literature review</td>
<td>Compare surgical vs TT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery overall</td>
<td></td>
<td>100</td>
<td>12.4 +/- 1.7 2.7 +/- 2.3 8.9 +/- 2.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT - low dose</td>
<td>Ozkun 2013</td>
<td>28 15/13 100</td>
<td>Low dose tPA</td>
<td>Single center</td>
<td>Pregnant pts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT - low dose</td>
<td>Ozkun 2015</td>
<td>114 77/43 90</td>
<td>Low dose tPA</td>
<td>Single center</td>
<td>Prospective use of low dose tPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Data Supplement 8. Selective Studies of VKA in Patients with Bioprosthetic Valve Thrombosis (Section 11.7.3)**

<table>
<thead>
<tr>
<th>Author; Year Published</th>
<th>Study Type</th>
<th>Study Design; Study Size</th>
<th>Patient Population</th>
<th>Endpoints and Results</th>
<th>Comment(s) / Summary/ Conclusion</th>
</tr>
</thead>
</table>
| Jander et al. 2012 (130) 2200772 | Study type: Retrospective | Size: n= 6 pts | Inclusion criteria: Pts presenting with obstructive BPV (of all pts who received a single stented bioprosthetic AV); 01/2007-12/2008; single hospital. | Endpoints: MPG | All 6 pts had received a porcine valve, were hemodynamically stable, and were taking ASA 100 mg/d. Echocardiography showed an increase in MPG early postoperatively from 23.3±4–57.0±10 mm Hg (p <0.001). No adverse events were observed with phenprocoumon. The authors concluded that ‘oral anticoagulation with phenprocoumon is a safe and effective treatment in clinically stable pts with obstructive BPVT, thus obviating repeat valve surgery or thrombolysis’.

<p>| Butnaru, et al | Study type: | Inclusion criteria: 9 pts with clinical or | Endpoints: echocardiographic findings (transvalvular gradient, thrombus) | 8 of the 9 pts presented with HF symptoms at 16±12 mo after implantation. |</p>
<table>
<thead>
<tr>
<th>Year</th>
<th>Study Type</th>
<th>Size</th>
<th>Inclusion Criteria</th>
<th>Endpoints</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Retrospective</td>
<td>n=9 pts</td>
<td>Echocardiographic evidence of valve malfunction were identified after screening 149 consecutive pts who underwent MVR with a bioprosthesis; 2002-2011; single center</td>
<td>Mitral BVPT thrombosis occurred in 9 pts (6%). Of those, 6 pts received anticoagulation with resolution of the echocardiographic findings (reduction in gradients; complete thrombus resolution).</td>
<td>The authors concluded that ‘surgery should be reserved for those who are not responsive or pts in whom the hemodynamic status does not allow delay’.</td>
</tr>
<tr>
<td>2015</td>
<td>Study type: Retrospective Size: n=31 pts</td>
<td>Inclusion criteria: pts diagnosed with BPVT; 1997-2013; single institution</td>
<td>Endpoints: MPG, clinical outcomes (NYHA class, death, stroke, embolic events)</td>
<td>Pts treated initially with VKA group (N = 15) were compared to surgery/thrombolysis (N = 17); [non-randomized]. VKA and surgery/thrombolysis decreased MPG to a similar extent: VKA group: 13±5–6 ±2 mm Hg in mitral position, 9 ± 3–5 ± 1 mm Hg in tricuspid position and 39±3–24±7 mm Hg in aortic/pulmonary position; non-VKA group: 16 ± 12–5 ± 1 mm Hg in mitral, 10 ± 5–4 ± 1 mm Hg in tricuspid and 57 ± 9–18 ± 6 mm Hg in aortic position (p=0.59 for group effect). NYHA class improved in 11 of 15 pts in the VKA group and 10 of 17 pts in the non-VKA group (p=0.39). No deaths, strokes or recognized embolic events in either group.</td>
<td>Peak incidence of BPVT was 13-24 mo after implantation in both groups. 1 pt in each group experienced gastrointestinal bleeding requiring transfusion. The authors concluded that ‘VKA therapy resulted in hemodynamic and clinical improvement with minimal risk, and should be considered the first-line therapy in hemodynamically stable pts’.</td>
</tr>
<tr>
<td>2015</td>
<td>Study type: Retrospective Size: n=187 pts</td>
<td>Inclusion criteria: Study analyzed data from 55 pts in a TAVR clinical trial, and 2 single-center registries of 132 pts undergoing either TAVR or surgical AV bioprosthesis implantation</td>
<td>Endpoints: 4D CT imaging (for reduced leaflet motion detection), clinical outcomes</td>
<td>Therapeutic anticoagulation with warfarin (as compared with DAPT), was associated with lower incidence of reduced leaflet motion (0% and 55%, respectively, p=0.01 in the clinical trial; and 0% and 29%, respectively, p=0.04 in the pooled registries). In pts reevaluated with follow-up CT: restoration of leaflet motion was noted in all 11 pts who were receiving anticoagulation and only 1 of 10 pts not receiving anticoagulation (p=0.001).</td>
<td>Sophisticated 4-D volume-rendered CT scan imaging was used to detect reduced leaflet motion. Reduced leaflet motion was noted on CT in 40% in the clinical trial and in 13% in the 2 registries. No differences in stroke or TIA between pts with reduced vs. normal leaflet motion in the clinical trial: a significant difference was detected in the pooled registries, (p=0.007). The authors concluded: “Reduced aortic-valve leaflet motion was shown in pts with bioprosthetic aortic valves. The condition resolved with therapeutic anticoagulation”.</td>
</tr>
<tr>
<td>2015</td>
<td>Study type: Retrospective Size: n=26 pts</td>
<td>Inclusion criteria: Pts with THV thrombosis (from a cohort of 4266 pts undergoing TAVR), 01/2008-09/2013, 12 centers.</td>
<td>Endpoints: Frequency/time frame, clinical/echocardiographic and treatment correlates of THV thrombosis</td>
<td>Echocardiographic findings: elevated MPG (41±14 mm Hg); thickened leaflets or thrombotic apposition of leaflets in 77% of pts, and a thrombotic mass on leaflets in 23% of pts. THV thrombosis definition: (1) THV dysfunction 2” to thrombosis diagnosed based on response to anticoagulation therapy, imaging or histopathology; or (2) mobile mass detected on THV suspicious of thrombus, irrespective of dysfunction and in absence of infection. 26 (0.61%) pts had THV thrombosis after TAVR implantation; median time to thrombosis post-TAVR: 181 d (interquartile range, 45-313); most common clinical presentation: exertional dyspnea (65%).</td>
<td></td>
</tr>
</tbody>
</table>
Anticoagulation resulted in a significant decrease in AV MPG in 88% of pts within 2 mo.

The authors concluded: "THV thrombosis is a rare phenomenon that was detected within the first 2 y after TAVR and usually presented with dyspnea and increased gradients. Anticoagulation seems to have been effective and should be considered even in pts without visible thrombus on echocardiography."

De Marchena, et al. 2015 (134) 2596444

| Study type: Retrospective |
| Size: n=4 pts |
| Inclusion criteria: Pts with THV thrombosis |
| Endpoints: Pathological/clinical correlates of early thrombosis after TAVR |

Results:
- 2 of the 4 cases had increasing MPG post-TAVR.
- 1 case was medically treated with oral anticoagulation with normalization of gradients.
- All 3 pathology cases showed presence of a valve thrombosis in at least 2 bioprosthetic leaflets on autopsy (not previously visualized by echocardiogram).
- The authors did a complimentary literature review and found 18 cases of early valve thrombosis after TAVR: in 12 of those, early anticoagulation therapy resolved the thrombus formation and normalized pressure gradients.
- The authors concluded: "Consideration should be given to treatment with dual antiplatelet therapy and oral anticoagulation in pts post-TAVR with increasing mean pressure gradients and maximum aortic valve velocity".

Data Supplement 9. Clinical Outcomes With VIV Procedures (Sections 11.7.3 and 11.8.3)

<table>
<thead>
<tr>
<th>Author; Year Published</th>
<th>Study Type/Design; Study Size</th>
<th>Patient Population</th>
<th>Endpoints and Results</th>
<th>Comment(s) / Summary/ Conclusion</th>
</tr>
</thead>
</table>
| Ye J, et al, 2015 (135) 26476608 | Study type: registry Size: n=73 pts (of whom 42 had VIV for bioprosthetic AV). | Inclusion criteria: pts with aortic (n=42) and mitral (n=31) bioprosthetic valve dysfunction undergoing transcatheter VIV implantation (2007-2013). Exclusion criteria: N/A | Endpoints: 30-d outcomes; mid/long-term survival, NYHA Results: Overall success rate: 98.6%. At 30 d: All-cause mortality: 1.4%, Disabling stroke 1.4%, Life-threatening bleeding: 4.1%, AKI requiring hemodialysis 2.7%, Coronary artery obstruction requiring intervention 1.4%.
At 2-y follow-up, 82.8% of aortic VIV pts were in NYHA functional class I/II. Estimated survival rates were 88.9%, 79.5%, 69.8%, 61.9%, and 40.5% at 1, 2, 3, 4, and 5 y, respectively. | • This has the longest follow-up (Median follow-up: 2.52 y with a maximum of 8 y) of all registries transcatheter aortic and mitral VIV implantation.
• Only Edwards balloon-expandable transcatheter valves (Edwards Lifesciences Inc., Irvine, California) were used.
• The small surgical valve size (19 and 21 mm) was an independent risk factor for reduced survival in aortic VIV pts.
• Transcatheter VIV procedures can be performed safely with a high success rate and minimal early mortality and morbidity, and provides encouraging mid/long-term clinical outcomes. |

Dvir D, et al. 2012 (90) 22052026 | Study type: multinational registry (data collected retrospectively and retrospectively) | Inclusion criteria: Either CoreValve or Edwards SAPIEN devices are included Exclusion criteria: N/A | Endpoints: Procedural success; adverse procedural outcomes; post-VIV gradients; 30 d mortality and NYHA III; 1-y survival. | • The was the first large, comprehensive evaluation of a transcatheter approach for failed surgically inserted aortic bioprostheses
• Pts receiving VIV in the stenosis group had worse 1-y survival (76.6%) in comparison with the regurgitation group (91.2%) and the combined group
<table>
<thead>
<tr>
<th>Study type</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Endpoints</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: n=202 pts</td>
<td>Pts with degenerated bioprosthetic valves undergoing VIV implantation (2007-2013)</td>
<td>VIV procedures performed using other devices than the self-expandable CoreValve (Medtronic) and balloon expandable Edwards SAPIEN devices (Edwards Lifesciences), or implanted in positions other than the aortic position.</td>
<td>Survival, Stroke, and NYHA functional class. [Major clinical endpoints were assessed according to the VARC criteria]</td>
<td>1-y Kaplan-Meier survival rate: 83.2% (95% CI: 80.8–84.7%). Within 1 mo: death: 7.6%; major stroke 1.7%; Survivors with NYHA I/II: 92.6%.</td>
</tr>
<tr>
<td>Study type: multinational registry (data retrospectively for cases performed before registry initiation and prospectively)</td>
<td>24 high-risk pts with failed bioprosthetic valves (n=10 were in the aortic position).</td>
<td></td>
<td>Procedural success and complications, 30-d mortality.</td>
<td>In the 10 pts with VIV in the aortic position: VIV implantation was uniformly successful with excellent improvement in valve function, no major morbidity. 30 d mortality: 0%.</td>
</tr>
<tr>
<td>Size: n=459 pts</td>
<td></td>
<td></td>
<td></td>
<td>Implanted devices included both balloon- and self-expandable valves. Pts with at least a moderate degree of both stenosis and regurgitation were included in the combined group. Pts in the stenosis group had worse 1-y survival (76.6%) in comparison with the regurgitation group (91.2%) and the combined group (83.9%) (p=0.01). Factors associated with 1-y mortality: small surgical bioprosthesis (≤21 mm) &amp; baseline stenosis (vs. regurgitation).</td>
</tr>
<tr>
<td>Study type: Case series</td>
<td></td>
<td>N/A</td>
<td>Major adverse cerebrovascular and cardiac events and prosthesis performance at 30 d and midterm follow-up.</td>
<td>The VIV technique was used in 3.6% of all 663 TAVR pts. The VIV group was a subpopulation from 663 consecutive pts who underwent TAVR with the 18-F CoreValve ReValving System (Medtronic, Inc., Minneapolis, Minnesota) at 14 centers across Italy. The study demonstrated that transcatheter aortic VIV after TAVR using the 3rd-generation CoreValve ReValving System is feasible, safe, and</td>
</tr>
<tr>
<td>Size: n=24 (of whom 10 pts had VIV in the aortic position).</td>
<td></td>
<td>N/A</td>
<td></td>
<td>Transcatheter VIV implantation is a reproducible option for the management of selected pts with bioprosthetic valve failure. The aortic, pulmonary, mitral, and tricuspid tissue valves may be amenable to this approach.</td>
</tr>
<tr>
<td>Study type: Prospective web-based multicenter registry.</td>
<td>Pts treated with the VIV technique for severe PVL following TAVR.</td>
<td>N/A</td>
<td>Major adverse cerebrovascular and cardiac events and prosthesis performance at 30 d and midterm follow-up.</td>
<td></td>
</tr>
</tbody>
</table>
In the transcatheter aortic VIV group:

30 d major adverse cerebrovascular and cardiac events: 0%
30-d mortality: 0%
12 mo major adverse cerebrovascular and cardiac events: 14.1%
12 mo mortality: 13.7%.

Thus, following TAVR, the VIV technique offers a viable therapeutic option in pts with acute significant PVL without recourse to emergent surgery.

- Multicenter (n=11) from Germany and Switzerland.
- Both transfemoral (n = 25) or transapical (n = 22) approaches.
- The transcatheter aortic VIV can be performed with high technical success rates, acceptable post-procedural valvular function, and excellent functional improvement.
- In this elderly high-risk pts with multiple comorbidities, transcatheter aortic VIV was associated with 17% mortality, often because of septic complications arising in the post-operative phase.

**Study type:** Retrospective observational study

**Size:** n=45

**Inclusion criteria:** Pts with degenerated surgically implanted BHVs undergoing aortic VIV procedures

**Exclusion criteria:** N/A

**Endpoints:** Procedural success, complications, 30-d mortality.

**Results:**
- The transcatheter aortic VIV was technically successful in all pts (2 pts requiring bailout implantation of a second TAVR prosthesis for severe regurgitation during the procedure).
- Vascular access complications: 13%.
- Pacemaker implantation: 11%.
- Renal failure requiring dialysis: 9%.
- 30-d mortality: 17% (3 of 8 fatalities the result of non-valve-related septic complications).

**Study type:** multicenter registry

**Size:** n=25

**Inclusion criteria:** High-risk pts with a failed aortic bioprosthesis

**Exclusion criteria:** N/A

**Endpoints:** Procedural success, 30-d complications, short-term survival, NYHA.

**Results:**
- Success rate was 100%; no procedural death.
- At 30 d:
  - Deaths 12%; MI: 8%; Pacemaker implantation: 12%;
  - At a mean follow-up of 6 mo, survival rate of 84%; NYHA functional class improved in all pts to I/II.
- Pts/prostheses were divided in type A (mainly stenotic, n = 9) and type B (mainly regurgitant, n = 16).
- VIV was performed using the CoreValve Revalving System (CRS) (Medtronic, Minneapolis, Minnesota) implantation.
- The VIV procedure is feasible and effective regardless of the prevalent mode of failure.

**Study type:** 3-center registry (prospectively collected data).

**Size:** n=21

**Inclusion criteria:** Pts undergoing aortic balloon-expandable TAVR due to THV failure with acute severe AR.

**Exclusion criteria:** N/A

**Endpoints:** Procedural success; 30-d/1-y mortality, mean gradient, PVL.

**Results:**
- Procedural success: 90%.
- Mortality at 30 ds and 1 y: 14.3% and 24%, respectively.
- After successful procedure:
  - Mean gradient reduced from 37 ± 12 mm Hg–13 ± 5 mm Hg (p<0.01); AVA increased from 0.64 ± 0.14–1.55 ± 0.27 cm² (p<0.01); PVL was none in 4 pts, mild in 13 pts, and moderate in 2 pts.
  - At 1-y follow-up: 1 pt had moderate and the others had mild/no PVL.

- AR was paravalvular in 18 pts and transvalvular in the remaining 3 pts.
- At one-y, the mean transaortic gradient was 15 ± 4 mm Hg, which was higher than in pts undergoing conventional TAVR (11 ± 4 mm Hg, p=0.02).
- Transcatheter VIV procedure in a failed THV is feasible and results in satisfactory short- and mid-term outcomes.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Endpoints</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bapat, 2012 (141) 23140962</td>
<td>Study type: single-center case-series</td>
<td>n=23</td>
<td>pts undergoing a VIV procedure with the Edwards Sapien valve to treat a failing AV bioprosthesis (2008-201).</td>
<td>Exclusion criteria: N/A</td>
<td>Endpoints: procedural success, short-term mortality, gradient.</td>
<td>Results:  • Procedural success: 100% (1 pt needed a second valve).  • Mean gradient was reduced from 31.2 ± 17.06 mm Hg– 9.13 ± 4.9 mm Hg.  • In-hospital and/or 30-d mortality: 0%.</td>
</tr>
<tr>
<td>Linke, et al 2012 (142) 23048050</td>
<td>Study type: single-center observational study</td>
<td>n=27</td>
<td>Consecutive symptomatic pts with failing AV bioprosthesis &amp; aged ≥65 y &amp; logistic EuroSCORE ≥10%; an inner diameter of the previously implanted bioprosthesis: 18.5-27 mm; ascending aorta diameter ≤45 mm above the sinotubular junction; access vessels ≥6 mm.</td>
<td>Exclusion criteria: N/A</td>
<td>Endpoints: procedural and short-term outcomes, 30-d mortality</td>
<td>Results:  • No intraprocedural death or MI.  • Using VARC criteria:  • major stroke: 7.4 %.  • life-threatening bleeding: 7.4%.  • kidney failure stage III: 7.4%. Major access site complication 11.1 %.  • 30-d mortality: 7.4%</td>
</tr>
<tr>
<td>Ihlberg, L et al. 2013 (143) 23998786</td>
<td>Study type: multicenter registry, retrospective.</td>
<td>45</td>
<td>All transcatheter VIV procedures in the Nordic countries between 2008 and 2012.</td>
<td>Exclusion criteria: N/A</td>
<td>Endpoints: Periprocedural and postoperative outcomes (assessed using the VARC criteria).</td>
<td>Results:  • No intraprocedural mortality.  • Technical success: 95.6%.  • All-cause 30-d mortality: 4.4%.  • 30-d major complications: stroke: 22%,  • Periprocedural MI: 4.4%,  • major vascular complication: 2.2%.  • At 1 mo, all but 1 pt had either no or mild PVL.  • 1 y survival: 88.1%.</td>
</tr>
<tr>
<td>Camboni, et al 2015 (144) 25661576</td>
<td>Study type: prospective single-center registry</td>
<td>31</td>
<td>Pts undergoing VIV procedure at single institution since 2009.</td>
<td>Exclusion criteria: TAVR pts not undergoing VIV (608 pts)</td>
<td>Endpoints: Procedural success, 30-d survival, post-VIV regurgitation.</td>
<td>Results:  • Procedural success: 88%.  • Post-procedural regurgitation: trace in 23% and moderate in 13% of pts.  • 30-d survival: 77% with a significantly improved NYHA class of 1.79 ± 0.58 (p=0.001).</td>
</tr>
</tbody>
</table>

13 pts had predominantly bioprosthetic stenosis, and the remaining had mostly regurgitation.  
Most VIV procedures (21/23) were performed via the transapical route.  
The transcatheter VIV is a safe and feasible alternative to treat high-risk pts with failing aortic bioprostheses.  
Failure of bioprosthetic valves may be safely corrected by TF implantation of MCV, irrespective of the failure mode and the bioprosthesis valve type.  
VIV implantation can be performed completely percutaneously under conscious sedation.  
VIV implantation results in marked, instantaneous improvement in hemodynamics, which remains evident at long-term follow-up.  
The type of failure was stenosis/ combined in 58% & regurgitation in 42% of cases.  
The SAPIENXT (Edwards LifeSciences, Irvine, CA) and CoreValve (Medtronic Inc, Minneapolis, Minn) systems were used.  
Access (transapical, transfemoral, transaortic, and subclavian).  
Mean follow-up: 14.4 mo.  
Transcatheter VIV is widely performed in most centers in the Nordic countries. The short-term results were excellent in this high-risk pt population, demonstrating a low incidence of device- or procedure-related complications.  
Pts were provided with 5 Medtronic CoreValves, 15 Edwards SapienXT, 1 Edwards Sapien 3, 7 Medtronic Engager, and 3 Symetis Acurate TA valves.The left main stem was occluded in 1 pt (Sapien XT 26 in a Mitroflow 25 mm) who underwent emergent Jeopardizing coronary blood flow was likely in stenotic and calcified bioprostheses, particularly in tubelike aortic sinuses.  
The investigators concluded that Planning, imaging, and the use of valves
| Conradi, et al 2015 (145) 26403870 | **Study type:** registry (prospectively-collected data)  
**Size:** 75 (of whom 54 pts with VIV in the aortic position)  
**Inclusion criteria:** Consecutive pts receiving VIV procedures from 2008 to 2014 at a single center  
**Exclusion criteria:** N/A  
**Endpoints:** procedural success and complications, short-term mortality, trans-AV gradients.  
**Results:** Overall VIV success rate: 97.3%.  
For aortic VIV:  
- procedural (≤72 h) and all-cause 30-d mortality: 1.9% (1/54) and 5.6% (3/54).  
- No periprocedural strokes or coronary obstruction.  
- After aortic VIV, gradients were max/mean 34.1 ± 14.2/20.1 ± 7.1 mm Hg and effective orifice area was 1.5 ± 1.4 cm².  
- This registry reported a single-center cumulative experience using 6 types of THVs in all anatomic positions.  
- VIV can be performed in all anatomic positions with acceptable hemodynamic and clinical outcome in high-risk pts. | allowing commissural alignment as well as leaflet capturing seem to reduce the risk. |
| --- | --- | --- |
| Conradi, et al 2015 (145) 26403870 | **Study type:** registry (prospectively-collected data)  
**Size:** 75 (of whom 54 pts with VIV in the aortic position)  
**Inclusion criteria:** Consecutive pts receiving VIV procedures from 2008 to 2014 at a single center  
**Exclusion criteria:** N/A  
**Endpoints:** procedural success and complications, short-term mortality, trans-AV gradients.  
**Results:** Overall VIV success rate: 97.3%.  
For aortic VIV:  
- procedural (≤72 h) and all-cause 30-d mortality: 1.9% (1/54) and 5.6% (3/54).  
- No periprocedural strokes or coronary obstruction.  
- After aortic VIV, gradients were max/mean 34.1 ± 14.2/20.1 ± 7.1 mm Hg and effective orifice area was 1.5 ± 1.4 cm².  
- This registry reported a single-center cumulative experience using 6 types of THVs in all anatomic positions.  
- VIV can be performed in all anatomic positions with acceptable hemodynamic and clinical outcome in high-risk pts. | allowing commissural alignment as well as leaflet capturing seem to reduce the risk. |
| Duncan BF, et al 2015 (146) 26215358 | **Study type:** case series, single center  
**Size:** 22  
**Inclusion criteria:** consecutive pts with failing stentless bioprostheses  
**Exclusion criteria:** N/A  
**Endpoints:** short-mid-term mortality, procedural complications.  
**Results:**  
- 30-d mortality: 0%.  
- No cases of MI, tamponade, stroke, severe bleeding, AKI, or major vascular complications.  
- 3 instances of device migration and 1 device embolization occurred.  
- Permanent pacing: 14%.  
- Mild-moderate PVL: 13.6%.  
- 6 mo and 1 y mortality was 4.8% and 14.3%, respectively.  
- 30-d predicted mortality STS score: 14%%, all had severe AR and highly symptomatic, all underwent TAVI with a self-expanding device.  
- The aortic VIV procedure may be performed in high-risk pts with a degenerate stentless bioprosthesis with low 30-d and 1-y mortality rates. |  
| Duncan BF, et al 2015 (146) 26215358 | **Study type:** case series, single center  
**Size:** 22  
**Inclusion criteria:** consecutive pts with failing stentless bioprostheses  
**Exclusion criteria:** N/A  
**Endpoints:** short-mid-term mortality, procedural complications.  
**Results:**  
- 30-d mortality: 0%.  
- No cases of MI, tamponade, stroke, severe bleeding, AKI, or major vascular complications.  
- 3 instances of device migration and 1 device embolization occurred.  
- Permanent pacing: 14%.  
- Mild-moderate PVL: 13.6%.  
- 6 mo and 1 y mortality was 4.8% and 14.3%, respectively.  
- 30-d predicted mortality STS score: 14%%, all had severe AR and highly symptomatic, all underwent TAVI with a self-expanding device.  
- The aortic VIV procedure may be performed in high-risk pts with a degenerate stentless bioprosthesis with low 30-d and 1-y mortality rates. |  
| Erlebach, et al 2015 (147) 26543594 | **Study type:** retrospective single-center observational study  
**Size:** 102  
**Inclusion criteria:** All consecutive pts undergoing VIV vs. redo surgical AVR (2001-2014).  
**Exclusion criteria:** previous mechanical or transcatheter valves, active endocarditis, concomitant cardiac procedures  
**Endpoints:** post-procedural complications, 30-d mortality, 1-y survival.  
**Results:**  
- Postoperative pacemaker implantation and chest tube output were higher in the reoperation surgical group compared to the TAV-in-SAV group [11 (21%) vs. 3 (6%), p=0.042 and 0.9±1.0 vs. 0.6±0.9, p=0.047, respectively].  
- NS differences in MI, stroke, dialysis postoperatively, or 30-d mortality.  
- 1-y survival was significantly lower in the VIV group (83% vs. 96%, p<0.001).  
- Pts in the VIV group were significantly older, had a higher logistic EuroSCORE and a lower LVEF.  
- Both groups, irrespective of different baseline comorbidities, show very good early clinical outcomes. While redo surgery is still the standard of care, a subgroup of pts may profit from the transcatheter VIV procedure. |  
| Ye, et al. 2015 (148) 26476608 | **Study type:** registry  
**Size:** 73 (of whom 42 had VIV for bioprosthetic AV).  
**Inclusion criteria:** pts with aortic (n=42) and mitral (n=31) bioprosthetic valve dysfunction undergoing transcatheter VIV implantation (2007-2013).  
**Endpoints:** 30-d outcomes; mid/long-term survival, NYHA.  
**Results:** Overall success rate: 98.6%.  
- This has the longest follow-up (Median follow-up: 2.52 y with a maximum of 8 y) of all registries transcatheter aortic and mitral VIV implantation.  
- Only Edwards balloon-expandable transcatheter valves (Edwards Lifesciences Inc., Irvine, California) were used.  
- The small surgical valve size (19 and 21 mm) was an independent risk factor for mortality. |  

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.
<table>
<thead>
<tr>
<th>Study type: systematic review</th>
<th>Exclusion criteria: N/A</th>
<th>Inclusion criteria: Pts undergoing transcatheter aortic VIV implantation and redo conventional AVR</th>
<th>Exclusion criteria: N/A</th>
<th>1° endpoints:</th>
<th>Other endpoints:</th>
</tr>
</thead>
</table>
| Size: n=823 pts (18 studies) | At 30 d:  
- All-cause mortality: 1.4%, Disabling stroke 1.4%,  
- Life-threatening bleeding: 4.1%,  
- AKI requiring hemodialysis 2.7%,  
- Coronary artery obstruction requiring intervention 1.4%. | Perioperative/30 d mortality  
PVLs  
Stroke  
Bleeding  
MI  
AKI  
Vascular complications  
Pacemaker implantation  
Mean Gradient  
Peak Gradient |  
Other endpoints:  
PVLs (VIV:3.3% vs. cAVR: 0.4%, p=0.022)  
Stroke (VIV:1.9% vs. cAVR:8.8%, p=0.002)  
Bleeding (VIV:6.9% vs. cAVR:9.1%, p=0.014)  
Mean Gradient (VIV: 38 mm Hg preoperatively to cAVR: 15.2 mm Hg postoperatively, p=0.001)  
Peak Gradient (VIV: 59.2 to cAVR: 23.2 mm Hg, p=0.0003). |

At 2-y follow-up, 82.8% of aortic VIV pts were in NYHA functional class I/II. Estimated survival rates were 88.9%, 79.5%, 69.8%, 61.9%, and 40.5% at 1, 2, 3, 4, and 5 y, respectively.

Transcatheter VIV procedures can be performed safely with a high success rate and minimal early mortality and morbidity, and provides encouraging mid/long-term clinical outcomes.

Similar hemodynamic outcomes achieved with VIV as compared to redo conventional AVR  
Lower risk of strokes and bleeding in VIV compared to redo conventional AVR  
Higher PVL rates in VIV compared to redo conventional AVR

*Selective contemporary studies of transcatheter VIV procedures for failed bioprosthetic valves (excluding small studies with <20 pts).
# Selective Studies on Surgical and Catheter-based Closure for Paravalvular Regurgitation (Section 11.8.3)

<table>
<thead>
<tr>
<th>Study Name, Author, Year</th>
<th>Study Aim</th>
<th>Study Type/Size (N)</th>
<th>Intervention vs. Comparator (n)</th>
<th>Patient Population</th>
<th>Endpoints</th>
<th>Adverse Events/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orszulak 1983 (150) 686002</td>
<td>To report outcome with surgical reoperation for PVR</td>
<td>Retrospective N=105</td>
<td>Surgical reoperative repair of prosthetic PVR</td>
<td>Aortic PVR (n=75) and mitral PVR (n=29)</td>
<td>Early mortality for entire cohort: 5.7%; 5-y survival was 94% for aortic PVR pts and 75% for mitral PVR pts.</td>
<td>N/A</td>
</tr>
<tr>
<td>Miller 1995 (151) 8566176</td>
<td>To identify clinical features that predict occurrence of PVR. Outcome after surgical repair also reported</td>
<td>Retrospective N=30</td>
<td>Surgical reoperative repair of aortic prosthetic PVR</td>
<td>Aortic prosthetic PVR</td>
<td>30-d survival=90%; 5-d survival=73%</td>
<td>N/A</td>
</tr>
<tr>
<td>Akins 2005 (152) 16359061</td>
<td>To examine acute and long-term outcome of surgery for PVR</td>
<td>Retrospective N=136</td>
<td>Surgical reoperative repair of aortic or mitral prosthetic PVR</td>
<td>Mitral PVR in 68% Aortic PVR in 32%</td>
<td>Operative mortality, 6.6% Penoperative stroke, 5.1% 10-y survival, 30%</td>
<td>N/A</td>
</tr>
<tr>
<td>Pate 2006 (153) 16969856</td>
<td>To describe outcome in series of pts undergoing percutaneous repair of PVR</td>
<td>Retrospective N=10 (10 defects)</td>
<td>Percutaneous repair of PVR</td>
<td>Mitral PVR (n=9) and aortic PVR (n=1); 9 were not surgical candidates</td>
<td>7 with successful procedure 3 pts died at 1 y</td>
<td>1 retroperitoneal bleed 1 device dislodgement</td>
</tr>
<tr>
<td>Shapira 2007 (154) 17578053</td>
<td>To examine the feasibility and early outcome of percutaneous repair of PVR</td>
<td>Retrospective N=11 (13 defects)</td>
<td>Percutaneous repair of PVR</td>
<td>Mitral PVR (n=8), aortic PVR (n=1), and both aortic and mitral PVR (n=2) Estimated surgical mortality, 17.8%</td>
<td>10 with device deployment 6 with reduction in regurgitation 5 with NYHA improvement by 1 class</td>
<td>Hemolysis improved in 4, worsened in 4, and was unchanged in 2 in early follow-up 3 deaths in follow-up</td>
</tr>
<tr>
<td>Cortes 2008 (155) 18237605</td>
<td>To examine utility of TEE in percutaneous repair of PVR</td>
<td>Retrospective N=27 (27 defects)</td>
<td>TEE before and procedure (n=27) and at follow-up ≥1 mo (n=17)</td>
<td>Mechanical mitral PVR in pts at high risk for surgery</td>
<td>62% with procedure success TEE helped guide procedure and identified variety of complications</td>
<td>N/A</td>
</tr>
<tr>
<td>Ruiz 2011 (156) 22078427</td>
<td>To examine feasibility and efficacy of the percutaneous repair of PVR</td>
<td>Retrospective N=43 (57 defects)</td>
<td>Percutaneous repair of PVR</td>
<td>Mitral PVR (n=36), aortic PVR (n=9), and both aortic and mitral PVR (n=2)</td>
<td>Device deployment success in 86% of pts and 86% of leaks Survival: 92% at 6 m, 86% at 18 m</td>
<td>12 pts required multiple procedures; reduction in need for transfusions or erythropoietin from 56%–5%; NYHA class improved by ≥1 in 2 device embolizations 1 emergency surgery 1 vascular complication 1 procedural death</td>
</tr>
<tr>
<td>Sorajja 2011 (157)</td>
<td>To examine the feasibility and early outcome of percutaneous repair of PVR</td>
<td>Retrospective N=115 pts (141 defects)</td>
<td>Percutaneous repair of PVR</td>
<td>78% mitral PVR, 22% aortic PVR</td>
<td>Device deployment in 89% Mild or no residual regurgitation in 77% No procedural death</td>
<td>Leaflet impingement in 4.3% Procedure time average 147 min and decreased with case experience</td>
</tr>
<tr>
<td>Sorajja 2011 (158)</td>
<td>To determine the long-term clinical efficacy of percutaneous repair of PVR</td>
<td>Retrospective N=126 (154 defects)</td>
<td>Percutaneous repair of PVR</td>
<td>79% mitral PVR, 21% aortic PVR</td>
<td>Average STS risk score=6.7%</td>
<td>Symptom improvement occurred only in pts with mild or no residual regurgitation Hemolytic anemia persisted in 14 of 29 pts</td>
</tr>
<tr>
<td>Nijenhuis 2014 (159)</td>
<td>To determine the safety and clinical efficacy of transcatheter PVL closure using an open TA approach</td>
<td>Prospective N= 36</td>
<td>Transcatheter PVL closure using an open transapical approach</td>
<td>Consecutive pts (mean age 67±12 y, STS score 7±4%). All had severe symptomatic PVL in the mitral (81%) or aortic (19%) position</td>
<td>Procedure success: 88%. 1-y survival rate: 66%. NYHA class and QoL significantly improved. Survival free of stroke, re-hospitalization, NYHA 3/4, and device-related dysfunction: 49% at 3 mo; 31% at 1 y.</td>
<td>30-d event-free survival: 84%. Moderate to severe residual PVL was associated with all-cause mortality (HR: 3.9; 95% CI: 1.2-12.1).</td>
</tr>
<tr>
<td>Taramasso 2014 (160)</td>
<td>To compare the in-hospital outcomes of pts who underwent surgery and TA closure for PVL</td>
<td>Retrospective N = 139</td>
<td>Surgery vs. TA-closure for PVL</td>
<td>122 pts (87.3%) underwent surgical treatment (68% mitral PVL; 32% aortic PVL) and 17 pts (12.2%) underwent a transcatheter closure via a surgical TA approach. (all the pts had mitral PVL; 1 case had combined mitral and aortic PVLs).</td>
<td>Acute procedural success: 98%. Surgical treatment was a risk factor for in-hospital death (OR: 8, 95% CI: 1.8-13).</td>
<td>Overall actuarial survival at follow-up: 39.8 ± 7% at 12 y; and was reduced in pts who had &gt;1 cardiac re-operation (42 ± 8 vs. 63 ± 6% at 9 y; p=0.009).</td>
</tr>
<tr>
<td>Gafoor 2014 (161)</td>
<td>To determine the safety and efficacy of percutaneous PVL closure after TAVR</td>
<td>Retrospective n= 5</td>
<td>Percutaneous closure of PVL</td>
<td>Pts who received TAVR with self-expandable valves</td>
<td>In all 5 pts, PVL went from moderate-severe to mild-moderate PVL</td>
<td>-</td>
</tr>
</tbody>
</table>

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.
<table>
<thead>
<tr>
<th>Study</th>
<th>Objective</th>
<th>Study Design</th>
<th>Number of Patients</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cruz-Gonzales, I (162)</td>
<td>To analyze the feasibility and efficacy of PVL closure with the Amplatz Vascular Plug III</td>
<td>Retrospective</td>
<td>n = 33</td>
<td>Successful device implantation: 93.9% (in 2 pts, a 2nd planned procedure was needed). Successful closure (defined as regurgitation reduction ≥1 grade): 90.9%. At 90 d: Survival: 100%. Significant clinical improvement: 90.3%.</td>
</tr>
<tr>
<td>Millan 2015 (163)</td>
<td>To assess whether a successful transcatheter PVL reduction is associated with improvement in clinical outcomes</td>
<td>Systematic review/Meta-analysis</td>
<td>n = 362 pts</td>
<td>Comapred with a failed intervention, a successful transcatheter PVL reduction was associated with lower cardiac mortality (OR: 0.08; 95% CI: 0.01–0.90). A successful transcatheter PVL reduction was associated with: Superior improvement in functional class or hemolytic anemia. (OR: 9.95; 95% CI: 2.10–66.73). Fewer repeat surgeries (OR: 0.08; 95% CI: 0.01–0.40).</td>
</tr>
<tr>
<td>Goktekin 2016 (164)</td>
<td>To evaluate early and midterm outcomes of percutaneous PVL closure utilizing a novel device (Occlutech PVL Device)</td>
<td>Case series</td>
<td>n = 21</td>
<td>≥1 grade reduction in regurgitation was achieved in all pts. No deaths due to any cause, stroke or surgery for prosthetic impingement, worsening or relapse of PVL occurred at follow-up (90 d and 12 mo). No in-hospital mortality. 1 case of hemotherax in 1 pt and 1 case of pneumothorax in another</td>
</tr>
<tr>
<td>Author/Year</td>
<td>Aim of Study</td>
<td>Study Type</td>
<td>Study Size (N)</td>
<td>Patient Population</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Jault, 1997 (165)</td>
<td>Identify significant predictors of operative mortality, reoperation, and recurrent IEs</td>
<td>Retrospective single-center surgical cohort study</td>
<td>247</td>
<td>NVE alone; surgery 100%</td>
</tr>
<tr>
<td>Castillo 2000 (166)</td>
<td>To determine the clinical features and long-term prognosis of IE in pts who were not drug users.</td>
<td>Prospective single-center case series</td>
<td>138</td>
<td>NVE 69%, PVE 31%; surgery 51%</td>
</tr>
<tr>
<td>Alexiou 2000 (167)</td>
<td>Single-center experience in the surgical treatment of active culture-positive IE and identify determinants of early and late</td>
<td>Retrospective single-center surgical cohort study</td>
<td>118</td>
<td>NVE 70%, PVE 30%; 100% of pts underwent surgery</td>
</tr>
<tr>
<td>Wallace, 2002 (193)</td>
<td>To identify clinical markers available within the first 48 h of admission that are associated with poor outcome in IE</td>
<td>Retrospective single-center cohort study</td>
<td>208</td>
<td>NVE 68%, PVE 32%; surgery 52%</td>
</tr>
</tbody>
</table>
To derive and externally validate a prognostic classification system for pts with complicated left-sided native valve IE

Retrospective multicenter cohort study

Pts with left-sided NVE with current indication of surgery in 45%

Registration of clinical information, sociodemographic data, comorbid conditions, previous heart disease, symptoms, physical findings, blood cultures, electrocardiogram, echocardiography, type of surgery performed, and operative findings

In the derivation and validation cohorts, the 6-mo mortality rates were 25% and 26%, respectively. In the derivation cohort, pts were classified into 4 groups with increasing risk for 6-mo mortality: 5%, 15%, 31%, and 59% (p<0.001). In the validation cohort, a similar risk among the 4 groups was observed: 7%, 19%, 32%, and 69% (p<0.001).

5 baseline features were independently associated with 6 mo mortality (comorbidity [p=0.03], abnormal mental status [p=0.02], moderate-to-severe congestive HF [p=0.01], bacterial etiology other than viridans streptococci [p=0.001 except S. aureus, p=0.004], and medical therapy without valve surgery [p=0.002])

To determine whether valve surgery is associated with reduced mortality in pts with complicated, left-sided native valve IE

Retrospective multicenter cohort study; Propensity analysis

Pts with left-sided NVE with current surgical intervention in 45%

Registration of clinical information, sociodemographic data, comorbid conditions, previous heart disease, symptoms, physical findings, blood cultures, ECG, echocardiography, type of surgery performed, and operative findings

After adjustment for baseline variables associated with mortality (including hospital site, comorbidity, HF, microbial etiology, immunocompromised state, abnormal mental status, and refractory infection), valve surgery remained associated with reduced mortality (adjusted HR: 0.35; 95% CI: 0.23–0.54; p<0.02).

In further analyses of 218 pts matched by propensity scores, valve surgery remained associated with reduced mortality (15% vs. 28%; HR: 0.45; 95% CI: 0.29–0.66; p=0.01).

After additional adjustment for variables that contribute to heterogeneity and confounding within the propensity-matched group, surgical therapy remained significantly associated with a lower mortality (HR: 0.40; 95% CI: 0.18–0.91; p=0.03).

In this propensity-matched group, pts with moderate-to-severe HF showed the greatest reduction in mortality with valve surgery. Stratifying the data by congestive HF among propensity-matched pts undergoing surgery revealed that among pts with none to mild HF, valve surgery was not associated with reduced mortality compared with medical therapy (HR: 1.04; 95% CI: 0.43–2.48; p=0.93). Among propensity-matched pts with moderate-to-severe HF, valve surgery was associated with a significant reduction in mortality compared with medical therapy (HR: 0.22; 95% CI: 0.08–0.53; p=0.01).

To identify prognostic markers in 104 pts with PVE and the effects of a medical vs. surgical strategy outcome in PVE

Retrospective multicenter cohort study

100% PVE pts; surgery 49%

Registration of epidemiological, clinical, microbiological and other laboratory features, echocardiography data, and treatment strategy

Overall, 22 (21%) died in hospital. By multivariate analysis, severe HF (OR: 5.5) and S. aureus infection (OR: 6.1) were the only independent predictors of in-hospital death. Among 92 in-hospital survivors, 21 (26%) died during a 32 mo follow-up.

Mortality was not significantly different between surgical and nonsurgical pts (17% vs. 25%, respectively, not significant).

Both in-hospital and long-term mortality were reduced by a surgical approach in high-risk subgroups of pts with staphylococcal PVE and complicated PVE.

Factors associated with in-hospital death were severe comorbidity (6% of survivors vs. 41% of those who died; p=0.05), renal failure (28% vs.45%, p=0.05), moderate-to-severe regurgitation (22% vs. 54%; p=0.006), staphylococcal infection (16% vs. 54%; p=0.001), severe HF (22% vs. 64%; p=0.001), and occurrence of any complication (60% vs. 90%; p=0.05).
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study Design</th>
<th>NVE</th>
<th>PVE</th>
<th>Surgery</th>
<th>Study Details</th>
<th>Outcome Measures</th>
<th>Hospitalization outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revilla, 2007</td>
<td>(171)</td>
<td>Prospective multicenter cohort study</td>
<td>608</td>
<td>NVE 66%, PVE 34%; surgery studied for the present report</td>
<td>Brucella, Q fever, Legionella, and Mycoplasma. Persistent infection despite appropriate antibiotic treatment (31%).</td>
<td>Of these 508 episodes, 132 (34%) were electively operated on, and 89 pts required urgent surgery (defined as prior to completion of antibiotic course). 1° reasons for urgent surgery in these 89 pts were HF that did not respond to medication (72%) and persistent infection despite appropriate antibiotic treatment (31%). 32 pts (36%) died during their hospital stay. 32% of NVE died vs. 45% of pts with PVE. Late PVE was associated with a higher mortality than early PVE (53% vs. 36%).</td>
<td>Univariate analysis identified renal failure, septic shock, Gram-negative bacteria, persistent infection, and surgery for persistent infection as factors associated with mortality. Multivariate analysis confirmed only persistent infection and renal insufficiency as factors independently associated with a poor prognosis.</td>
<td></td>
</tr>
<tr>
<td>Hill, 2007</td>
<td>(172)</td>
<td>Analyze epidemiology, optimal treatment, and predictors of 6-mo mortality in IE</td>
<td>193</td>
<td>NVE 66%, PVE 34%; surgery 63%</td>
<td>Registration of epidemiological, clinical, microbiological and other laboratory features, echocardiography data, and treatment strategy</td>
<td>43% included staphylococci, 26% streptococci, and 17% enterococci. At least 1 complication occurred in 79% of the episodes and 63% had surgical intervention. 6-mo mortality was 22%; 33% for staphylococci, 24% for enterococci, and 8% for streptococci. 74% of pts with a contraindication to surgery died when compared with 7% with medical treatment without a contraindication and 16% with surgical/treatment.</td>
<td>S. aureus, contraindication to surgery (present in 50% of deaths).</td>
<td></td>
</tr>
<tr>
<td>Remadi, 2007</td>
<td>(173)</td>
<td>Prospective multicenter cohort study</td>
<td>116</td>
<td>S. aureus IE alone; NVE 83%, PVE 17%; surgery 47%</td>
<td>Registration of epidemiological, clinical, microbiological and other laboratory features, echocardiography data, and treatment strategy. Antibiotic treatment.</td>
<td>In-hospital mortality rate was 26%, and the 36-mo survival rate was 57%. Surgical group mortality was 16% vs. 34% in the medically treated group (p=0.05) In unadjusted analyses, early surgery performed in 47% of pts was associated with lower in-hospital mortality (16% vs. 34%; p=0.034) and with better 36-mo survival (77% vs. 39%; p=0.001). Multivariate analyses identified comorbidity index, HF, severe sepsis, prosthetic valve IE, and major neurologic events as predictors of in-hospital mortality. Severe sepsis and comorbidity index were predictors of overall mortality. After adjustment of baseline variables related to mortality, early surgery.</td>
<td>Revealed that surgery was associated with decreased mortality (HR: 0.27; 95% CI: 0.13–0.55). A HX of DM (HR: 4.81; 95% CI: 2.41–9.62), the presence of chronic IV catheters at the beginning of the episode (HR: 2.65; 95% CI: 1.31–5.33), and with increased mortality.</td>
<td></td>
</tr>
<tr>
<td>Akso, 2007</td>
<td>(174)</td>
<td>Prospective single-center cohort study with propensity score matching</td>
<td>428</td>
<td>NVE 69%, PVE 19%, &quot;other&quot; 12%; surgery in 29%</td>
<td>Registration of epidemiological, clinical, microbiological and other laboratory features, echocardiography data, and treatment strategy. Pts' propensities for surgery</td>
<td>The fit of the propensity model to the data was assessed using the concordance index with pts who underwent surgery matched to those who did not undergo surgery, using individual propensity scores. The following factors were statistically associated with surgical therapy: age, transfer from an outside hospital, evidence of IE on physical examination, the presence of infection with staphylococci, HF, intracardiac abscess, and hemodialysis without a chronic catheter.</td>
<td>Revealed that surgery was associated with decreased mortality (HR: 0.27; 95% CI: 0.13–0.55). A HX of DM (HR: 4.81; 95% CI: 2.41–9.62), the presence of chronic IV catheters at the beginning of the episode (HR: 2.65; 95% CI: 1.31–5.33), and with increased mortality.</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Reference</td>
<td>Design</td>
<td>NVE</td>
<td>PVE</td>
<td>Surgery Rate</td>
<td>Methodology</td>
<td>Results</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-----------</td>
<td>--------</td>
<td>-----</td>
<td>-----</td>
<td>--------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Tleyjeh, 2007 (175)</td>
<td>2007</td>
<td>17372170</td>
<td>Matched propensity analysis</td>
<td>546</td>
<td>NVE alone; surgery 24%</td>
<td>Propensity score to undergo valve surgery was used to match pts in the surgical and nonsurgical groups. To adjust for survivor bias, the follow-up time was matched so that each pt in the nonsurgical group survived at least as long as the time to surgery in the respective surgically-treated pt.</td>
<td>Death occurred in 99 of the 417 pts (23.7%) in the nonsurgical group vs. 35 deaths among the 129 pts (27.1%) in the surgical group. 18 of 35 (51%) pts in the surgical group died within 7 d of valve surgery. After adjustment for early (operative) mortality, surgery was not associated with a survival benefit (adjusted HR: 0.92; 95% CI: 0.48–1.76).</td>
<td></td>
</tr>
<tr>
<td>Tleyjeh, 2008 (176)</td>
<td>2008</td>
<td>18308866</td>
<td>Retrospective single-center cohort propensity analysis</td>
<td>546</td>
<td>NVE alone; surgery 24%</td>
<td>The association between time from IE dx to surgery and all-cause 6 mo mortality was assessed using Cox proportional hazards modeling after adjusting for the propensity score (to undergo surgery 0–11 d vs. 11 d, median time, after IE dx).</td>
<td>The median time between IE dx and surgery was 11 d (range 1–30). Using Cox proportional hazards modeling, propensity score and longer time to surgery (in d) were associated with unadjusted HRs of (1.15, 95% CI: 1.04–1.28, per 0.10 unit change; p=0.009) and (0.93; 95% CI: 0.88–0.99, per d; p=0.03), respectively. In multivariate analysis, a longer time to surgery was associated with an adjusted HR: (0.97; 95% CI: 0.90–1.03). The propensity score and time from dx to surgery had a correlation coefficient of r=20.63, making multicollinearity an issue in the multivariable model. On univariate analysis, a longer time to surgery showed a significant protective effect for the outcome of mortality. After adjusting for the propensity to undergo surgery early vs. late, a longer time to surgery was no longer significant, but remained in the protective direction.</td>
<td></td>
</tr>
<tr>
<td>Thuny, 2009 (177) 19329497</td>
<td>2009</td>
<td>19329497</td>
<td>Retrospective single-center cohort propensity analysis</td>
<td>291</td>
<td>NVE 82%, PVE 18%; surgery 100%</td>
<td>The time between the beginning of the appropriate antimicrobial therapy and surgery was used as a continuous variable and as a categorical variable with a cut-off of 7 d to assess the impact of timing of surgery. 2 groups of pts were formed according to the timing of surgery: the &quot;&lt;1st wk surgery group&quot; and the &quot;≥1st wk surgery group&quot;. The impact of the timing of surgery on 6 mo mortality, relapses, and PVD was analyzed using PS.</td>
<td>1st wk surgery was associated with a trend of decrease in 6-mo mortality in the quintile of pts with the most likelihood of undergoing this early surgical management (quintile 5: 11% vs. 33%; OR: 0.18, 95% CI: 0.04–0.83; p=0.03). Pts of this subgroup were younger, were more likely to have S. aureus infections, congestive HF, and larger vegetations. &lt;1st wk surgery was associated with an increased number of relapses or PVD (16% vs. 4%, adjusted OR: 2.9, 95% CI: 0.99–8.40; p=0.05). Very early surgery (&lt;7 d) associated with improved survival (especially in highest risk pts), but greater likelihood of relapse or post-operative valve dysfunction.</td>
<td></td>
</tr>
<tr>
<td>Author(s)</td>
<td>Year</td>
<td>Title</td>
<td>Study Design</td>
<td>Institution</td>
<td>NVE</td>
<td>PVE</td>
<td>Surgery</td>
<td>Outcome Measures</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>-------</td>
<td>--------------</td>
<td>-------------</td>
<td>-----</td>
<td>-----</td>
<td>---------</td>
<td>----------------</td>
</tr>
<tr>
<td>Manne, 2012</td>
<td>178</td>
<td>Manne, 2012</td>
<td>428</td>
<td>Retrospective single-center surgical cohort study</td>
<td>NVE 56%, PVE 42%; surgery 100%</td>
<td>Registration of epidemiological, clinical, microbiological and other laboratory features, echocardiography data, and treatment strategy</td>
<td>Overall 90% of pts survived to hospital discharge. When compared with pts with NVE, pts with PVE had significantly higher 30-d mortality (13% vs. 5.6%; p&lt;0.01), but long-term survival was not significantly different (35% vs. 29%; p=0.19). Pts with IE caused by S. aureus had significantly higher hospital mortality (15% vs. 8.4%; p&lt;0.05), 6 mo mortality (23% vs. 15%; p=0.05), and 1 y mortality (28% vs. 18%; p=0.02) compared with non-S. aureus IE.</td>
<td></td>
</tr>
<tr>
<td>Kang, 2012</td>
<td>179</td>
<td>Kang, 2012</td>
<td>76</td>
<td>Prospective randomized trial at 2 centers with intention to treat analysis</td>
<td>Left-side NVE and high risk of embolism to early surgery (49%) vs. conventional treatment (51%)</td>
<td>Pts were randomly assigned in a 1:1 ratio to the early-surgery group or the conventional-treatment group with the use of a Web-based interactive response system. The protocol specified that pts who were assigned to the early-surgery group should undergo surgery within 48 h after randomization. Pts assigned to the conventional-treatment group were treated according to AHA guidelines, and surgery was performed only if complications requiring urgent surgery developed during medical treatment or if symptoms persisted. The 1° endpoint (composite of in-hospital death and embolic events that occurred within 6 wk after randomization) occurred in 1 pt (3%) in the early surgery group as compared with 9 (23%) in the conventional-treatment group (HR: 0.10; 95% CI: 0.01–0.82; p=0.03). There was no significant difference in all-cause mortality at 6 mo in the early-surgery and conventional- treatment groups (3% and 5%, respectively; HR: 0.51; 95% CI: 0.05–5.66; p=0.59). The rate of the composite en point of death from any cause, embolic events, or recurrence of IE at 6 mos was 3% in the early-surgery group and 28% in the conventional-treatment group (HR: 0.08; 95% CI: 0.01–0.65; p=0.02). As compared with conventional treatment, early surgery in pts with IE and large vegetations significantly reduced the composite endpoint of death from any cause and embolic events by effectively decreasing the risk of systemic embolism.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
To establish guidelines for the surgical treatment of pts with IE who have cerebrovascular complications

Eishi, 1995

Retrospective study of 181 pts with cerebral complications among 2523 surgical cases of IE

181 pts

Predominately left sided IE; 37.5% PVE and 62.5% NVE with neurological complications of IE

Questionnaire consisting of 2 parts: (1) Each center was asked for a summary of the number and outcome of pts with IE according to the types of IE 1 (active/healed and native valve/prosthetic valve) and the presence of cerebral complications; (2) the other portion inquired about each pt with cerebral complications, asking for details such as age, gender, AF, anticoagulant therapy, diseased valve, organism, effectiveness of antimicrobial therapy, reason for early cardiac operation, interval between the onset of symptoms and the cardiac operation, type of cerebral complication, cerebral aneurysm, prior cerebral surgery, severity, influence of operation on cerebral damage, and outcome.

To study the influence of cardiac surgery on preoperative cerebral complications, we analyzed the interval between the onset of cerebral complications and performance of the cardiac operation, as well as other preoperative variables. The effectiveness of antimicrobial therapy was ranked in 3 grades (1 = ineffective, 2 = effective, and 3 = well controlled). A correlation between the interval and the exacerbation of cerebral complications was evaluated by means of the Spearman rank correlation coefficient. The intervals were then classified in several groups, and variability between the groups for the exacerbation was estimated by Scheffe’s F procedure for post-hoc comparisons, according to the Kruskal-Wallis test. To analyze the risk factors affecting exacerbation of cerebral complications, we expressed preoperative variables as mean ± standard error. The difference between the groups with and without exacerbation was tested for significance by the unpaired t test, and incidence was expressed as percentage of pts having the variable compared with the entire group of pts and then compared by χ2 analysis. Moreover, all variables and incidence (transformed to continuous variables) were estimated by stepwise regression analysis. Statistical significance was accepted at a p level of <0.05. These analyses were done with the Stat View system (Abacus Concepts, Inc., Berkeley, Calif.).

The rate of exacerbation of cerebral complications decreased to 10% in pts who underwent surgical treatment more than 15 d after cerebral infarction and to 2.3% in those operated on more than 4 wk later. Preoperative risk factors were severity of cerebral complications, interval from onset of symptoms to operation, and uncontrolled HF as the indication for cardiac surgery. More than 15 d after cerebral hemorrhage, the risk of the progression of cerebral damage is still significant, and this risk persists even 4 wk later.

Garcia-Cabrera, 2013

Assess the incidence of neurological complications in pts with infective endocarditis, the risk factors for their development, their influence on the clinical outcome, and the impact of cardiac surgery

Retrospective analysis of prospectively collected data on a multicenter cohort

1345pts

Consecutive Left sided endocarditis cases from 8 Centers in Spain

Specific variables from registries were analyzed including the date of IE dx; pts age and sex; type of endocarditis (native or prosthetic); location and size of vegetations on echocardiography; infecting microorganism; date, type, and extent of neurological complications; anticoagulant therapy given; date of the start of antimicrobial treatment; date of surgery (if performed); and outcome.

To determine the risk factors associated with the development of all neurological complications

Predictors of neurological complications were vegetation size ≥3 cm (HR: 1.91; 95% CI: 1.07–3.43; p=0.029), S aureus as the cause of IE (HR: 2.47; 95% CI: 1.94–3.15; p<0.001), anticoagulant therapy at IE dx (HR: 1.31; 95% CI: 1.00–1.72; p=0.048), and MV involvement (HR: 1.29; 95% CI: 1.02–1.61; p=0.03). Further analysis showed that elderly pts (≥70 y) had lower complication rates than younger ones, and only hemorrhagic events showed statistical significance (HR: 0.36; 95% CI: 0.16–0.83; p=0.014). Anticoagulant treatment was particularly associated with cerebral hemorrhage (HR: 2.71; 95% CI: 1.54–4.76; p=0.001).
<table>
<thead>
<tr>
<th>Barsic, B, 2013 (182) 23074311</th>
<th>Examine the relationship between the timing of surgery after stroke and the incidence of in-hospital and 1-y mortalities.</th>
<th>Post-hoc review of the International Collaboration on Endocarditis—Prospective Cohort Study of patients with definite IE who were admitted to 64 centers June 2000–December 2006</th>
<th>198 pts of 857 pts with IE complicated by ischemic stroke who underwent valve replacement surgery post-stroke</th>
<th>Data were obtained from the International Collaboration on Endocarditis—Prospective Cohort Study of 4794 pts with definite IE who were admitted to 64 centers from June 2000 through December 2006. Multivariate logistic regression and Cox regression analyses were performed to estimate the impact of early surgery on hospital and 1-y mortality after adjustments for other significant covariates.</th>
<th>Estimate the impact of early surgery on hospital and 1-y mortality after adjustments for other significant covariates.</th>
<th>After adjustment for other risk factors, early surgery was not significantly associated with increased in-hospital mortality rates (OR: 2.308; 95% CI: .942–5.652). Overall, probability of death after 1-y follow-up did not differ between 2 treatment groups (27.1% in early surgery and 19.2% in late surgery group, p=.328; adjusted HR: 1.138; 95% CI: .802–1.650).</th>
</tr>
</thead>
</table>

© 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation.


